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ETIOLOGY AND CLASSIFICATION 
Lower extremity peripheral artery disease (PAD) is the clinical manifestation of systemic 
atherosclerosis affecting the infrarenal aorta and the lower limb arteries. Atherosclerosis 
is a chronic and slowly developing pathological process with formation of atherosclerotic 
plaques which results in progressive stenosis and occlusion of the arteries supplying 
oxygenated blood to the lower extremity muscles. There is a broad spectrum of clinical 
manifestations of PAD, ranging from asymptomatic patients with a decreased ankle-
brachial index (ABI) to patients with classic intermittent claudication or atypical exercise-
induced leg symptoms. End-stage PAD, critical limb ischemia, is characterized by ischemic 
rest pain in the foot, or lower limb ulceration or gangrene. Intermittent claudication, i.e. 
exertional pain in the calf or thigh of one or both legs that resolves after a short period 
of rest, is by far the most common symptomatic form of PAD.1 The development and 
course of PAD are associated with risk factors which are identical to those for other forms 
of atherosclerotic disease such as coronary heart disease and cerebrovascular disease. 
These include smoking, hypertension, diabetes mellitus, dyslipidemia, and chronic kidney 
disease.2 Smoking and diabetes are the strongest independent risk factors which are 
associated with the worst outcomes.3   
EPIDEMIOLOGY AND CLINICAL COURSE 
PAD is a highly prevalent, morbid, and mortal disease, affecting more than 200 million 
individuals globally.4 The prevalence of PAD is strongly age-related with 3-10% of adults 
being affected and increasing to 15-20% in patients over 70 years.2,5,6 The prevalence 
of PAD has enormously increased over a period of 10 years by 30% in low- and 
middle-income countries and by 15% in high-income countries.4 In the absence of 
preventive efforts, the burden of PAD will rise even further to pandemic proportions. 
An estimated 10-30% of patients with PAD have the classic claudication manifestation, 
while the majority of the patients with PAD are asymptomatic or present with atypical leg 
symptoms.7 Nevertheless, these estimations may be inaccurate given the different criteria 
used in studies to determine claudication and the limitations in mobility caused by other 
conditions. Furthermore, elderly patients deem to consider their complaints as part of 
normal ageing and consequently may not report claudication symptoms. 
In general, the clinical course of intermittent claudication is relatively benign for 
the affected limbs; only 1 in 4 patients deteriorate to a more severe clinical stage8 and 
the risk of limb loss is only 1-3% during the first 5 years after the onset of symptoms.9 
Nevertheless, patients with intermittent claudication experience significant functional 
disability over time associated with a diminished ability to perform their daily activities, 
resulting in a sedentary lifestyle10,11 and impaired quality of life.12,13 As opposed to the 
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relatively benign course for the legs, patients with PAD have a 3-fold higher all-cause 
mortality risk compared to individuals without PAD even after adjustment for the 
traditional cardiovascular risk factors.14 PAD is strongly associated with other manifestations 
of atherosclerotic cardiovascular disease: over 50% of PAD patients have coronary heart 
disease, cerebrovascular disease, or both at presentation. In fact in data from registries 
patients with PAD even had a higher 1-year incidence of cardiovascular death, myocardial 
infarction or stroke as compared to patients with coronary heart disease (5.4% vs. 4.5%).15 
Within 5 years after the onset of claudication symptoms, 1 in 5 patients will die, mostly due 
to a cardiovascular cause, and 1 in 3 patients will experience a non-fatal cardiovascular 
event.14,15 This stresses the importance of raising physician and patient awareness for 
detection of PAD and secondary prevention of cardiovascular events by managing the 
cardiovascular risk factors. 
MANAGEMENT OF INTERMITTENT CLAUDICATION 
Treatment for intermittent claudication should include a broad approach focusing on the 
prevention of future cardiovascular events as well as on the improvement of claudication 
symptoms and quality of life. Although cardiovascular risk management is crucial for 
the prognosis of the patient, in clinical practice patients with PAD are less likely than 
those with coronary artery or cerebrovascular disease to receive adequate secondary 
prevention measures.16 All patients with PAD should receive an anti-platelet agent and 
aggressive medical management of hypertension, dyslipidemia, diabetes, and obesity, 
as well as lifestyle interventions to promote smoking cessation, healthy nutrition and 
physical activity according to current clinical guidelines.1,17 The studies in this thesis will 
focus on treatment strategies to improve leg symptoms and quality of life in patients with 
intermittent claudication.
Pharmacotherapy 
Three medications have been investigated for relief of claudication symptoms: cilostazol, 
pentoxifylline, and naftidrofuryl. The latter two have no or only very limited effects on 
walking distance compared to placebo.18 Only cilostazol, a type 3 phosphodiesterase 
inhibitor, provides a modest improvement in pain-free and maximum walking distance 
of approximately 50% compared with placebo.19 Yet, in clinical practice adherence to 
cilostazol is low due to frequent adverse effects including headache, palpitations and 
diarrhea.20,21 Hence, there is no widely available effective medical agent to improve 
walking distance and quality of life in patients with claudication.  
Exercise therapy 
Exercise therapy has become the cornerstone in the management of intermittent 
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claudication. The potential mechanisms of exercise therapy to improve claudication 
symptoms are not completely clear. A variety of adaptive mechanisms in the lower 
extremity muscles have been suggested, including improved skeletal muscle mitochondrial 
metabolism, improved endothelial vasodilator function, lower blood viscosity, and more 
efficient biomechanics of walking.22  
The first randomized clinical trial (RCT) describing the positive effects of exercise 
therapy on claudication was published in 1966 by Larsen et al.23 Many RCTs with different 
types of exercise programs followed, all of them showing mainly positive effects on 
improving walking distances in patients with intermittent claudication. A Cochrane meta-
analysis of these RCTs showed that exercise therapy on average improved the maximum 
walking distance by 150%, e.g. from 200 to 500 meters.24 A second Cochrane systematic 
review showed that treadmill training supervised by an exercise therapist was superior to 
unsupervised training, i.e. a walking advice, in terms of improvement in maximum walking 
distance.25 Although supervision seems to be an important aspect of exercise training, the 
optimal frequency, intensity, mode of exercise, and duration of the programs remains to 
be established. 
Taken together, the evidence convincingly demonstrates that exercise therapy 
improves walking performance compared with no exercise and that supervised exercise 
gives superior results to unsupervised exercise. Current evidence-based clinical guidelines 
recommend supervised exercise therapy as the first-line treatment for all patients with 
intermittent claudication, regardless of the level of lower extremity arterial disease.1,17 
Despite these recommendations, the value of exercise therapy in routine clinical practice 
remains uncertain, as supervised exercise programs are underutilized due to slow results, 
reimbursement issues, poor patient compliance, and limited access in most countries. As 
a consequence, endovascular revascularization, though more expensive, is increasingly 
being performed as an attractive first-line alternative.26
Revascularization
Since the first endovascular revascularization procedure to restore blood flow in the 
lower extremity with balloon angioplasty by Dotter and Judkins in 196427, technological 
developments have advanced endovascular revascularization. The endovascular repertoire 
now includes bare metal and covered balloon-expandable and self-expandable stents, 
as well as drug-coated balloons, drug-eluting stents and bioabsorbable stents which 
have advanced endovascular revascularization as a safe and durable treatment option 
in the management of symptomatic PAD. In the literature effectiveness of endovascular 
revascularization  is usually reported as procedural success rate and patency rates 
over time, which varies between different segments of the arterial tree. For aortoiliac 
procedures, the procedural success rate is over 90%, with 5-year primary patency rates 
ranging from 60-86%.28 Femoropopliteal procedures have comparable procedural 
success rates, however much lower primary patency rates of 50-60% after 2-3 years of 
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follow-up. With the recent introduction of drug-coated balloons, the primary patency rate 
has improved to 70-80% after 2 years of follow-up.29 While patency rates are reported as 
measures of success, clinical outcomes such as walking distances and quality of life are of 
more concern to patients with intermittent claudication. 
The number of endovascular procedures performed in the United States for 
PAD increased by 400% between 1999 and 2007.30 The higher rate of endovascular 
procedures has associated costs, risks of procedure-related morbidity and mortality, 
and re-intervention rates. A substantial proportion of patients require additional 
revascularization procedures for restenosis at the target lesion site and/or for other 
lesions in the ipsilateral or contralateral leg. Given the extent of the arterial lesions in 
PAD and the limited durability of endovascular revascularization, interventions beget 
more interventions. While endovascular or surgical revascularization is the treatment of 
choice for patients with critical limb ischemia to reduce pain, promote wound healing, and 
prevent amputation, the role of revascularization as first-line treatment for patients with 
intermittent claudication is still under debate. Several RCTs have compared endovascular 
revascularization versus supervised exercise therapy as initial treatment for intermittent 
claudication and have demonstrated no clear advantage for one of the treatment options 
in terms of improving walking distance and quality of life in the short-term, data with long-
term follow up is scarce. In addition given the different mechanisms by which supervised 
exercise and endovascular revascularization improves walking distance and quality of life 
combining both treatment options might have the most beneficial effects. 
AIMS AND OUTLINE OF THIS THESIS
The main objective of this thesis is to determine the optimal treatment for patients with 
intermittent claudication.
In part I we summarize the existing evidence regarding the management of 
intermittent claudication using systematic reviews and meta-analyses. In chapter 2 we 
performed a systematic review and meta-analysis to first summarize the effectiveness 
of supervised walking therapy in the management of intermittent claudication and 
second identify the components including the duration, intensity and exact content of 
the walking therapy programs that provide maximal improvement in walking distances. 
A substantial number of patients with intermittent claudication are not able to perform 
supervised exercise which consists of walking therapy on a treadmill due to concomitant 
comorbidities. For these patients other modes of supervised exercise such as cycling, 
upper-arm ergometer exercise and strength training might be an plausible alternative. In 
chapter 3 we performed a systematic review and meta-analysis to assess the effects of 
different modes of supervise exercise on walking distances and quality of life in patients 
with intermittent claudication. Endovascular revascularization is being considered as an 
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attractive alternative for conservative management (i.e. supervised exercise) as first-line 
treatment for intermittent claudication and the number of endovascular procedures has 
increased dramatically in the past 10 years. In chapter 4 we performed a systematic 
review and meta-analysis to summarize the effect of endovascular revascularization 
versus or combined with conservative management.
In part II we assess the clinical effectiveness of different treatment strategies for 
intermittent claudication. Studies comparing long-term effectiveness of SE training and 
endovascular revascularization are scarce. In chapter 5 we present the long-term results 
from a RCT comparing supervised exercise therapy with endovascular revascularization 
for intermittent claudication. As supervise exercise programs are not widely available 
and not fully reimbursed, in chapter 6 we compare the effectiveness of a structured 
home-based exercise program with a supervised exercise program in patients with 
intermittent claudication. A combination therapy of endovascular revascularization and 
supervise exercise seems promising as it might combine the immediate improvement 
in claudication symptoms after revascularization with the added long-term benefits of 
exercise therapy. However level 1 evidence from a large RCT was missing to evaluate this 
hypothesis.  In chapter 7 we present the results from the Endovascular Revascularization 
And Supervised Exercise (ERASE) trial comparing a combination therapy of endovascular 
revascularization plus supervised exercise with supervised exercise therapy only in patients 
with intermittent claudication. 
In part III we address the cost-effectiveness of different treatment strategies for 
intermittent claudication to better inform policymakers on implementation of these 
treatment strategies. In chapter 8 we constructed a Markov model assessing the cost-
effectiveness of supervised exercise therapy versus endovascular revascularization in the 
long-term. In chapter 9 we perform a cost-effectiveness analysis of the ERASE trial to 
assess whether a combination therapy of endovascular revascularization and supervised 
exercise is cost-effective from a societal perspective compared to supervised exercise 
only.  
We conclude the thesis by summarizing and discussing the main findings in chapter 10 
and providing future perspectives for clinical practice and research.
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ABSTRACT
Objective
Exercise therapy is a common intervention for the management of intermittent 
claudication. However, considerable uncertainty remains about the effect of different 
exercise components such as intensity, duration, or content of the exercise programs. 
The aim of this study was to assess the effectiveness of supervised walking therapy as 
treatment in patients with Intermittent claudication and to update and identify the most 
important exercise components resulting in an optimal training protocol for patients with 
Intermittent claudication.
Methods 
A systematic literature search using MEDLINE, EMBASE, and Cochrane Central Register of 
Controlled Trials databases was performed. Randomized controlled trials (RCTs) published 
between January 1966 and February 2012 were included if they evaluated the effectiveness 
of supervised walking therapy. Predefined exercise components were extracted, including 
treadmill use during training, claudication pain end point used during walking, length of 
the supervised walking therapy program, and total training volume. A meta-analysis and 
meta-regression was performed to evaluate the weighted mean difference in maximum 
walking distance (MWD) and pain-free walking distance (PFWD) between supervised 
walking therapy and noninterventional observation.
Results
Twenty-five RCTs (1054 patients) comparing supervised walking therapy vs noninterventional 
observation showed a weighted mean difference of 180 meters (95% confidence interval, 
130-230 meters) in MWD and 128 meters (95% confidence interval, 92-165 meters) in 
PFWD, both in favor of the supervised walking therapy group. In multivariable meta-
regression analysis, none of the predefined exercise components were independently 
associated with significant improvements in MWD or PFWD.
Conclusions
Supervised walking therapy is effective in improving MWD and PFWD in patients with 
intermittent claudication. However, pooled results from the RCTs did not identify any of 
the exercise components including intensity, duration, or content of the program as being 
independently associated with improvements in MWD or PFWD 
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Peripheral arterial disease (PAD) is prevalent in Western countries, affecting 4.3% of the 
population aged $40 years and increases with age to 14.5% in the elderly population aged 
$70 years.1 Intermittent claudication (intermittent claudication), a common manifestation 
of PAD, defined as muscle discomfort in the legs that is elicited by exercise and relieved by 
a short period of rest, is associated with significant functional disability, reduced quality of 
life,2 and an increased risk for nonfatal and fatal cardiovascular events.3
Treatment strategies for intermittent claudication include pharmacotherapy,4 physical 
exercise therapy,5 and surgical or percutaneous vascular interventions.6,7 Considerable 
evidence is available to suggest that exercise therapy should have a central role in the 
management of intermittent claudication by significantly improving the pain-free walking 
distance (PFWD) and maximum walking distance (MWD) and lowering the risk for 
cardiovascular events.5,8 In particular, supervised exercise therapy, which usually involves 
walking on a treadmill, is considered more effective than unsupervised exercise therapy,9,10 
and therefore, the general consensus is to initially treat patients with intermittent 
claudication with supervised exercise therapy.6,7
Although supervision and (treadmill) walking are considered important components 
of the exercise program, a lot of uncertainty remains about the intensity, duration, and 
content of the programs. In a 1995 meta-analysis, Gardner et al11 determined the most 
important exercise components for providing optimal improvements in walking ability in 
patients with intermittent claudication. The authors concluded that the optimal exercise 
program consists of intermittent walking to near-maximal pain for a period of at least 6 
months. However, these recommendations were based on results from nonrandomized 
(un)controlled studies. Since this publication 16 years ago, many randomized controlled 
trials (RCTs) evaluating the effectiveness of supervised walking therapy (supervised walking 
therapy) programs with a great variety in exercise protocols have been published. In 
addition, new methodologic evidence about meta-analytic approaches is available, and 
experience has accumulated since the last meta-analysis on this topic.
Therefore, the primary aim of this study was to determine whether supervised walking 
therapy in patients with intermittent claudication is effective in improving MWD and PFWD, 
and secondly, to update and identify the components of supervised walking therapy that 
provide maximal improvement in MWD and PFWD. Implementation of this state-of-the-
art systematic review and meta-analysis of supervised walking therapy programs may 
optimize the therapeutic benefits of supervised walking therapy as a noninvasive first-line 
treatment in the large population of patients with intermittent claudication.
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METHODS
Data sources 
Two authors (F.F., K.L.) collaborated with a professional librarian to independently develop 
multiple search strategies to identify RCTs, which evaluated supervised walking therapy 
in patients with intermittent claudication, published between January 1966 and February 
2012. We first performed an electronic search in MEDLINE and EMBASE. This search 
was subsequently reproduced using the Cochrane Central Register of Controlled Trials 
Register of Controlled Trials. Relevant keywords relating to disease of interest (claudica* 
and intermitten* or vascular disease* or peripheral arterial occlusive disease* or peripheral 
arterial disease* or peripheral artery disease* or ischemi* or ischaemi* or Fontaine 2) were 
used in combination with keywords relating to exercise program (exercise or exercise or 
training or walking or gymnast*) using a Boolean search strategy. Reference lists of all 
eligible studies were handsearched for additional studies, and no language restriction 
was applied.
Study selection
Identified studies were initially selected by a review of titles and abstracts by three reviewers 
(K.L., E.R., and S.S) independently. Final selection was based on a full-text evaluation of the 
selected studies by two reviewers (F.F., S.S.) independently. Disagreements between the 
reviewers were discussed and resolved by consensus. Studies were included if they were 
(1) an RCT comparing supervised walking therapy and noninterventional observation in 
patients with intermittent claudication and (2) assessed PFWD or MWD, or both, or time 
using a treadmill test before and after supervised walking therapy. When data from the 
same patient population were published in various journals, we examined the results and 
included the data only once in our systematic review.
Quality assessment
Methodologic quality of the included studies was assessed using the Physiotherapy 
Evidence Database (PEDro) scale.12 The following quality criteria are included and rated 
in the PEDro score: eligibility criteria specified, randomization of subjects, concealed 
allocation, baseline similarity of groups regarding the most important prognostic 
indicators, blinding of subjects, blinding of therapists, blinding of assessors, completeness 
of follow-up, outcomes analyzed by intention-to-treat principle, between-group statistical 
comparison reported, and point measures and measure of variability reported.
Data extraction
One reviewer (F.F.) extracted all required data from each included study using a 
standardized form that consisted of (1) study characteristics, including year of publication, 
study location, and number of patients in each group; (2) patient baseline characteristics, 
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including mean age and sex; and (3) primary outcomes, including MWD and PFWD before 
and after supervised walking therapy. If the walking performance was reported in a unit 
of time, this was converted to walking distances by using the reported tread-mill speed.
To evaluate supervised walking therapy we recorded the following components from 
each program:
 – Mode of exercise, defined as “walking” or “walking plus,” which was a combination 
of walking and alternative modes of exercises, including heel raises, knee bends, 
step-ups, and arm exercises, among others;
 – Treadmill use during training;
 – Length of walking program in weeks;
 – Number of sessions per week;
 – Duration of each session in minutes;
 – Pain end point used during walking, which was defined as PFW, walking to mild or 
moderate claudication pain, or walking to (near) maximum claudication pain.
Training volume, which was the total duration of the supervised walking therapy program 
(in minutes), was calculated by multiplying the length of the program (in weeks), number 
of sessions per week, and duration per session (in minutes).
Data analysis
The primary and secondary outcomes of interest were the weighted mean difference in 
MWD and PFWD between the supervised walking therapy and control groups. Mean 
post-training MWD and PFWD from each trial were combined and weighted in a meta-
analysis using a DerSimonian and Laird random effects model to estimate the pooled 
effect of the outcomes. These estimates were expressed as a weighted mean difference in 
MWD and PFWD, including 95% confidence intervals (95% CI).13 Statistical heterogeneity 
was assessed for the mean differences in MWD and PFWD by calculating the Q statistics 
and the I2 statistic.
Selective dissemination of evidence was assessed by plotting for each study the 
weighted mean difference in MWD and PFWD, against precision (1/standard error) in a plot 
with P value contours. Funnel plot asymmetry, specifically with apparent absent of studies 
in high P value areas of the plot, can be indicative of selective evidence dissemination.14 
Funnel plot asymmetry was formally evaluated by Begg and Egger tests.15,16 If there was an 
indication of selective evidence dissemination, we performed a “trim and fill” procedure 
by imputing the potentially missing studies and checking whether this would change our 
results significantly.17
The heterogeneity of the weighted mean differences in MWD and PFWD between 
the supervised walking therapy programs and the potential effect of supervised walking 
therapy program components on this heterogeneity was first investigated by performing 
a subgroup meta-analysis of each supervised walking therapy program component 
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separately. Then, a multivariable random effects meta-regression model was used to 
determine whether an individual supervised walking therapy component or a combination 
of components would significantly explain the variation between the studies and thus 
was/ were independently associated with improvement in MWD and PFWD.
Individual study effect on the results was evaluated by an exclusion sensitivity analysis. 
In addition, sensitivity analysis by removing studies with a PEDro score 4 was performed to 
observe whether removing RCTs with a very low PEDro score would significantly change 
the results.
A two-sided P = .05 was considered statistically significant, except for the tests for 
selective evidence dissemination, for which the recommended levels are P = .10. Analyses 
were performed using SPSS 17 software (SPSS Inc, Chicago, Ill), STATA 12 (StataCorp, 
College Station, Tex), and MIX Professional 2.0.18
RESULTS
Literature search
From the original electronic search, 2778 citations published between January 1966 
and February 2012 were retrieved (Fig 1). Of these, 992 studies were excluded because 
they were duplicates, and 1746 studies were excluded after the titles and abstracts were 
reviewed. Subsequently, of the 40 selected studies for full text review, another 15 studies 
were excluded for failing to meet predefined criteria (Fig 1); finally, 25 RCTs19-43 met our 
inclusion criteria and were included in the analysis.
Study characteristics
The selected RCTs included 1054 patients (76% male), with studies ranging in sample size 
from 13 to 177 patients. The mean patient age was 66.0 7.0 years (Table I). Twenty-four 
RCTs offered supervised walking therapy-plus as intervention, whereas one RCT offered a 
supervised pole-striding program to the intervention group. The control groups in three 
RCTs were advised to walk as much as possible at home, but no exercise instructions were 
given. The control group patients in one RCT received placebo tablets (Table I).
Quality assessment
The methodologic quality of the included RCTs according to the PEDro scale is presented 
in Table I. Eight RCTs (32%) reported a proper concealment of randomization, whereas 
18 (72%) reported baseline similarity between the intervention and control groups. None 
of the RCTs blinded the participants or the therapists who administrated the therapy, 
and only four RCTs (16%) reported blinding the assessors who measured one or more 
outcomes. In 17 RCTs (68%), measurement of at least one key outcome was obtained from 
85% of the participants initially allocated to groups, and only five (20%) reported outcome 
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Figure 1. Flow diagram of studies identified from literature search. SWT, Supervised walking 
 therapy.
analysis according to the intention-to-treat principle. Yet, 23 RCTs (92%) performed and 
reported between-group statistics for the main outcomes, and all included RCTs reported 
point measurements and measurements of variability for at least one of the key outcomes.
Overall, the methodologic quality of the included RCTs was low, with an average PEDro 
score of 5 of 10 points. However, due to the nature of the comparison (supervised walking 
therapy vs no exercise) in the RCTs, it was impossible to blind the subjects and therapists 
for the randomized groups; therefore, the maximum PEDro score that could be achieved 
by the RCTs was 8 points.
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Supervised walking therapy program characteristics
Walking was the only mode of exercise used in 21 RCTs, a combination of walking and 
additional lower limb aerobic exercises was used in three RCTs, and polestriding was used 
as the mode of exercise in the intervention group in one RCT. Patients in 10 RCTs exercised 
till (near) maximum claudication pain before taking a short rest dur-ing the walking 
sessions, patients in 11 studies walked till mild/moderate claudication pain, and patients 
in four studies exercised pain free. Treadmill walking during the exercise sessions was 
reported in 19 of 25 programs (Table II). The total length of supervised walking therapy 
programs included varied between 4 and 104 weeks, with 60% of the programs lasting 
between 12 and 26 weeks. An average of four training sessions was held weekly, with an 
average duration of 49 minutes per session (range, 10-120 minutes; Table II).
Table I. Characteristics of the randomized controlled trials included in the systematic review
First author Year
Study
location
Treatment
group Control group
Patients
(No.)
Male
(%)
Agea
(years)
PEDro
scoreb
Dahllof19 1974 Sweden SWT plusc Placebo tablets 18 72 61 ±5 4
Hiatt20 1990 U.S. SWT No intervention 19 100 60 ±12 4
Jansen21 1991 Germany SWT No intervention 48 NR NR 4
Hiatt22 1994 U.S. SWT No intervention 20 100 67 ±6 5
Tisi23 1997 U.K. SWT Advice to walk 39 69 68 NR 5
Gibellini24 2000 Italy SWT No intervention 40 90 67 ±7 3
Gardner25 2001 U.S. SWT No intervention 52 91 71 ±1 6
Gelin26 2001 Sweden SWT No intervention 177 67 67 NR 5
Gardner27 2002 U.S. SWT No intervention 31 NR 72 ±1 5
Langbein28 2002 U.S. Pole-striding No intervention 52 98 67 ±9 5
Tsai29 2002 Taiwan SWT No intervention 53 83 76 ±4 5
Mika30 2005 Poland SWT No intervention 80 83 61 ±6 5
Sandri31 2005 Germany SWT No intervention 18 NR 57 ±2 5
Hobbs32 2006 U.K. SWT plusc No intervention 14 71 72 NR 5
Mika33 2006 Poland SWT No intervention 55 87 59 ±8 6
Sanderson34 2006 Australia SWT No intervention 27 59 61 ±8 6
Wood35 2006 Australia SWT No intervention 13 69 60 ±8 4
Hobbs36 2007 U.K. SWT plusc No intervention 18 78 67 NR 5
Crowther37 2008 U.S. SWT No intervention 21 47 69 ±8 5
Hodges38 2008 U.K. SWT Advice to walk 28 NR 68 ±8 3
Treat-Jacobson39 2009 U.S. SWT Advice to walk 19 71 67 ±10 5
Schlager40 2011 Austria SWT No intervention 40 60 69 ±10 7
Leicht41 2011 Australia SWT No intervention 25 56 67 ±8 5
Gardner42 2011 U.S. SWT No intervention 79 49 66 ±11 5
Mika43 2011 Poland SWT No intervention 68 88 63 ±7 5
NR, Not reported; SWT, supervised walking therapy; U.K., United Kingdom; U.S., United States.
aData presented as mean standard deviation.
bPEDro Score: Physiotherapy Evidence Database scale is a tool to assess the methodological quality of the included random-
ized controlled trials (score between 0 and 10).
cTherapy consisted of walking combined with additional lower limb aerobic exercises.
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Effect of supervised walking therapy on walking distance
Twenty-four RCTs reported MWD measurements before and after training from the 
intervention and control groups, and 20 RCTs also reported PFWD measurements (Table 
III). The weighted mean difference in MWD from 24 RCTs comprising 916 patients was 180 
meters (95% CI, 130-230 meters), which was statistically significant in favor of supervised 
walking therapy compared with noninterventional observation (Fig 2). Similarly, the 
weighted mean difference in PFWD from 20 RCTs comprising 708 patients was statistically 
significant, with 128 meters (95% CI, 92-165 meters) in favor of the supervised walking 
therapy group (Fig 3).
Table III. Results of the randomized controlled trials included in the systematic reviewa
Patients analyzed MWD (m) SWT group
First author Year Intervention Control Pretraining Post-training
Dahllof19 1974 10 8 296±150 620±160
Hiatt20 1990 10 9 341±91 741±187
Jansen21 1991 24 24 191±27 320±50
Hiatt22 1994 10 8 515±306 789±392
Tisi23d 1997 22 17 104 (72-148) 175 (103-258)
Gibellini24 2000 20 20 217±79 451±170
Gardner25 2001 28 24 396±211 702±279
Gelin26 2001 73 76 258±142 247±111
Gardner27 2002 17 14 425±139 800±445
Langbein28 2002 27 25 505±433 1420±1156
Tsai29 2002 27 26 397±209 671±199
Mika30 2005 41 39 NR NR
Sandri31 2005 9 9 152±34 210±47
Hobbs32e 2006 7 7 111 (69-237) 124 (74-352)
Mika33 2006 27 28 408±56 609±74
Sanderson34 2006 13 14 NR Δ 180±46c
Wood35 2006 7 6 686±400 905±375
Hobbs36 2007 9 9 99 (81-241) 218 (122-339)
Crowther37 2008 10 11 300±125 661±278
Hodges38 2008 14 14 347±219 622±310
Treat-Jacobson39 2009 11 8 483±291 Δ 295±164c
Schlager40 2011 20 20 102 (66-155) 154 (97-230)
Leicht41 2011 8 9 NR 296±150
Gardner42 2011 33 33 289±150 480±250
Mika43 2011 30 31 551±57 848±61
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Assessment of selective evidence dissemination
The funnel plots (Fig 4 and Fig 5), the Begg tests, and the Egger regression tests were all 
suggestive of potential selective dissemination bias. The “trim and fill” correction changed 
the weighted mean differences in MWD and PFWD to 148 (95% CI, 136-160 meters) and 
97 meters (95% CI, 92-165 meters), respectively, both still in favor of supervised walking 
therapy.
Figure 3. Mean difference in pain-free walking distance (PFWD) from randomized controlled trials 
comparing super-vised walking therapy (SWT) vs noninterventional observation. CI, Confidence 
interval; SD, standard deviation.
Figure 2. Mean difference in maximum walking distance (MWD) from randomized controlled trials 
comparing super-vised walking therapy (SWT) vs noninterventional observation. CI, Confidence 
interval; SD, standard deviation
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Association between supervised walking therapy components and walking 
distance
Subgroup analysis
In subgroup meta-analysis, supervised walking therapy programs selected by their 
predefined components showed statistically significant improvements in MWD and PFWD 
Figure 4. Heterogeneity funnel plot of the 
mean difference in max-imum walking distance 
(MWD) from the included randomized con-
trolled trials.
Figure 5. Heterogeneity funnel plot of the 
mean difference in pain-free walking distance 
(PFWD) from the included randomized con-
trolled trials.
Table IV. Weighted mean changes in MWD and PFWD sorted by supervised walking therapy 
program component
Component SWT program
Studies
(No.)
Change in MWDa
(meters) P
Studies
(No.)
Change in PFWDa
(meters) P
Pain end point
Pain free 3 257(164-351) .01 4 128(92-165) .01
Mild/moderate pain 11 151(85-217) .01 8 101(63-140) .01
Maximum pain 10 177(97-257) .01 8 100(45-156) .01
Length SWT program (weeks)
Short-term (4-11) 5 123(41-204) .01 5 100(20-179) .01
Medium-term (12-26) 14 223(149-298) .01 11 146(94-197) .01
Long-term (  26) 5 145(27-263) .02 4 109(27-190) .01
Total program volume (minutes)
0-1080 5 105(6-205) .04 4 128(-92-165) 0.1
1081-2340 11 237(151-323) .01 10 146(95-198) .01
2340 8 154(72-236) .01 6 111(52-170) .01
Treadmill use during SWT
No 6 100(2-199) .05 4 57(-13 to 126) .11
Yes 18 200(150-250) .01 16 128(92-165) .01
MWD, Maximum walking distance; PFWD, pain-free walking distance; SWT, supervised walking therapy.
aData are presented as mean (95% confidence interval).
PSM 20180914 Proefschrift Farzin Fakhry BW.indd   38 21-11-18   14:24
Supervised walking therapy for claudication
39
2
compared with their control groups, except for studies in which no treadmill was used 
during the supervised walking therapy and the total supervised walking therapy volume 
was 1080 minutes (Table IV).
Multivariable meta-regression
Multivariable random effects meta-regression, which included all the supervised walking 
therapy components listed in Table IV as covariables, indicated that only a small fraction 
of the heterogeneity in the weighted mean difference in MWD or PFWD between the 
included RCTs could be explained by the covariables entered in the random effects meta-
regression model. In other words, none of the entered components from supervised 
walking therapy programs were independently associated with the improvements in 
MWD or PFWD.
None of the studies had excessive effect on the results, as evaluated by an exclusion 
sensitivity analysis. Furthermore, sensitivity analysis by removing studies with a PEDro 
score 4, did not have a major effect on the results.
DISCUSSION
We evaluated the effectiveness of supervised walking therapy as initial treatment in patients 
with intermittent claudication by performing a systematic review and meta-analysis of 
RCTs that compared supervised walking therapy with non-interventional observation. In 
addition, we performed multivariable meta-regression to identify the most important 
exercise components in supervised walking therapy programs.
Results from our meta-analysis, based on RCTs comparing supervised walking 
therapy with noninterventional observation, demonstrated that supervised walking 
therapy is associated with significantly greater improvement in both MWD and PFWD. 
These results are consistent with two previous systematic reviews that demonstrated that 
supervised exercise therapy improves walking distance compared with unsupervised 
exercise therapy9 or usual care.10 We only included RCTs evaluating walking programs 
and excluded other modes of exercise therapies, such as strength training, cycling, 
pneumatic calf compression, and upper limb exercises, to make the exercise studies more 
comparable.
In multivariable meta-regression, none of the exercise components, including 
treadmill use during training, claudication pain end point used during walking, length 
of the supervised walking therapy program, or total training volume, seemed to be 
independently associated with significant mean improvements in MWD or PFWD. Yet 
in subgroup analysis, there seemed to be a tendency to greater mean improvement 
in MWD and PFWD in supervised walking therapy programs with a middleterm length 
(12-26 weeks) compared with the shorter ( 12 weeks) or longer ( 26 weeks) programs. 
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This tendency was also observed in total training volume (Table IV). This suggests that 
supervised walking therapy between 12 and 26 weeks, with three sessions per week and 
30 minutes of walking per session, would give the best results. However, these results 
were not confirmed by meta-regression analysis and need to be evaluated properly in 
an RCT.
A meta-analysis based on RCTs to evaluate the effect of various exercise components 
on clinical improvement is difficult, given the lack of RCTs directly comparing different 
exercise components. In a previous systematic review from 1995 that combined results 
from RCTs and uncontrolled studies, Gardner et al11 determined that the optimal exercise 
program for patients with intermittent claudication consists of intermittent walking to 
near-maximal pain for at least 6 months. Although the present systematic review used 
results from RCTs only and therefore is less prone to confounding due to selection bias, our 
results do not support these prior recommendations: no single exercise component was 
independently associated with a significant improvement in walking distance. In line with 
the present study, a more recent review by Parmenter et al44 on the same topic concluded 
that improvements in MWD were not related to various components of exercise training; 
however, the focus in the review by Parmenter et al was not on supervised walking therapy 
but on any mode of exercise therapy for patients with intermittent claudication.
The recommended supervised exercise therapy programs,6,7 consisting of walking 30 
to 60 minutes to (maximum) claudication pain three to five times weekly for a duration 
of 3 to 6 months, are usually experienced as very intensive and time-consuming. 
Consequently, these recommended programs are affiliated with low patient compliance 
and high dropout rates.45
In addition to improving walking ability, exercise training is also effective in preventing 
cardiovascular events,8,46 and this can fulfill an important role in cardiovascular risk 
factor management in patients with intermittent claudication by encouraging patients 
to quit smoking and adhere to prescribed medication. Hence, every attempt to increase 
patient compliance with supervised walking therapy programs should be considered and 
evaluated carefully. The results of this systematic review suggest that low-intensity (pain-
free) supervised walking therapy or a shorter training duration, or both, might be as 
equally beneficial as high-intensity exercise programs with a relatively long duration, while 
promoting patient compliance with the supervised walking therapy. However, clinical RCTs 
evaluating each component from supervised walking therapy independently are essential 
to determine the optimal supervised walking therapy protocol, resulting in improvement 
in walking distance and higher patient compliance.
A full economic evaluation of the supervised walking therapy components from 
patient and societal perspectives is necessary to determine the cost-effectiveness of 
different supervised walking therapy programs. van Asselt et al47 evaluated the cost-
effectiveness of supervised exercise therapy compared with “go home and walk” advice 
and concluded that at the willingness-to-pay threshold of €40,000 per quality-adjusted 
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life-year, exercise therapy is likely to be a cost-effective treatment option. This was based 
on exercise therapy consisting of two to three sessions of 30 minutes weekly for 1 year, 
the frequency of which could be adjusted depending on the patient’s progress and need. 
The remaining question is whether a less intensive supervised walking therapy program is 
going to be cost-effective compared with the recommended supervised walking therapy 
programs at regular intensity.
Some limitations of this systematic review should be addressed. The results of the 
systematic review are limited by the methodologic quality of the original studies. The 
mean PEDro score was low (average, 5 points), with most studies not reporting allocation 
concealment or data analysis according to the intention-to-treat principle. The sample 
size of the included studies was relatively small (average, 42 patients), which might have 
resulted in lack of statistical representation or precision in effect estimation. Negative or 
nonsignificant studies with low precision seem to be missing in the funnel plot, which 
might be an indication of selective reporting or publication. Still, performing a “trim and 
fill” procedure by imputing the potentially missing studies did not change our results 
significantly. Another issue was missing data, especially data on compliance or adherence 
to the supervised walking therapy programs were lacking. Next, the studies did not 
use similar standardized treadmill tests to assess the walking distances before and after 
supervised walking therapy. The recommendation is to use a standardized progressive 
tread-mill test with a constant walking speed of 3.2 km/h and gradual increase in inclination 
of 2% every 2 minutes till a maximum grade of 10%.48 However, most of the included 
studies used other treadmill test protocols with varying speed and gradual incline of the 
treadmill, which might have resulted in inaccurate outcome assessment in several RCTs.
Results on the effectiveness of exercise programs from our systematic review 
and previous systematic reviews are based on pooled results from RCTs evaluating 
nonstandardized exercise programs with very diverse training components regarding 
duration, mode, and intensity of the programs. Nevertheless, our results confirm the 
suggestion that, despite the diversity in supervised walking therapy, these studies have 
one thing in common: they all show significant clinical benefits for patients with intermittent 
claudication independent of the frequency, duration, mode, or intensity of the programs.
CONCLUSIONS
This systematic review showed that supervised walking therapy is effective in improving 
MWD and PFWD in patients with intermittent claudication. However, pooled results from 
the RCTs evaluating supervised walking therapy programs did not identify a statistically 
significant association between the improvements in MWD or PFWD and individual 
supervised walking therapy program components.
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Modes of exercise training for intermittent claudication
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ABSTRACT
Background
According to international guidelines and literature, all patients with intermittent 
claudication should receive an initial treatment of cardiovascular risk modification, lifestyle 
coaching, and supervised exercise therapy. In most studies, supervised exercise therapy 
consists of treadmill or track walking. However, alternative modes of exercise therapy have 
been described and yielded similar results to walking. Therefore, the following question 
remains: Which exercise mode gives the most beneficial results?
Objectives
Primary objective: To assess the effects of different modes of supervised exercise therapy 
on the maximum walking distance (MWD) of patients with intermittent claudication.
Secondary objectives: To assess the effects of different modes of supervised exercise 
therapy on pain-free walking distance (PFWD) and health-related quality of life scores 
(HR-QoL) of patients with intermittent claudication.
Search methods
The Cochrane Peripheral Vascular Diseases Group Trials Search Coordinator searched the 
Cochrane Peripheral Vascular Diseases Group Specialised Register (July 2013); CENTRAL 
(2013, Issue 6), in The Cochrane Library; and clinical trials databases. The authors searched 
the MEDLINE (1946 to July 2013) and Embase (1973 to July 2013) databases and reviewed 
the reference lists of identified articles to detect other relevant citations.
Selection criteria
Randomised controlled trials of studies comparing alternative modes of exercise training 
or combinations of exercise modes with a control group of supervised walking exercise 
in patients with clinically determined intermittent claudication. The supervised walking 
programme needed to be supervised at least twice a week for a consecutive six weeks 
of training.
Data collection and analysis
Two authors independently selected studies, extracted data, and assessed the risk of bias 
for each study. Because of different treadmill test protocols to assess the maximum or 
pain-free walking distance, we converted all distances or walking times to total metabolic 
equivalents (METs) using the American College of Sports Medicine (ACSM) walking 
equation.
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Main results
In this review, we included a total of five studies comparing supervised walking exercise 
and alternative modes of exercise. The alternative modes of exercise therapy included 
cycling, strength training, and upper-arm ergometry. The studies represented a sample 
size of 135 participants with a low risk of bias. Overall, there was no clear evidence of 
a difference between supervised walking exercise and alternative modes of exercise in 
maximum walking distance (8.15 METs, 95% confidence interval (CI) -2.63 to 18.94, P = 
0.14, equivalent of an increase of 173 metres, 95% CI -56 to 401) on a treadmill with no 
incline and an average speed of 3.2 km/h, which is comparable with walking in daily life.
Similarly, there was no clear evidence of a difference between supervised walking  exercise 
and alternative modes of exercise in painfree walking distance (6.42 METs, 95% CI -1.52 
to 14.36, P = 0.11, equivalent of an increase of 136 metres, 95% CI -32 to 304). Sensitivity 
analysis did not alter the results significantly.
Quality of life measures showed significant improvements in both groups; however, 
because of skewed data and the very small sample size of the studies, we did not perform 
a meta-analysis for health-related quality of life and functional impairment.
Authors’ conclusions
There was no clear evidence of differences between supervised walking exercise and 
alternative exercise modes in improving the maximum and pain-free walking distance of 
patients with intermittent claudication. More studies with larger sample sizes are needed 
to make meaningful comparisons between each alternative exercise mode and the current 
standard of supervised treadmill walking. The results indicate that alternative exercise 
modes may be useful when supervised walking exercise is not an option for the patient.
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BACKGROUND
Description of the condition
Peripheral arterial occlusive disease (PAOD) is a chronic arterial occlusive disease caused 
by progressive atherosclerosis. Several arterial segments can be affected, such as the 
aorta; iliac; and femoral, popliteal, and tibial arteries in the limbs. The most common 
symptom is intermittent claudication, defined as a cramping pain in the muscles of the 
leg(s) that occurs during exercise and is relieved by a short period of rest. Because of this 
condition, patients have a diminished maximum and pain-free walking capacity, leading 
to diminished health-related quality of life1. The incidence of intermittent claudication 
increases with age, with an annual incidence rate of 0.7%, 3.9%, and 10.6% among 35- to 
44-year-old men, 45- to 54-year-old men, and 55- to 64-year-old men, respectively2. 
In women, the incidence rates are approximately 50% lower2. Intermittent claudication 
restricts patients’ activity and mobility and considerably reduces their health-related 
quality of life1,3. In addition, because of the ongoing generalised atherosclerotic process, 
intermittent claudication is closely associated with cardiovascular morbidity and mortality. 
Patients with intermittent claudication have a five-year all-cause mortality rate of 10% to 
15% and a 20% chance of a non-fatal cardiovascular event4. When intermittent claudication 
progresses to critical limb ischaemia, an even higher mortality rate of 25% after one year 
is found5.
Description of the intervention
Because of the serious health risks, all patients with intermittent claudication should 
receive a multicomponent therapy consisting of cardiovascular risk modification, lifestyle 
coaching, and exercise therapy5. Several randomised controlled trials and systematic 
reviews compared walking exercise supervised by a physical or exercise therapist to non-
supervised exercise, usual care, placebo, single walking advice, endovascular interventions, 
or bypass surgery6-10. The current evidence supports supervised exercise therapy as the 
primary treatment for improvement of walking capacity and health-related quality of 
life in patients with intermittent claudication. Furthermore, community-based supervised 
exercise appears to be at least as efficacious as programmes provided in a hospital 
setting11-13. However, less attention has been paid to the mode of (supervised) exercise. 
Besides walking, alternative modes of supervised exercise training, such as cycling, upper-
extremity cycle ergometer exercise and strength training exist and are associated with a 
significantly improved walking capacity14-16.
How the intervention might work
A number of potential mechanisms have been suggested for the reduced functional 
capacity in intermittent claudication, such as blood flow limitation due to arterial 
obstruction, disruption of endothelial function, altered skeletal muscle phenotype by 
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mitochondrial dysfunction, increased blood viscosity, and inflammatory activation17. 
Exercise has the potential to reverse these pathological events and thereby interrupt the 
clinical course toward disability17.
Why it is important to do this review
In most studies, supervised exercise programmes involve treadmill or track walking that 
is of sufficient intensity to bring on claudication pain. Walking exercise is alternated with 
rest over the course of a 30- to 60-minute session. Exercise therapy for intermittent 
claudication is recommended at least three times a week for three months, although 
there does not seem to be a clear dose-response relationship between exercise volume or 
intensity and symptom relief5,18. Unfortunately, some groups of patients with intermittent 
claudication are not capable of completing the exercise protocol because of concomitant 
comorbidities, such as arthrosis, chronic obstructive pulmonary disease, stroke, or cardiac 
complaints. For these patients, an adjusted protocol or alternative exercise regime may 
be proposed. 
Recently, a systematic review comparing any mode of exercise, whether supervised 
or unsupervised, was published18. It suggested that alternative modes of aerobic exercise, 
other than walking, appear equally beneficial compared to walking exercise, while the 
effects of progressive resistance training and upper body exercise seem only promising. 
The effect size of each exercise mode was calculated and compared to the effect size of 
walking exercise. However, because of heterogeneity, no meta-analysis was performed 
on specific randomised controlled trials (RCTs) comparing the standard of supervised 
walking exercise to alternative exercise regimes. 
Therefore, the question regarding which exercise mode gives the most beneficial 
results in walking distance, health-related quality of life, or both, in patients with 
intermittent claudication remains to be answered. Previous Cochrane systematic reviews 
focused on the effect of exercise compared with usual care and the value of a supervised 
exercise programme in relation to non-supervised exercise7,19. This systematic review will 
determine the effect of alternative exercise modes by analysing randomised controlled 
trials comparing the current standard of supervised walking exercise to alternative modes 
of exercise. Studies focusing on this research topic are increasing, implicating the need for 
a regular update of this review in the upcoming years.
Objectives
Primary objective: To assess the effects of different modes of supervised exercise therapy 
on the maximum walking distance (MWD) of patients with intermittent claudication. 
Secondary objectives: To assess the effects of different modes of supervised exercise 
therapy on pain-free walking distance (PFWD) and health-related quality of life scores 
(HR-QoL) of patients with intermittent claudication.
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METHODS
Criteria for considering studies for this review
Types of studies
We We included parallel-group, randomised controlled trials (RCTs) comparing 
(combinations of) alternative modes of exercise training (for example, ergometry, 
strength training, aerobic exercise, etc.) with supervised walking exercise in patients with 
intermittent claudication. We excluded crossover, factorial, or cluster RCTs.
Types of participants
The study population consisted of adults (18 years and older) with clinically determined 
intermittent claudication, according to Fontaine stage II or Rutherford stages 1 to 3, who 
were considered for conservative treatment. We excluded studies of participants with 
asymptomatic lower-limb atherosclerosis identified by testing. When studies described a 
mixture of asymptomatic and symptomatic participants, we contacted the authors to ask 
if a subanalysis was available. If not, we excluded these studies.
Types of interventions
We included all RCTs comparing alternative modes of exercise training (e.g. arm ergometry, 
strength training, cycling, etc.) or combinations of exercise modes with a control group 
of supervised walking exercise. Supervised walking exercise needed to be supervised at 
least twice a week for a consecutive six weeks of training. We excluded studies reporting 
an exercise programme with a duration of less than six weeks of training or with less than 
two supervised walking sessions a week. 
Since different types of alternative exercise modes are associated with an increased 
walking capacity, we combined all studies with different alternative exercise modes in one 
analysis. However, to analyse the effect of each individual or combined alternative exercise 
modes, we performed a subgroup analysis on the exercise mode (or combination) if 
more than one study was available. We excluded all types of mechanical intermittent 
compression treatments as we did not consider them to be exercise training. Furthermore, 
we did not include studies comparing different types of walking exercise (supervised 
versus unsupervised, community versus hospital-based) or comparisons of different 
walking protocols (low- versus high-frequency training, low- versus high-intensity training, 
different treadmill exercise protocols). 
Types of outcome measures
Primary outcomes
The primary outcome measurement was the maximum walking distance (MWD) measured 
by a treadmill test. Outcome measurements needed to be available at baseline and after 
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at least six weeks of follow up. In case of different treadmill test protocols, we converted 
walking times or distances to total metabolic equivalents (total METs or sum of METs 
during the walking period). 
Secondary outcomes
Secondary outcome measurements were the pain-free walking distance (PFWD) and 
health-related quality of life (HR-QoL) scores. Besides a baseline measurement, results 
needed to be available after at least six weeks of follow up. In case of different treadmill 
test protocols, we converted walking times or distances to METs.
Search methods for identification of studies
We applied no language restrictions.
Electronic searches
The Cochrane Peripheral Vascular Diseases Group Trials Search Coordinator (TSC) 
searched the Cochrane Peripheral Vascular Diseases Group Specialised Register (last 
searched July 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL) 
2013, Issue 6, part of The Cochrane Library, www.thecochranelibrary.com. The Specialised 
Register is maintained by the TSC and is constructed from weekly electronic searches of 
MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The 
full list of the databases, journals and conference proceedings which have been searched, 
as well as the search strategies used are described in the Specialised Register section of 
the Cochrane Peripheral Vascular Diseases Group module in The Cochrane Library www. 
thecochranelibrary.com. 
The TSC searched the following trial databases (July 2013) for details of ongoing and 
unpublished studies using the terms exercise and claudication: 
 – The World Health Organization International Clinical Trials Registry (ICTRP) 
platform (apps.who.int/trialsearch/). 
 – The US National Institutes of Health Ongoing Trials Register (www.clinicaltrials.gov). 
 – The metaRegister of Controlled Trials (www.controlledtrials.com/isrctn/).
Searching other resources
The authors searched MEDLINE (1946 to 15 July 2013) and Embase (1973 to 15 July 2013). 
We reviewed the reference lists of articles identified by the above search strategies to 
identify other relevant citations. 
Data collection and analysis
Selection of studies
GJL and FF independently selected trials for this review. SS and JT confirmed the suitability 
of selected trials for inclusion in the review. We sought additional information for included 
trials, if necessary.
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Data extraction and management
GJL and FF independently extracted data using a standard data collection form created 
for this review. We entered the data into Review Manager (RevMan 5.2). We resolved 
disagreements between the review authors by discussion. SS acted as arbiter if no 
consensus was achievable. The extracted study data consisted of the following: 
 – Study characteristics, including study design, method of randomisation, exclusions 
postrandomisation, publication year, country, and study period; 
 – Baseline characteristics, including number of participants, losses to follow up, mean 
age, gender distribution, and inclusion and exclusion criteria;  
 – Type of interventions, including mode(s) of exercise, duration of programme, 
number of sessions, number of supervised sessions, and exercise protocol; and 
 – The mean maximum walking distance or time, mean painfree walking distance or 
time, and mean quality of life scores at baseline and follow-up periods.
Assessment of risk of bias in included studies
The authors (GJL and FF) assessed the risk of bias for each study as described in the 
Cochrane Handbook for Systematic Reviews of Interventions20 for each of the following 
domains:Randomisation and sequence generation.
 – Allocation concealment.
 – Blinding (of participants, personnel, and outcome assessors).
 – Incomplete outcome data.
 – Selective outcome reporting.
 – Publication and other sources of bias.
For each of the six domains, we assessed risk of bias as ’low’ or ’high’, or as ’unclear’ when 
available information was insufficient to permit judgement on risk of bias.
Measures of treatment effect
To analyse treatment effect, we assessed the MWD, PFWD, and HR-QoL scores after 
participation in the exercise programme. In the case of different treadmill test protocols, 
we converted walking times or distances to total METs (sum of METs during the walking 
period) using the American College of Sports Medicine (ACSM) walking equation21. The 
ACSM walking equation includes the time, speed, and inclination of the treadmill test. 
Since direct conversion of the walking times or distances to METs was not possible 
because of the absence of individual participant data, we simulated a new dataset for each 
study. We used post intervention walking distances and variances from the intervention 
and control group to simulate a new dataset assuming a normal distribution. For each 
simulated individual, we calculated the number of METs using the ACSM walking equation. 
We used the summary measures (mean METs and variances) from each simulated dataset 
as post intervention outcomes from the included studies. 
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Unit of analysis issues
We searched for RCTs with at least six weeks’ duration of training and a parallel-group 
design. We included no crossover trials in this review. In assessment of the primary and 
secondary outcomes, we considered the participant the unit of analysis. 
Dealing with missing data
We expected missing standard deviations for walking distances. In the case of missing 
data, we requested data from the original investigators, if appropriate. We did not impute 
missing outcome data for the primary and secondary outcomes.
Assessment of heterogeneity
For all the outcome measures, we assessed statistical heterogeneity by calculating the 
Q-statistic or Chi2 test (P < 0.10 considered as heterogeneous) and the I2 statistic (I2 
statistic greater than 50% considered as moderate to substantial risk of heterogeneity) in 
order to assess to what degree the data from the included studies were heterogeneous20.
Assessment of reporting biases
In case of sufficient studies (> 10 studies), we planned to assess publication bias with a 
funnel plot with the maximum walking distance on the X axis and the standard error of 
each study on the Y axis20. If there is bias, for example, because smaller studies without 
statistically significant effects remain unpublished, this will lead to an asymmetrical 
appearance of the funnel plot. In this situation, the effect calculated by the meta-analysis 
will tend to overestimate the intervention effect. Therefore, we also planned to evaluate 
funnel plot asymmetry using Begg and Egger tests22,23 performed with Stata statistical 
software24.
Data synthesis
To analyse treatment effect, we used the DerSimonian and Laird random-effects 
model. This model takes the variance between studies and the variance within a study 
into account25. We summarised the data of each study in forest plots and calculated 
summary estimates with a 95% confidence interval. We considered a two-sided P <0.05 as 
statistically significant, except for the test of publication bias for which the recommended 
levels are P <0.10. We performed analyses using RevMan 5.2. 
Subgroup analysis and investigation of heterogeneity
We performed a subgroup analysis of each type of alternative exercise mode if we 
found more than one trial comparing the specific exercise mode with walking exercise. 
Furthermore, because most studies and international guidelines advise a 12-week 
supervised exercise programme, we reported outcomes both at the end of training and 
at 12 weeks of training. Finally, we performed a subgroup analysis on the combination of 
alternative exercise modes in relation to supervised walking exercise.
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Sensitivity analysis
We examined individual study effects on the results by removing each study one at a time 
to examine whether removing a particular study would significantly change the results. In 
addition, we planned to perform sensitivity analyses on the methodological quality of the 
studies. We planned to exclude studies with apparent methodological flaws and risk of 
bias and examine whether removing these studies significantly changed results. 
RESULTS
Results of the search
See Figure 1.
Included studies
We identified 10 publications comparing an alternative exercise regime to supervised 
walking exercise for intermittent claudication. Of these 10 publications, we identified five 
primary studies15,16,26-28. These five randomised controlled trials published in peer-reviewed 
journals fulfilled the inclusion criteria, and we considered these for inclusion in this review. 
Five additional publications described the results of three of the primary studies more 
extensively29-33.
Three trials compared supervised walking exercise to an exercise or progressive 
resistance regime26-28, one trial compared arm ergometry to supervised walking exercise16 
and one trial compared cycling exercise to supervised walking exercise15. These five trials 
randomised a total of 184 participants with intermittent claudication, with 135 participants 
randomised to the treatment arms relevant to this review. The number of participants per 
study was small, with a variation of between 29 and 45 participants. The mean age of the 
participants in the included trials varied between 62.0 and 71.7 years, and all trials included 
both men and women. The trials were conducted in the United States (3), Brazil (1), and 
Australia (1). 
Enrolment criteria were rather homogeneous. All trials included participants if 
a declination in ankle brachial index was present with coinciding limiting or disabling 
symptoms of intermittent claudication. One trial26 assessed claudication symptoms by 
a questionnaire (San Diego Claudication Questionnaire). In all trials, the presence of 
critical limb ischaemia was an exclusion criterion. Participants were also excluded if the 
exercise capacity was limited by another factor than intermittent claudication (e.g. angina, 
chronic obstructive pulmonary disease, arthrosis). In three of the five trials, claudication 
symptoms needed to be stable for, respectively, three months27 six months28, or more 
than 12 months15. Two trials27,28  excluded participants if a revascularisation procedure was 
performed in the previous year. One RCT16 excluded participants if a coronary or lower-
extremity revascularization procedure was performed within the past three months. The 
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two remaining trials15,26 excluded participants if they recently underwent surgery or a 
cardiovascular event. Treatment duration varied between studies ranging from six weeks’ 
training15 ,12-week training16,27,28  to 24-week training periods26.
Excluded studies
After title/abstract screening, we excluded 3626 studies. After full text assessment, we 
excluded another 18 studies for various reasons. We excluded three studies as they were 
not randomised controlled trials34-36. We excluded four studies37-40 as they were meeting 
Figure 1. Study flow diagram.
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posters with a limited description of the methods and results; no articles of these meeting 
posters were published yet. We excluded nine studies40-48 because they did not assess 
(adequate) supervised exercise therapy according to our inclusion criteria for this review. 
Five studies41,43,44,46,49 did not report the primary and secondary outcome measures of 
this review. We excluded one study50 because the outcome measures were unclearly 
described. We tried to contact the authors but did not receive additional information. 
We excluded one study51 because we did not consider the intervention (pole walking) an 
alternative exercise regime in comparison to supervised walking.
Risk of bias in included studies
See Figure 2 for a summary of the risk of bias in each included study.
Allocation
Two studies described adequate sequence generation and allocation concealment by 
means of computer randomisation26,28. Two studies an adequate sequence generation, 
but did not describe the allocation concealment15,16. One study did not describe the 
randomisation process27.
Blinding
In the included studies, participants and direct personnel could not be blinded to the 
intervention (exercise). For this reason, bias could be introduced. However, since all studies 
experienced the same limitation, we considered the risk of bias to be low for all studies. 
Detection bias can be avoided by blinding the outcome assessors. Three studies achieved 
this16,16,28.
Incomplete outcome data
Most studies well-described reasons for missing data, and we considered these plausible 
and well distributed among the groups. One study addressed asymptomatic participants 
with PAOD as well as symptomatic participants26. After contacting the authors, we derived 
the data of the sole symptomatic group with intermittent claudication. However, it is unclear 
which of the missing data described in the article related to the symptomatic group. For 
this reason, we considered the incomplete outcome data in this study to be unclear.
Selective reporting
All studies described relevant outcomes. For three studies15,16,26, we retrieved additional 
outcome data by contacting the authors. 
Other potential sources of bias
Since we identified only five studies, we could not detect publication bias with a funnel 
plot. Additional Begg and Egger tests did also exclude any indication of publication 
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bias (Begg: adjusted Kendall’s score = 4, P = 0.462; Egger: bias 1.11, 95% confidence 
interval (CI) 0.43 to -2.77, P = 0.430). One of the studies26 did not describe the baseline 
characteristics of the subgroup of participants with intermittent claudication. This was 
due to the study setting. (The study included participants with asymptomatic as well 
as symptomatic peripheral arterial disease.) However, we identified no other potential 
sources of bias in the included trials.
Effects of interventions
Walking exercise versus alternative exercise
Maximum walking distance [METs] 
Data for the maximum walking distance (MWD) obtained at the end of each study were 
available in all of the included trials, with a total sample size of 135 participants. We 
calculated the pooled treatment effect after standardising the reported walking distances. 
For this reason, we converted all distances to metabolic equivalents (METs) using the 
American College of Sports Medicine (ACSM) formulas for metabolic calculations. We 
considered the impact of heterogeneity as low with an I2 statistic of 13%. At the end of 
Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for 
each included study
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training, the pooled MWD increased with an overall non-significant effect size of 8.15 
METs (95% confidence interval (CI) -2.63 to 18.94, P = 0.14) in favour of walking exercise. 
This is the equivalent of an increase of 173 metres (95% CI -56 to 401metres) on a treadmill 
with no incline and an average speed of 3.2 km/h, which is comparable with walking in 
daily life (Analysis 1.1). However, because of the width of the CI of the pooled MWD, we 
could not identify any clear evidence of difference between interventions.
Analysis 1. 1 Walking exercise versus alternative exercise, Maximum walking distance at the end 
of training.
Furthermore, we calculated the effect size after 12 weeks of training. After this follow-up 
period, data from three trials on MWD were available with a sample size of 74 
participants16,27,28. We considered the impact of heterogeneity as moderate to substantial 
with an I2 statistic of 52%. In these trials, the pooled MWD increased with a non-significant 
effect size of 13.05 METs (95% CI -11.43 to 37.54, P = 0.30) in favour of walking exercise. 
This correlates with 276 metres (95% CI -242 to 795 metres) on a treadmill with no incline 
and an average speed of 3.2 km/h (Analysis 1.2).
Analysis 1.2. Walking exercise versus alternative exercise, Maximum walking distance after 12 
weeks of training.
Pain-free walking distance [METs] 
Data for the pain-free walking distance (PFWD) obtained at the end of each study were 
available in four of the five included trials, with a total sample size of 116 participants15,16,26-28. 
We calculated the effect after converting the reported walking distances to standardised 
METs. We considered the impact of heterogeneity as moderate with an I2 statistic of 
49%. At the end of training, the PFWD increased with an overall non-significant effect 
size of 6.42 METs (95% CI -1.52 to 14.36, P = 0.11) in favour of walking exercise. This is the 
equivalent of an increase of 136 metres (95% CI -32 to 304 metres) on a treadmill with no 
incline and an average speed of 3.2 km/h, which is comparable with walking in daily life 
(Analysis 1.3). However, because of the width of the CI of the pooled PFWD, we could not 
identify any clear evidence of a difference between interventions.
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ANALYSIS 1.3. Walking exercise versus alternative exercise, Pain-free walking distance at the end 
of training.
Furthermore, we calculated the effect size after 12 weeks of training. After this followup 
period, data for two trials for PFWD were available, with a sample size of 55 participants16,28. 
We considered the impact of heterogeneity as low with an I2 statistic of 0%. In these trials, 
the pooled PFWD increased with a non-significant effect size of 2.37 METs (95% CI -5.81 to 
10.56, P = 0.57) in favour of walking exercise. This correlates with 50 metres (95% CI -123 to 
224 metres) on a treadmill with no incline and an average speed of 3.2 km/h (Analysis 1.4).
Analysis 1.4. Walking exercise versus alternative exercise, Pain-free walking distance after 12 weeks 
of training.
Health-related quality of life (HR-QoL) and functional impairment 
Two of the included studies described HR-QoL and functional impairment26,27. One study 
used the Medical Outcomes Study (MOS) SF-20; another study used the SF-36 Physical 
Functioning score to collect HR-QoL data. Both studies used the Walking Impairment 
Questionnaire (WIQ) to describe functional impairment. 
Data on HR-QoL and functional impairment (WIQ) from one study, with a total sample 
size of 19 participants, showed an increase in HR-QoL with a significant effect size of 
26.50% (95% CI 2.67 to 50.33, P = 0.03) in favour of walking exercise27. WIQ distance 
score increased with an effect size of 2.00% (95% CI -16.04 to 20.04, P = 0.83) in favour of 
walking exercise. WIQ speed score decreased with an effect size of -4.50% (95% CI -27.34 
to 18.34, P = 0.70) in favour of alternative exercise. WIQ stair-climbing score decreased 
with an effect size of -29.50%(95% CI -51.65 to -7.35, P = 0.009) in favour of alternative 
exercise. 
Unfortunately, both the SF-36 Physical Functioning score and WIQ data from the 
second study were not normally distributed. SF-36 Physical Functioning score improved 
in both the strength (n = 14) and treadmill walking group (n = 17), with a median of, 
respectively, 12.5 points (interquartile range = -5.00 to 20.00) and 10.0 points (interquartile 
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range = 5.00 to 20.00), P = 0.811. WIQ distance score improved in both the strength (n 
= 15) and treadmill walking group (n = 15), with a median of, respectively, 14.0 points 
(interquartile range = 1.56 to 26.6) and 7.46 points (interquartile range = -0.36 to 25.0), 
P = 0.431. WIQ speed score improved in both the strength (n = 15) and treadmill walking 
group (n = 16), with a median of, respectively, 3.26 points (interquartile range = -7.61 to 
26.1) and 1.63 points (interquartile range = -3.80 to 28.8), P = 0.736. WIQ stair-climbing 
score improved in the strength training group (n = 15), with a median of, respectively, 12.5 
points (interquartile range = 4.17 to 25.0), while we saw no improvement in the median 
score in the treadmill walking group (n = 16, median score of 0.00 points, interquartile 
range = 0.00 to 14.6), P = 0.13626. Because of the skewed data of one of the studies and 
the small sample size of both studies, we did not transform these data to perform a meta-
analysis of the two studies.
Sensitivity analysis 
We performed a sensitivity analysis to assess whether excluding an individual study 
would significantly change the main results on MWD and PFWD at the end of the study. 
For MWD, removing any individual study did not alter the results significantly, although 
by removing one study28, the MWD increased almost significantly, in favour of walking 
exercise, with an overall effect size of 10.16 METs (95% CI -0.40 to 20.71, P = 0.06). This is 
the equivalent of an increase of 215 metres (95% CI - 8 to 439 metres) on a treadmill with 
no incline and an average speed of 3.2 km/h. For PFWD, removing one of the studies did 
not alter the results significantly, although by removing one study28, the PFWD increased 
almost significantly in favour of walking exercise, with an overall effect size of 8.30 METs 
(95% CI -0.26 to 16.86, P = 0.06). This is the equivalent of an increase of 176 metres (95% 
CI -6 to 357 metres) on a treadmill with no incline and an average speed of 3.2 km/h. 
We did not perform a sensitivity analysis on the methodological quality of the studies 
because of the limited number of studies.
Walking exercise versus alternative exercise 
Maximum walking distance [METs] 
Data for MWD obtained at the end of each study were available in three of the five 
included trials, with a total sample size of 82 participants26-28. We considered the impact 
of heterogeneity as moderate to substantial with an I2 statistic of 52%. At the end of the 
study, the pooled MWD increased with an overall non-significant effect size of 8.11 METs 
(95% CI -11.68 to 27.90, P = 0.42) in favour of walking exercise. This is the equivalent to an 
increase of 172 metres (95% CI -247 to 591 metres) on a treadmill with no incline and an 
average speed of 3.2 km/h, which is comparable with walking in daily life (Analysis 2.1).
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Analysis 2.1. Walking exercise versus strength training, Maximumwalking distance at the end of 
training
Furthermore, we calculated the effect size after 12 weeks of training. After this followup 
period, data for two trials for MWD were available, with a sample size of 49 participants27,28. 
We considered the impact of heterogeneity as substantial with an I2 statistic of 76%. The 
pooled MWD increased with a non-significant effect size of 14.10 METs (95% CI -32.10 to 
60.29, P = 0.55) in favour of walking exercise. This correlates with 299 metres (95% CI 
-680 to 1277 metres) on a treadmill with no incline and an average speed of 3.2 km/h 
(Analysis 2.2).
Analysis 2.2. Walking exercise versus strength training, Maximum walking distance after 12 weeks 
of training.
Pain-free walking distance [METs] 
Data for the PFWD at the end of the study were available in two of the included trials, 
with a total sample size of 63 participants26,28. We considered the impact of heterogeneity 
as low with an I2 statistic of 0%. At the end of the study, the pooled PFWD increased with 
an overall non-significant effect size of 2.66 METs (95% CI -5.06 to 10.39, P = 0.50) in 
favour of walking exercise. This is the equivalent of an increase of 56 metres (95% CI -107 
to 220 metres) on a treadmill with no incline and an average speed of 3.2 km/h, which is 
comparable with walking in daily life (Analysis 2.3).
Analysis 2.3. Walking exercise versus strength training, Pain-free walking distance at the end of 
training.
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Walking exercise versus a combination of exercise modes  
Maximum walking distance [METs] 
Two trials analysed the effect of a combination of exercise modes in relation to supervised 
walking exercise on the MWD16,27. One trial compared a combination of walking exercise 
and arm ergometry to sole walking exercise16. The second trial compared a combination 
of walking exercise and strength training to sole walking exercise27. In total, the two trials 
had a sample size of 41 participants for analysis of the MWD at the end of the studies. We 
considered the impact of heterogeneity as low with an I2 statistic of 0%. The pooled MWD 
increased with an overall non-significant effect size of 9.31METs (95%CI -12.77 to 31.40, P = 
0.41) in favour of sole walking exercise. This is the equivalent of an increase of 197 metres 
(95% CI -270 to 665 metres) on a treadmill with no incline and an average speed of 3.2 
km/h, which is comparable with walking in daily life (Analysis 3.1).
Analysis 3.1. Walking exercise versus a combination of exercise modes , Maximum walking dis-
tance at the end of training
Pain-free walking distance [METs] 
Data for PFWD obtained at the end of each study were available in one of the included 
trials with a total sample size of 25 participants.16 At the end of this study, the PFWD 
increased with an overall non-significant effect size of 3.30 METs (95% CI -6.01 to 12.61, P 
= 0.49) in favour of sole walking exercise. This is the equivalent of an increase of 70 metres 
(95% CI - 127 to 267 metres) on a treadmill with no incline and an average speed of 3.2 
km/h, which is comparable with walking in daily life.
DISCUSSION 
Summary of main results
We included five RCTs in this review, with a total of 135 participants. We could not find any 
clear evidence of a statistical difference in maximum or pain-free walking distance when 
comparing supervised treadmill walking with an alternative exercise regime. Furthermore, 
sensitivity analysis did not significantly alter the results. Regarding quality of life, two 
studies described health related quality of life and functional impairment26,27. However, 
the data in one of the two studies were not normally distributed26. Therefore, we could 
not make any meaningful comparison between studies.
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Overall completeness and applicability of evidence
Although the topic of this review is contemporary18, this review identified only five RCTs, 
with a total of 135 participants. The five RCTs described only three alternative exercise 
modes: strength training26-28, arm-ergometry16 , and cycling exercise15. In total, three of 
the five studies26-28 compared strength training to supervised treadmill walking, for which 
we performed a subanalysis. Eventually, more studies are needed to make meaningful 
comparisons between each alternative exercise mode and the current standard of 
supervised treadmill walking. Therefore, the applicability of the current evidence is limited.
Quality of the evidence
The risk of bias of the included studies was, in general, low (see Figure 2), reflecting 
good methodological quality of the included studies. We could not detect publication 
bias because we could not assess asymmetry in a funnel plot with the limited number of 
studies. The quality of this review is however limited because of the small sample size of 
135 participants. At analysis, we experienced some heterogeneity in Analysis 1.2, Analysis 
2.1, and Analysis 2.2 using the I2 statistic and in Analysis 2.2 using the Q-statistic or Chi2 
test. Sensitivity analysis did not significantly alter the results of the review.
Potential biases in the review process
We tried to limit all potential biases in the review process. To limit bias and make a 
meaningful comparison, we standardised maximum walking distance (MWD) and pain-
free walking distance (PFWD) from each study by converting walking distances to total 
metabolic equivalents (METs) according to the American College of Sports Medicine 
(ACSM) formulas for metabolic calculations21. However, direct conversion of the walking 
times or distances to METs was not possible due to the absence of individual participant 
data. We therefore simulated a new dataset for each study to make a meaningful 
comparison. It is unclear to what extent this could have biased our findings. 
We excluded one study solely because it did not report the correct outcome 
measures49. Although we were careful to ascertain that relevant outcomes were not 
available because they were not measured rather than not reported, this could be a 
potential bias in the review process. In future updates, we will pay further attention to this 
potential source of bias
Agreements and disagreements with other studies or reviews
We agree with a previous published systematic review 18 that there was no clear evidence 
of difference between alternative exercise modes and supervised walking exercise for 
intermittent claudication. Results seem promising, but additional studies are urgently 
needed to validate these exercise modes in relation to the standard of supervised walking 
exercise.
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AUTHOR’S CONCLUSIONS
Implications for practice
Few studies were found and there was no clear evidence of a difference between supervised 
walking exercise and alternative exercise modes. More studies with larger sample sizes are 
needed to make meaningful comparisons between each alternative exercise mode and 
the current standard of supervised treadmill walking. The results indicate that alternative 
exercise modes may be useful when supervised walking exercise is not an option for the 
patient.
Implications for research
More studies are urgently needed to make meaningful comparisons between each 
alternative exercise mode and the current standard of supervised treadmill walking.
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CHARACTERISTICS OF STUDIES
Characteristics of included studies 
McDermott 2009
Methods RCT
Participants 1009 participants with asymptomatic and symptomatic PAOD were assessed for 
eligibility; 156 participants were randomised; after contacting authors, 33 ran-
domised participants were affected by intermittent claudication
Interventions Group 1: 24 weeks of supervised treadmill walking
Group 2: 24 weeks of supervised lower-extremity resistance training
Group 3 (control group): 11 nutritional information sessions over 6 months
Outcomes 6-minute walk test, Short physical performance battery, Brachial artery flow-
mediated dilation, Physical activity (accelerometry), Maximum treadmill walking 
time, Treadmill time to onset of leg symptoms, SF-36 physical functioning score, 
Walking Impairment Questionnaire, Knee extension isometric strength/power, 
Plantarflexion isometric strength
Notes We contacted the authors for more information regarding study results for the 
subgroup of participants with intermittent claudication
Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Low risk Participants were randomised by computer using a randomly 
permuted block method. Randomisation was stratified by the 
presence versus absence of intermittent claudication
Allocation concealment 
(selection bias)
Low risk Participants were randomised by computer using a randomly 
permuted block method
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
Low risk In all of the included studies, participants and direct person-
nel could not be blinded to the intervention (exercise). For this 
reason, bias could be introduced. However, since all studies 
experienced the same limitation, we considered the risk of bias 
to be low for all studies
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Low risk Examiners were blinded to participant group assignment
Incomplete outcome 
data (attrition bias) 
All outcomes
Unclear risk Intention-to-treat analyses were performed for dropouts. Anal-
yses were repeated using multiple imputation for persons who 
died or dropped out before completing 6-month follow-up test-
ing. However, because of the study setting, it is not clear which 
participants with intermittent claudication (instead of asympto-
matic peripheral arterial disease) dropped out. The paper stated 
that missing data at follow-up were more common in more frail 
participants. On the other hand, the authors performed a sensi-
tivity analysis and showed that the missing data were not likely to 
have significantly altered the findings
Selective reporting 
(reporting bias)
Low risk All relevant outcomes were described. Although not all sec-
ondary outcomes were mentioned in the trial registration, all 
outcomes mentioned in the study protocol were reported in the 
final draft of the paper
Other bias Unclear risk Because of the study setting (the study included participants 
with asymptomatic or symptomatic peripheral arterial disease), 
the baseline characteristics of the subgroup of participants with 
intermittent claudication were not described. We identified no 
other forms of bias
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Regensteiner 1996
Methods RCT
Participants 44 participants evaluated: 15 were excluded before randomisation; 29 participants 
were enrolled and randomised
Interventions Group 1: 12 weeks of supervised walking exercise. Secondly, 12 weeks of additional 
supervised walking exercise
Group 2: 12 weeks of strength training. Secondly, 12 weeks of additional super-
vised walking exercise
Group 3 (control group): no treatment for 12 weeks. Secondly, 12 weeks of a com-
bination of supervised walking exercise and strength training
Outcomes Peak treadmill walking time, Ankle brachial indices (in rest and after exercise), 
Walking Impairment Questionnaire score, Physical Activity Recall score, Medical 
Outcomes Study Questionnaire score, Vitalog activity monitor
Notes -
Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Unclear risk Not described
Allocation concealment 
(selection bias)
Unclear risk Not described
Blinding of participants 
and personnel (perfor-
mance bias)
All outcomes
Low risk In all of the included studies, participants and direct person-
nel could not be blinded to the intervention (exercise). For this 
reason, bias could be introduced. However, since all studies 
experienced the same limitation, we considered the risk of bias 
to be low for all studies
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Unclear risk To minimise the potential for bias in the self-evaluation of walk-
ing ability and functional status, questionnaires were adminis-
tered before the treadmill test. Thus, participants’ questionnaire 
responses were not influenced by their treadmill exercise perfor-
mance. In addition, the interviewer and participant were blinded 
to previous questionnaire scores.
The paper did not describe whether examiners were blinded to 
participant group assignment
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk 2 participants in the control group were not available for follow-
up at the 12-week evaluation. They were excluded from further 
analysis. In the supervised walking and strength training group, 
no missing outcome data were described
Selective reporting 
(reporting bias)
Low risk All relevant outcomes were described
Other bias Low risk No significant differences in baseline characteristics were found. 
We identified no other forms of bias
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Ritta‐Dias 2010
Methods RCT
Participants 34 participants were randomised; 4 participants did not complete training; 30 
participants completed the study protocol (15 per group)
Interventions Group 1: 12 weeks of supervised treadmill exercise
Group 2: 12 weeks of strength training
Outcomes Initial claudication distance, Total walking distance, Peak VO₂, VO₂ at the first 
stage of treadmill test, Ischaemic window, Leg strength with lower ABI, Leg 
strength with higher ABI
Notes No intention-to-treat analysis
Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Low risk Randomisation was performed by computer random number 
generation
Allocation concealment 
(selection bias)
Low risk Randomisation was performed by computer random number 
generation
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
Low risk In all of the included studies, participants and direct person-
nel could not be blinded to the intervention (exercise). For this 
reason, bias could be introduced. However, since all studies 
experienced the same limitation, we considered the risk of bias 
to be low for all studies
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Low risk Participants were evaluated at baseline (pre-training) and after 12 
weeks of exercise training (post-training) by a physician who was 
blinded to the exercise programme performed by participants
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk 4 participants (2 in the strength training groups and 2 in the 
walking exercise groups) did not complete the training pro-
grammes for the following reasons: inguinal hernia (n = 1), gas-
trointestinal infection (n =1), ongoing treatment for lung cancer 
(n = 1), and diagnosis of abdominal aneurysm (n = 1)
Although no intention-to-threat analysis was performed, reasons 
for missing data were plausible and well distributed among 
intervention groups
Selective reporting 
(reporting bias)
Low risk All relevant outcomes were described in the study results
Other bias Low risk No significant differences in baseline characteristics were found. 
We identified no other forms of bias
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Sanderson 2006
Methods RCT
Participants 694 participants were assessed for eligibility; 43 participants were randomised
Interventions Group 1: 6 weeks of supervised treadmill walking
Group 2: 6 weeks of supervised cycling
Group 3 (control group): cardiovascular risk management and exercise advice
Outcomes Maximum walking time, Pain-free walking time, Maximum cycling time, Pain-free 
cycling time, Submaximal and peak heart rate/VO₂/respiratory exchange ratio/
minute ventilation
Notes We contacted the authors and received relevant outcome data, which were not 
clearly described in the paper
Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Low risk A closed-envelope system was used to randomise participants 
from the stratified groups to a control group, a cycle-training 
group, or a treadmill training group
Allocation concealment 
(selection bias)
Unclear risk Not described
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
Low risk In all of the included studies, participants and direct person-
nel could not be blinded to the intervention (exercise). For this 
reason, bias could be introduced. However, since all studies 
experienced the same limitation, we considered the risk of bias 
to be low for all studies
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Unclear risk No blinding of outcome assessment was described
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk 1 participant in the treadmill training group withdrew after 1 week 
of training. The baseline data have been omitted
Selective reporting 
(reporting bias)
Low risk Relevant outcome data for this review (maximum and pain-free 
walking time) were only presented in a figure; no numerical data 
were given. However, after contacting the authors, we collected 
these data
Other bias Low risk No significant differences in baseline characteristics were found. 
We identified no other forms of bias
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Treat‐Jacobson 2009
Methods RCT
Participants 102 participants were assessed for eligibility; 45 participants were randomised
Interventions Group 1: 12 weeks of arm ergometry
Group 2: 12 weeks of supervised treadmill walking
Group 3: 12 weeks of a combination of arm ergometry and supervised treadmill 
walking
Group 4 (control group): usual care (cardiovascular management and exercise 
advice)
Outcomes Maximum walking distance, Pain-free walking distance, Resting ankle-brachial 
index/heart rate/blood pressure, Functional capacity (Peak VO₂)
Notes The study paper mentioned only the change in walking distances. To retrieve all 
data, we contacted the authors and received the exact outcome data at follow-up
Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Low risk Eligible participants were randomised by simple randomisation 
tables to 1 of the 4 study groups
Allocation concealment 
(selection bias)
Unclear risk Not described
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
Low risk In all of the included studies, participants and direct person-
nel could not be blinded to the intervention (exercise). For this 
reason, bias could be introduced. However, since all studies 
experienced the same limitation, we considered the risk of bias 
to be low for all studies
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Low risk The physician supervising the treadmill tests was blinded to 
treatment group assignment. However, other staff assisting with 
testing were not blinded. To mitigate for this limitation, care was 
taken to ensure standardisation of exercise-testing protocols
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk Incomplete outcome data are well described and equally 
distributed among intervention groups. 4 of the 45 participants 
withdrew from the study before completing exercise training 
(2 participants in the arm- ergometry group and 2 participants 
in the treadmill walking group). Therefore, only 41 participants 
completed the 12-week follow-up. 31 participants completed the 
24-week follow-up
Selective reporting 
(reporting bias)
Low risk All relevant outcomes were described in the study results
Other bias Low risk No significant differences in baseline characteristics were found. 
We identified no other forms of bias
ABI: ankle brachial index.
RCT: randomised controlled trial.
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Characteristics of excluded studies 
Study Reason for exclusion
Collins 2012 Alternative exercise regime
Dedes 2010 Meeting poster; no journal article available
Gardner 2011 Commentary on other journal article; not a RCT
Jones 1996 Outcome measures unclearly described; no information from authors
Kim 2006 Commentary on other journal article; not a RCT
Kuwabara 2010 Meeting poster; no article available
Nawaz 2001 No intervention group with adequate supervised walking therapy; no correct 
outcome measures
Ornelas 2011 Meeting poster; no article available
Parr 2009 No intervention group with adequate supervised walking therapy
Roitman 2010 Editorial; not a RCT
Saxton 2008 No control group with adequate SET, no correct outcome measures
Saxton 2011 No control group with adequate SET, no correct outcome measures (MWD 
assessed by shuttle-walk test instead of protocolised treadmill test)
Tebbutt 2011 No control group with adequate SET
Treat-Jacobson 2011 No correct outcome measures
Treat-Jacobson 2012 Meeting poster; no journal article available; no control group with adequate SET
Walker 2000 No control group with adequate SET; no correct outcome measures (no treadmill 
test)
Wang 2008 No control group with SET
Zwierska 2005 No control group with adequate SET
MWD: maximum walking distance.
RCT: randomised controlled trial.
SET: supervised exercise therapy.
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Characteristics of ongoing studies 
NCT00895635
Trial name or title Exercise training to reduce claudication: arm ergometry versus treadmill walking.
Evaluating two exercise training programs to reduce leg pain in people with 
peripheral arterial disease (The EXERT study)
Methods Allocation: randomised
End point classification: efficacy study
Intervention model: parallel assignment
Masking: single-blind (outcomes assessor)
Primary purpose: treatment
Participants 150 participants of both gender, 18 to 90 years old, who comply with the inclusion 
and exclusion criteria
Inclusion criteria
• Has lifestyle-limiting claudication
• Able to walk on a treadmill at 2 mph
• Able to perform arm-ergometry exercise
• Able to complete a 12-week exercise programme
Exclusion criteria
• Physical activities are limited for reasons other than claudication
• Uncontrolled high blood pressure
• Uncontrolled diabetes
• Unstable coronary heart disease
• Ischaemic rest pain or tissue loss
• Recent (in the 3 months before study entry) coronary or peripheral 
revascularisation
Interventions Study arms:
Experimental: treadmill exercise training
Participants will take part in a 12-week supervised treadmill exercise training 
programme
Intervention: behavioural: treadmill exercise training
Experimental: arm-ergometry exercise training
Participants will take part in a 12-week supervised aerobic arm-ergometry exer-
cise training programme
Intervention: behavioural: arm-ergometry exercise training
Active comparator: usual care control group
Participants will receive usual care for PAD from their doctor
Intervention: behavioural: usual care
Outcomes Primary outcome measures
• Maximal walking distance (time-frame: measured at baseline and weeks 6, 12, 
and 24)
• Pain-free walking distance (time-frame: measured at baseline and weeks 6, 12, 
and 24)
• Secondary outcome measures
• Limb blood flow (time-frame: measured at baseline and weeks 6, 12, and 24)
• Cardiovascular function (time-frame: measured at baseline and weeks 6, 12, 
and 24)
• Quality of life (time-frame: measured at baseline and weeks 6, 12, and 24)
Starting date January 2009
Contact information Contact: Diane J Treat-Jacobson, PhD, RN612-624-7613treat001@umn.edu
Contact: Laura N Kirk, PhD, RN612-626-4687kirk0013@umn.edu
Notes -
mph: miles per hour.
PAD: peripheral arterial disease.
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ABSTRACT
Background
Intermittent claudication is the classic symptomatic form of peripheral arterial disease 
affecting an estimated 4.5% of the general population aged 40 years and older. Patients 
with intermittent claudication experience limitations in their ambulatory function resulting 
in functional disability and impaired quality of life (QoL). Endovascular revascularisation 
has been proposed as an effective treatment for patients with intermittent claudication 
and is increasingly performed.
Objectives
The main objective of this systematic review is to summarise the (added) effects of 
endovascular revascularisation on functional performance and QoL in the management 
of intermittent claudication.
Search methods
For this review the Cochrane Vascular Information Specialist (CIS) searched the Specialised 
Register (February 2017) and the Cochrane Central Register of Controlled Trials (CENTRAL; 
2017, Issue 1). The CIS also searched trials registries for details of ongoing and unpublished 
studies.
Selection criteria
Randomised controlled trials (RCTs) comparing endovascular revascularisation 
(± conservative therapy consisting of supervised exercise or pharmacotherapy) versus no 
therapy (except advice to exercise) or versus conservative therapy (i.e. supervised exercise 
or pharmacotherapy) for intermittent claudication.
Data collection and analysis
Two review authors independently selected studies, extracted data, and assessed the 
methodological quality of studies. Given large variation in the intensity of treadmill 
protocols to assess walking distances and use of different instruments to assess QoL, we 
used standardised mean difference (SMD) as treatment effect for continuous outcome 
measures to allow standardisation of results and calculated the pooled SMD as treatment 
effect size in meta-analyses. We interpreted pooled SMDs using rules of thumb (< 0.40 
= small, 0.40 to 0.70 = moderate, > 0.70 = large effect) according to the Cochrane 
Handbook for Systematic Reviews of Interventions. We calculated the pooled treatment 
effect size for dichotomous outcome measures as odds ratio (OR).
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Main results
We identified ten RCTs (1087 participants) assessing the value of endovascular 
revascularisation in the management of intermittent claudication. These RCTs compared 
endovascular revascularisation versus no specific treatment for intermittent claudication 
or conservative therapy or a combination therapy of endovascular revascularisation 
plus conservative therapy versus conservative therapy alone. In the included studies, 
conservative treatment consisted of supervised exercise or pharmacotherapy with 
cilostazol 100 mg twice daily. The quality of the evidence ranged from low to high and 
was downgraded mainly owing to substantial heterogeneity and small sample size.
Comparing endovascular revascularisation versus no specific treatment for intermittent 
claudication (except advice to exercise) showed a moderate effect on maximum walking 
distance (MWD) (SMD 0.70, 95% confidence interval (CI) 0.31 to 1.08; 3 studies; 125 
participants; moderate-quality evidence) and a large effect on pain-free walking distance 
(PFWD) (SMD 1.29, 95% CI 0.90 to 1.68; 3 studies; 125 participants; moderate-quality 
evidence) in favour of endovascular revascularisation. Long-term follow-up in two studies 
(103 participants) showed no clear differences between groups for MWD (SMD 0.67, 95% 
CI -0.30 to 1.63; low-quality evidence) and PFWD (SMD 0.69, 95% CI -0.45 to 1.82; low-
quality evidence). The number of secondary invasive interventions (OR 0.81, 95% CI 0.12 to 
5.28; 2 studies; 118 participants; moderate-quality evidence) was also not different between 
groups. One study reported no differences in disease-specific QoL after two years.
Data from five studies (n = 345) comparing endovascular revascularisation versus 
supervised exercise showed no clear differences between groups for MWD (SMD -0.42, 
95% CI -0.87 to 0.04; moderate-quality evidence) and PFWD (SMD -0.05, 95% CI - 0.38 
to 0.29; moderate-quality evidence). Similarliy, long-term follow-up in three studies (184 
participants) revealed no differences between groups for MWD (SMD -0.02, 95% CI 
-0.36 to 0.32; moderate-quality evidence) and PFWD (SMD 0.11, 95% CI -0.26 to 0.48; 
moderate-quality evidence). In addition, high-quality evidence showed no difference 
between groups in the number of secondary invasive interventions (OR 1.40, 95% CI 0.70 
to 2.80; 4 studies; 395 participants) and in disease-specific QoL (SMD 0.18, 95% CI -0.04 
to 0.41; 3 studies; 301 participants).
Comparing endovascular revascularisation plus supervised exercise versus supervised 
exercise alone showed no clear differences between groups for MWD (SMD 0.26, 95% 
CI -0.13 to 0.64; 3 studies; 432 participants; moderate-quality evidence) and PFWD (SMD 
0.33, 95% CI -0.26 to 0.93; 2 studies; 305 participants; moderate-quality evidence). Long-
term follow-up in one study (106 participants) revealed a large effect on MWD (SMD 
1.18, 95% CI 0.65 to 1.70; low-quality evidence) in favour of the combination therapy. 
Reports indicate that disease-specific QoL was comparable between groups (SMD 0.25, 
95% CI -0.05 to 0.56; 2 studies; 330 participants; moderate-quality evidence) and that the 
number of secondary invasive interventions (OR 0.27, 95% CI 0.13 to 0.55; 3 studies; 457 
participants; high-quality evidence) was lower following combination therapy.
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Two studies comparing endovascular revascularisation plus pharmacotherapy 
(cilostazol) versus pharmacotherapy alone provided data showing a small effect on MWD 
(SMD 0.38, 95% CI 0.08 to 0.68; 186 participants; high-quality evidence), a moderate effect 
on PFWD (SMD 0.63, 95% CI 0.33 to 0.94; 186 participants; high-quality evidence), and a 
moderate effect on disease-specific QoL (SMD 0.59, 95% CI 0.27 to 0.91; 170 participants; 
high-quality evidence) in favour of combination therapy. Long-term follow-up in one 
study (47 participants) revealed a moderate effect on MWD (SMD 0.72, 95% CI 0.09 
to 1.36; P = 0.02) in favour of combination therapy and no clear differences in PFWD 
between groups (SMD 0.54, 95% CI -0.08 to 1.17; P = 0.09). The number of secondary 
invasive interventions was comparable between groups (OR 1.83, 95% CI 0.49 to 6.83; 199 
participants; high-quality evidence).
Authors’ conclusions
In the management of patients with intermittent claudication, endovascular revascularisation 
does not provide significant benefits compared with supervised exercise alone in terms of 
improvement in functional performance or QoL. Although the number of studies is small 
and clinical heterogeneity underlines the need for more homogenous and larger studies, 
evidence suggests that a synergetic effect may occur when endovascular revascularisation 
is combined with a conservative therapy of supervised exercise or pharmacotherapy with 
cilostazol: the combination therapy seems to result in greater improvements in functional 
performance and in QoL scores than are seen with conservative therapy alone.
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BACKGROUND
Description of the condition
Lower extremity peripheral arterial disease (PAD) is a manifestation of systemic 
atherosclerosis and is considered a major cause of morbidity in the elderly population.1 
Intermittent claudication, the most frequent symptomatic presentation of PAD, is 
defined as discomfort in the legs with exertion that resolves after a short period of rest. 
Intermittent claudication is highly prevalent in Western countries, affecting an estimated 
4.5% of the general population aged 40 years and older2, and is likely to become more 
prevalent given the ageing population. Although individuals with claudication have a 
relatively benign prognosis for their affected limb, with a major amputation risk of only 
1% to 3% over a five-year period2, their functional performance deteriorates significantly, 
and this results in a sedentary lifestyle3, along with severely limited quality of life (QoL)4,5. 
Additionally, claudication is associated with significantly increased risk of all-cause and 
cardiovascular mortality independent of other atherosclerotic risk factors6,7.
Description of the intervention
Treatment of intermittent claudication consists of multiple components that focus on 
preventing future cardiovascular events and related mortality, as well as on ameliorating 
claudication symptoms. Pharmacotherapy and exercise therapy are established as 
effective first-line conservative treatment options, improving walking distance and QoL in 
patients with claudication8-10. However, in clinical practice, endovascular revascularisation 
is considered an attractive first-line alternative owing to its immediate effect and relatively 
low complication rates. Although both exercise therapy and endovascular revascularisation 
are effective in improving symptoms, it should be noted that neither therapy completely 
removes the disability in most patients11. In 1964 Dotter and Judkins first performed and 
reported on endovascular revascularisation of the lower extremities12. Since that time, 
important technological developments including the introduction of balloon angioplasty 
and drugeluting balloons and stents has advanced endovascular revascularisation as a 
safe and durable treatment option for management of symptomatic PAD. Endovascular 
revascularisation is performed with the patient under local anaesthesia, and access to the 
stenosed or occluded peripheral artery is usually gained via the common femoral artery. 
Subsequently, an angioplasty procedure that involves (balloon) dilatation of a stenosed 
peripheral artery or recanalisation of an occluded peripheral artery is performed. This 
is followed by stent placement if suboptimal results are achieved with angioplasty 
only13. After a successful endovascular revascularisation procedure, patients are usually 
ambulatory on the same day and are able to resume all normal activities within a few 
days. Furthermore, procedure-related morbidity and mortality is reported to be lower 
than 0.5%14, and haematoma at the puncture site and embolization are reported as the 
most common procedure related complications.
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How the intervention might work
After successful revascularisation, whereby the obstruction or occlusion in the peripheral 
artery is resolved and improved blood flow is restored, arterial perfusion in the lower 
extremity improves significantly. This is confirmed by significant improvement in the ankle 
brachial index (ABI) immediately after the procedure. Randomised controlled trials (RCTs) 
have demonstrated the effectiveness of endovascular revascularisation in improving 
functional performance (i.e. walking distance and ABI) and QoL in individuals with 
intermittent claudication16-18.
Why it is important to do this review
Intermittent claudication is a serious lifestyle-limiting symptom of PAD that has a large 
impact on patients’ functional performance and QoL. Conservative treatment strategies, 
including pharma-cotherapy and supervised exercise therapy, are recommended as first-
line therapy for claudication2,19. Yet their value in clinical practice remains uncertain, as 
medical drugs for claudication (e.g. cilostazol, pentoxifylline, naftidro-furyl) have limited 
effects20, and supervised exercise programmes are underutilised in clinical practice owing 
to limited access21, reimbursement issues, and poor patient compliance8. Consequently, 
researchers are noting an enormous increase in the use of endovascular revascularisation 
as first-line therapy for claudication22,23. Nonetheless, the (long-term) effectiveness of 
endovascular revascularisation as first-line therapy for intermittent claudication remains 
debatable. The only Cochrane review on this topic, which included two studies with a 
total of 98 participants comparing angioplasty versus non-surgical therapy, concluded 
that limited data suggest short-term benefit in favour of angioplasty24. Since the last 
update of this review, new randomised trials assessing the efficacy of endovascular 
revascularisation compared with conservative treatment have published their findings. 
Furthermore, new clinical studies have investigated the combination of exercise therapy 
and endovascular revascularisation, which takes advantage of immediate short-term 
effects of revascularisation and long-term benefits of exercise therapy17,25,26. However, 
clinical studies rarely have sufficient power to detect intervention effectiveness in terms 
of clinical outcomes such as functional performance, QoL, or cardiovascular events. 
Therefore, a Cochrane review identifying these studies systematically, evaluating their 
results independently, and updating results when new studies are published is important 
for reducing uncertainty about the (added) value of endovascular revascularisation in the 
management of patients with intermittent claudication.
Objectives
The main objective of this systematic review is to summarise the (added) effects of 
endovascular revascularisation on functional performance and QoL in the management 
of intermittent claudication.
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METHODS
Criteria for considering studies for this review
Types of studies
We systematically searched for and included only RCTs with parallel-group design 
comparing outcomes of endovascular revascularisation (with and without conservative 
therapy) versus no specific therapy or versus conservative therapy (i.e. supervised exercise 
or pharmacotherapy) in patients with intermittent claudication.
We included only studies comparing endovascular revascularisation (± conservative 
therapy) versus conservative therapies or no specific therapy for intermittent 
claudication. We excluded studies providing any kind of surgical revascularisation in the 
comparison group. We also excluded studies comparing different types of endovascular 
revascularisation procedures (e.g. angioplasty vs angioplasty plus stenting).
Types of participants
Patients with stable intermittent claudication, according to Rutherford category 1 to 
3 or Fontaine stage II2, who are eligible for both endovascular revascularisation and 
conservative management.
Types of interventions
In the intervention group, participants underwent endovascular revascularisation (± 
conservative therapy). We considered all percutaneous endovascular revascularisation 
procedures including angioplasty (any type, e.g. balloon, laser) or angioplasty plus 
(selective) stent placement (any type of stent including drugeluting) for atherosclerotic 
lesion(s) in arteries of the lower extremity. In the comparison group, participants received 
only conservative therapy or no specific therapy for intermittent claudication. Conservative 
therapy included specific pharmacotherapy for intermittent claudication (e.g. cilostazol, 
pentoxifylline, naftidrofuryl) or supervised exercise therapy.
We considered the following comparisons.
 – Endovascular revascularisation versus no specific therapy for intermittent 
claudication except verbal advice to exercise.
 – Endovascular revascularisation versus conservative therapy (pharmacotherapy or 
supervised exercise).
 – Endovascular revascularisation plus conservative therapy versus conservative 
therapy.
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When investigators provided cardiovascular risk factor modification (e.g. lipid control, 
hypertension control, anti-smoking advice) in the intervention group, it was also provided 
equally in the comparison group.
Types of outcome measures
Primary outcomes
 – Functional performance outcomes
• Maximum walking distance (MWD), as assessed on a treadmill
• Pain-free walking distance (PFWD), as assessed on a treadmill
 – Secondary invasive interventions during follow-up
• Endovascular or surgical revascularisation
• Amputation
Secondary outcomes
 – Quality of life, including health-related (general and disease-specific) QoL measures
 – Procedure related complications (e.g. local haematoma, artery dissection, 
embolisation)
 – Cardiovascular events (e.g. myocardial infarction, stroke)
 – Functional performance measures not assessed on a treadmill (e.g. six-minute walk 
test, selfreported walking distance)
 – Mortality
Search methods for identification of studies
We applied no language restrictions.
Electronic searches
The Cochrane Vascular Information Specialist (CIS) searched the following databases for 
relevant trials.
 – Cochrane Vascular Specialised Register (21 February 2017).
 – Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1) via the 
Cochrane Register of Studies Online.
The Cochrane Vascular Specialised Register is maintained by the CIS and is constructed 
from weekly electronic searches of MEDLINE Ovid, Embase Ovid, the Cumulative Index 
to Nurs-ing and Allied Health Literature (CINAHL), and the Allied and Complementary 
Medicine Database (AMED), and through handsearching of relevant journals. We have 
provided the full list of databases, journals, and conference proceedings searched, as well 
as the search strategies used, in the Specialised Register section of the Cochrane Vascular 
Module in the Cochrane Library (www.cochranelibrary.com).
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The CIS also searched the following trials registries for details of ongoing and 
unpublished studies (21 February 2017).
 – ClinicalTrials.gov (www.clinicaltrials.gov).
 – World Health Organization International Clinical Trials Registry Platform (www.who.
int/trialsearch).
 – International Standard Randomised Controlled Trial Number (ISRCTN) Register 
(www.isrctn.com/)
Searching other resources
We handsearched the reference lists of all eligible studies for additional relevant studies.
Data collection and analysis
Selection of studies
Two review authors (FF and HF) initially selected identified studies independently upon 
reviewing titles and abstracts. Final selection was based on full-text evaluation of selected 
studies by the two review authors (FF and HF) working independently. Review authors 
discussed and resolved disagreements by consensus. If no consensus was reached, a third 
review author (MH) acted as arbiter.
Data extraction and management
Two review authors (FF and HF) extracted all required data from each included study using 
a standardised form, which consisted of (1) study characteristics including study design, 
year of publication, study location, source of funding, sample size estimation, follow-up, 
and applied inclusion and exclusion criteria; (2) participant baseline characteristics 
including number of participants in each group, mean age, and gender distribution; (3) 
intervention characteristics, compliance, and losses to follow-up; and (4) primary and 
secondary outcomes, as specified under Types of outcome measures.
Assessment of risk of bias in included studies
Two review authors (FF and HF) independently assessed the methodological quality 
of included studies, as described in the Cochrane Handbook for Systematic Reviews of 
Interventions27, for the following domains.
 – Randomisation and sequence generation.
 – Allocation concealment.
 – Blinding (of participants, personnel, and outcome assessors).
 – Incomplete outcome data.
 – Selective outcome reporting.
 – Publication and other sources of bias.
For each of the six domains, we assessed risk of bias as ’low’ or ’high’, or as ’unclear’ when 
available information was insufficient to permit judgement on risk of bias.
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Measures of treatment effect
To analyse the treatment effect of endovascular revascularisation in each study for 
continuous outcome measures, including the primary outcomes MWD and PFWD and the 
secondary outcome QoL, we extracted the value of each outcome measure at different 
time points (6 to 12 months and over the long term) for both intervention and comparison 
groups. For studies reporting treadmill walking time instead of treadmill walking distance, 
we calculated MWD and PFWD by converting walking time to distance using the reported 
treadmill speed.
Given large variation in the intensity of treadmill protocols to assess MWD and PFWD 
and use of different instruments to assess QoL in each study, we used standardised mean 
differences (SMDs) and 95% confidence intervals (CIs) as treatment effects for these 
outcome measures to allow standardisation of results to a uniform scale. We calculated 
the pooled SMD, which is the pooled treatment difference between groups normalised to 
the pooled standard deviation of the difference, as treatment effect size in meta-analysis. 
We interpreted pooled SMDs using rules of thumb (< 0.40 = small effect, 0.40 to 0.70 
= moderate effect, > 0.70 = large effect), as described in the Cochrane Handbook for 
Systematic Reviews of Interventions27.
For dichotomous outcome measures, including secondary invasive intervention, 
procedurerelated complications, cardiovascular events, or death during follow-up in each 
treatment group, we calculated odds ratios (ORs) and corresponding 95% CIs as measures 
of treatment effect, if appropriate.
Unit of analysis issues
In this systematic review, we included only RCTs with parallel-group design. The unit of 
randomisation was the individual participant.
Dealing with missing data
In the case of missing data on dropouts, withdrawals, and outcome measures, we 
contacted the original investigators and requested data when appropriate. If studies 
reported medians and interquartile ranges (IQRs) as measures of variance for walking 
distance, we converted these values to means and standard deviations (SDs), assuming 
a normal distribution for walking distance so we could include these studies in the meta-
analysis. We tested this assumption by performing sensitivity analysis. Missing data 
indicating the variance of outcome measures (e.g. SD, CI) were to be expected, in which 
case we used the methods described in the Cochrane Handbook for Systematic Reviews 
of Interventions27 to calculate or impute these data.
Assessment of heterogeneity
We assessed the statistical heterogeneity of outcome measures by calculating the Q 
statistics and the I² statistic, as suggested in the Cochrane Handbook for Systematic 
Reviews of Interventions27.
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Assessment of reporting biases
We created a funnel plot providing enough studies were included for each outcome 
measure, with effect size on the x-axis and precision on the y-axis to investigate possible 
publication bias.
Data synthesis
We calculated treatment effects using corresponding 95% CIs for both continuous and 
dichotomous outcome measures by applying random-effects models. Subsequently, 
when appropriate, we calculated the pooled treatment effect size from the random-
effects model meta-analysis and presented this as a forest plot for each outcome measure 
separately. We considered two-sided P ≤ 0.05 as statistically significant and performed all 
data analyses using RevMan 5.328, when appropriate.
Subgroup analysis and investigation of heterogeneity
We considered the following subgroup analyses for primary outcomes, provided we 
identified enough studies for each subgroup.
 – Types of endovascular revascularisation procedures (e.g. angioplasty, angioplasty 
plus stenting).
 – Types of pharmacotherapy (e.g. cilostazol, pentoxifylline, naftidrofuryl).
 – Types of exercise therapy (i.e. supervised or non-supervised programme).
 – Separate segments (i.e. aortoiliac, femoropopliteal, or combined).
Sensitivity analysis
We planned to perform several sensitivity yses provided we could include enough 
studies in the meta-analysis. We assessed individual study effects by excluding each study 
separately from the analysis to examine whether exclusion of an individual study would 
significantly change the results. Likewise we planned to perform sensitivity analysis on the 
methodological quality of studies by removing studies with high risk of (methodological) 
bias to observe whether excluding these studies would significantly change the results. 
In addition, in performing sensitivity analyses, we removed from meta-analysis studies 
reporting only median and IQR walking distances, to observe whether excluding these 
studies would significantly change the results.
RESULTS
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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Included studies
After fulltext assessment, we included in this systematic review ten studies described in 
25 publications assessing the value of endovascular revascularisation in the management 
of patients with intermittent claudication25,26,29-36. Results from all included studies had 
been published in peer-reviewed journals. Greenhalgh reported two separate trials that 
included participants in one of the two trials on the basis of lesion site (femoropopliteal 
or aortoiliac) and consequently randomised them to one of two treatment arms26. 
Nordanstig randomised participants to a non-invasive treatment group or an invasive 
treatment group that included both open surgical or endovascular revascularisation 
procedures at baseline33. To include this study in this systematic review, we sought and 
received from study authors outcome data from the subgroup of participants undergoing 
endovascular revascularisation.
All included studies used a parallel-group design, with seven studies randomising 
between two arms comparing endovascular revascularisation versus cardiovascular 
risk factor management alone (i.e. no specific therapy for intermittent claudication 
except verbal advice to exercise)34,36, endovascular revascularisation versus supervised 
exercise29,35, endovascular revascularisation plus supervised exercise versus supervised 
exercise alone26,26, or endovascular revascularisation plus cilostazol 100 mg twice 
daily versus cilostazol 100 mg twice daily33. Three studies had three arms comparing 
endovascular revascularisation versus cardiovascular risk factor management alone 
(i.e. no specific therapy for claudication) versus supervised exercise30, endovascular 
revascularisation versus supervised exercise versus endovascular revascularisation plus 
supervised exercise31, or endovascular revascularisation plus cilostazol 100 mg twice daily 
versus cilostazol 100 mg twice daily alone versus supervised exercise plus cilostazol 100 
mg twice daily32. All studies were conducted in Europe (n = 9) and North America (n = 1) 
and recruited a total number of 1087 participants, ranging from 23 to 212 participants in 
each individual study. All participants had stable intermittent claudication, and most were 
recruited from outpatient clinics in university and non-university hospitals. Seven out of ten 
studies included participants with claudication due to both aortoiliac and femoropopliteal 
disease25,26,29,33-36, two studies included only participants with femoropopliteal disease30,31, 
and one study included only participants with aortoiliac disease32. Most included 
participants were male (61%) with an average age ranging from 61 to 70 years. All studies 
except one study29 reported to a greater or lesser extent some sort of cardiovascular 
risk factor management (e.g. providing smoking cessation advice, promoting physical 
activity, providing dietary advice or medical therapy for cardiovascular risk factors) 
offered to participants in each treatment arm at the start of the study, in addition to their 
specific treatment for intermittent claudication, if applicable. In all studies, endovascular 
revascularisation consisted of balloon angioplasty; in four studies, investigators placed a 
stent if initial balloon angioplasty results were unsatisfactory (selective stenting)25,26,34,35; in 
one study always placed a stent after initial balloon angioplasty (primary stenting)32; in one 
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study always placed a stent in the aortoiliac segment (primary stenting) but placed a stent 
in the femoropopliteal segment only if angioplasty results were unsatisfactory (selective 
stenting)33; and four studies placed no stent and performed only balloon angioplasty 
(no stenting)29-31,36. In studies comparing endovascular revascularisation (± conservative 
therapy) versus conservative therapy for intermittent claudication, conservative treatment 
consisted of pharmacotherapy with cilostazol 100 mg twice daily in two studies32,33, 
comprised a supervised exercise programme in six studies25,26,29-31,35, and included a 
combination of cilostazol 100 mg twice daily and supervised exercise in one study32. The 
duration of supervised exercise programmes varied between studies, with most studies 
offering a programme of 12 weeks with a frequency of two to three sessions per week. In 
two studies21,35 the supervised exercise programme continued until six months, and in one 
study25 the programme continued up to 12 months, with a declining number of sessions 
per week after the initial three months of training depending on participants’ progress.
Duration of follow-up was homogeneous between studies, with all studies reporting 
a follow-up duration of at least six months. Eight out of ten studies recorded outcome 
measures at 12 months’ follow-up25,26,29,31-35; six studies reported long-term follow-up 
(longer than 12 months), with follow-up duration of 18 months in one study32, two years in 
three studies31,34,36, six years in one study29, and seven years in another study35.
In assessing functional performance measures (i.e. MWD and PFWD), studies used 
different treadmill protocols with varying treadmill speed and incline and total duration 
of assessment. Six studies used a 10% incline with treadmill speed between 2.5 km/h 
and 4 km/h and duration from 5 to 20 minutes26,29,30,31,34,36. Two studies used a treadmill 
protocol with constant speed of 3.2 km/h and graded incline starting at 0%, increasing 
each two minutes up to a maximum of 10%25,32. One study25 recorded walking distances 
up to 30 minutes walking on the treadmill, and one study32 limited this time to 12 minutes. 
One study33 used a treadmill protocol with progressively increasing incline (0 to 12%) and 
speed (1.5 to 4.5 km/h). In the final study35, the treadmill protocol allowed no graded 
incline and used a constant speed of 3.5 km/h, permitting participants to walk up to 30 
minutes on the treadmill.
Nine out of ten studies reported secondary invasive (endovascular or surgical) 
interventions during follow-up25,26,29,31-36, but only four studies explicitly reported data on 
numbers of amputations25,32,33,35. Seven studies reported data on general QoL25,26,31-35, and 
six studies presented data on disease-specific QoL25,31-35, yet the validated questionnaires 
used to assess QoL were quite heterogeneous between studies.
Excluded studies
After fulltext assessment, we excluded nine studies37-45. One study40 reported outcome 
measures for participants randomised to open or endovascular revascularisation as one 
invasive treatment group, and corresponding authors could provide no data for the 
subgroup of participants receiving endovascular revascularisation. For this reason, we 
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decided to exclude this study from further evaluation. We excluded another eight studies 
for not including a non-interventional control group37-39,44, not providing relevant outcome 
measures for this systematic review42,43, not using a formal randomisation process41, or 
publishing only abstract data, with study authors not able to provide additional data45.
Ongoing studies
We classified two studies as ongoing studies46,47.
Risk of bias in included studies
See Figure 2 and Figure 3 for a graphical summary of risk of bias for the ten included studies.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as 
percentages across all included studies.
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each 
included study.
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Allocation
Although all ten included studies were RCTs, seven studies described an adequate sequence 
generation method performed by means of computerised randomisation25,26,32-36. In the 
remaining three studies, researchers randomised participants to one of the treatment 
arms, yet did not report the exact sequence generation methods used, making adequate 
judgement of risk of bias impossible29-31. Similarly, most studies reported an adequate 
allocation concealment method25,26,31-36. Two studies provided insufficient information to 
allow a definitive judgement on concealment29,30.
Blinding
None of the included studies performed blinding of participants and personnel to the 
allocated treatment, given the nature of endovascular revascularisation as the intervention 
in each study. This might have introduced performance bias. Detection bias could be 
avoided by blinding outcome assessors, which three studies adequately performed 
and described25,32,35. The remaining seven studies provided no information on assessor 
blinding; thus we determined risk of detection bias to be unclear in these studies.
Incomplete outcome data
We determined risk of attrition bias to be low in eight studies, as censoring at 6 to 18 
months’ follow-up (if applicable) was minimal to moderate, and numbers and reasons 
for censoring across allocated groups were well balanced25,26,30-35. For one study, we 
assessed risk of attrition bias to be high, as at 12 months’ follow-up, a significant number 
of participants were not available for primary outcome assessment and information 
provided on distribution and reasons for dropouts was insufficient29. One study36 
excluded from analysis participants in the control group who underwent endovascular 
or open revascularisation, which might have introduced attrition bias, yet information on 
characteristics of these participants was insufficient to allow judgement for risk of bias.
Selective reporting
In nine studies25,29-36, investigators reported all relevant and expected outcome measures 
in the results section. In contrast to maximum walking distance, one study26 reported 
no absolute values for pain-free walking distance but rather percentage of participants 
attaining 200 metres without claudication pain; this was not prespecified in the methods 
section of this study.
Other potential sources of bias
One study34 received unrestricted grants from the industry, and two studies32,36 received 
partial support from the industry. Owing to slow recruitment in five studies26,29,30,32,34, 
investigators were unable to include their prespecified intended sample size based on 
power calculations for the primary outcome measure of walking distance, and this may 
have biased the results.
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Effects of interventions
Comparison 1. Endovascular revascularisation versus no specific therapy for intermittent 
claudication except verbal advice to exercise
Data from three studies comparing endovascular revascularisation versus no specific 
therapy for intermittent claudication (i.e. only cardiovascular risk factor management and 
verbal advice on ex-ercise) were eligible for inclusion with a total sample size of 134 
participants30,34,36.
Maximum walking distance
After 6 to 12 months’ follow-up, use of a random-effects model and pooled data from 
three studies (n = 125) showed that participants had higher MWD following endovascular 
revascularisation than after no specific therapy (Analysis 1.1), with a pooled SMD of 0.70 
(95% CI 0.31 to 1.08; P = 0.0004), which is equivalent to a moderate effect in favour of 
endovascular revascularisation. There was little heterogeneity (I² = 8%).
Analysis 1.1.  Endovascular revascularisation versus no specific therapy except verbal advice to 
exercise, outcome:  Maximum walking distance.
After long-term follow-up, use of a random-effects model and pooled data from two 
studies (n = 103) showed no clear differences in MWD between participants following 
endovascular revascularisation compared with those given no specific therapy (pooled 
SMD 0.67, 95% CI -0.30 to 1.63; P = 0.18) (Analysis 1.2). Het-erogeneity was substantial 
(I² = 83%).
Analysis 1.2. Endovascular revascularisation versus no specific therapy except verbal advice to 
exercise, outcome:  Maximum walking distance (long-term)
Pain-free walking distance
After 6 to 12 months’ follow-up, use of a random-effects model and pooled data from 
three studies (n = 125) showed that participants following endovascular revascularisation 
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had higher PFWD compared with those given no specific therapy (Analysis 1.3), with a 
pooled SMD of 1.29 (95% CI 0.90 to 1.68; P < 0.00001); this is equivalent to a large effect 
in favour of endovascular revascularisation. There was little heterogeneity (I² = 0%).
After long-term follow-up, use of a random-effects model and pooled data from two 
studies (n = 103) showed no clear differences in PFWD between participants following 
endovascular revascularisation and those given no specific therapy (pooled SMD 0.69, 
95% CI -0.45 to 1.82; P = 0.24) (Analysis 1.4). Heterogeneity was considerable (I² = 87%).
Analysis 1.3. Endovascular revascularisation versus no specific therapy except verbal advice to 
exercise, outcome:  Pain-free walking distance.
Analysis 1.4. Endovascular revascularisation versus no specific therapy except verbal advice to 
exercise, outcome:  Pain-free walking distance (long-term).
Secondary invasive interventions
Two studies reported data on the number of secondary invasive interventions during 
follow-up. During two-year follow-up, investigators performed a secondary invasive 
intervention in 4 of 58 participants in the endovascular revascularisation group and in 5 
of 60 participants in the no specific therapy group (OR 0.8, 95% CI 0.12 to 5.28; P = 0.82). 
There was little heterogeneity (I² = 29%) (Analysis 1.5).
Analysis 1.5. Endovascular revascularisation versus no specific therapy except verbal advice to 
exercise, outcome:  Secondary invasive interventions.
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Quality of life
One study assessed disease-specific QoL using Claudication Scale (CLAU-S) forms and 
reported no significant differences in all seven domains of the questionnaire between the 
two study groups after two years of follow-up34.
Two studies assessed and reported on general health-related QoL. One study used 
Nottingham Health Profile scores (six domains) to show no significant differences between 
groups in any domains during follow-up (P > 0.05) 36. The second study used the Short 
Form-36 (SF-36) questionnaire to show statistically significant differences between groups 
in the domains of physical functioning in favour of the no specific therapy group and 
emotional role functioning in favour of the endovascular revascularisation group34.
Procedure related complications
None of the three studies provided data on the number of complications following 
endovascular revascularisation. However, two studies reported that no major procedure-
related complications had occurred34,36.
Cardiovascular events
None of the included studies reported data on cardiovascular events during follow-up.
Non-treadmill functional performance measures
Two studies reported non-treadmill functional performance measures. One reported 
on self-reported walking distance and number of participants with at least 1 kilometre 
reported walking distance. At two years’ fol-low-up for both outcome measures, study 
authors reported no statistically significant differences between groups (P ≥ 0.70)36. After 
two years’ follow-up, the second study reported a higher visual analogue scale (VAS) 
score (functional status) following endovascular compared with no therapy34.
Mortality
Three studies reported data on all-cause mortality. During follow-up, 2 of 68 participants 
in the endovascular revascularisation group and 3 of 68 participants in the no therapy 
group had died (OR 0.75, 95% CI 0.13 to 4.44; P = 0.75) (Analysis 1.6). There was little 
heterogeneity (I² = 0%).
Analysis 1.6. Endovascular revascularisation versus no specific therapy except verbal advice to 
exercise, outcome: Mortality.
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Subgroup analysis
Given the limited number of studies, we performed no subgroup analysis.
Sensitivity analysis
Given the limited number of studies, we performed no sensitivity analysis.
Comparison 2. Endovascular revascularisation versus conservative therapy
Data from five studies comparing endovascular revascularisation versus conservative 
therapy for intermittent claudication were eligible for inclusion, with a total sample size 
of 412 participants29,30-32,35. The conservative therapy provided in these five studies was 
supervised exercise therapy.
Maximum walking distance
After 6 to 12 months’ follow-up, use of a random-effects model and pooled data from 
five studies (n = 345) showed no clear differences in MWD between participants following 
endovascular revascularisation and those given supervised exercise therapy (SMD -0.42, 
95% CI -0.87 to 0.04; P = 0.07; Analysis 2.1). Heterogeneity was substantial (I² = 69%).
After long-term follow-up, use of a random-effects model and pooled data from 
three studies (n = 184) showed no clear differences in MWD between participants following 
endovascular revascularisation and those given supervised exercise therapy (pooled 
SMD -0.02, 95% CI -0.36 to 0.32; P = 0.90; Analysis 2.2). There was little heterogeneity 
(I² = 24%).
Analysis 2.1. Endovasular revascularisation versus conservative therapy in form of supervised ex-
ercise, outcome: Maximum walking distance.
Analysis 2.2. Endovasular revascularisation versus conservative therapy in form of supervised ex-
ercise, outcome: Maximum walking distance (long-term).
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Pain-free walking distance
After 6 to 12 months’ follow-up, use of a random-effects model and pooled data from 
five studies (n = 345) showed no clear differences in PFWD between participants following 
endovascular revascularisation and those given supervised exercise therapy (SMD -0.05, 
95% CI -0.38 to 0.29; P = 0.79; Analysis 2.3). Heterogeneity was substantial (I² = 53%).
After long-term follow-up, use of a random-effects model and pooled data from two 
studies (n = 147) showed no clear differences in PFWD between participants following 
endovascular revascularisation and those given supervised exercise therapy (pooled SMD 
0.11, 95% CI -0.26 to 0.48; P = 0.54; Analysis 2.4). There was little heterogeneity (I² = 22%).
One study29 also assessed long-term PFWD (after 6 years’ follow-up) but provided 
no data on PFWD except for the statement that data showed no significant differences 
between groups over the long term.
Analysis 2.3. Endovasular revascularisation versus conservative therapy in form of supervised ex-
ercise, outcome: Pain-free walking distance.
Analysis 2.4. Endovasular revascularisation versus conservative therapy in form of supervised ex-
ercise, outcome: Pain-free walking distance (long-term).
Secondary invasive interventions
Four studies reported data on the number of secondary invasive interventions during 
follow-up. During 6 to 18 months’ follow-up, a secondary invasive intervention was 
performed in 22 of 201 participants in the endovascular revascularisation group, and in 16 
of 194 participants in the supervised exercise therapy group (OR 1.40, 95% CI 0.70 to 2.80; 
P = 0.33). There was little heterogeneity (I² = 0%) (Analysis 2.5).
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Analysis 2.5. Endovasular revascularisation versus conservative therapy in form of supervised ex-
ercise, outcome: Secondary invasive interventions.
Two studies reported data on the number of secondary invasive interventions during 
long-term follow-up (29; Spronk 2009). In one study29, after six years’ follow-up, 8 of 
30 participants in the endovascular revascularisation group and 9 of 30 participants in 
the control group needed a secondary invasive revascularisation procedure. In the 
other study35, after seven years’ follow-up, 17 of 75 participants in the endovascular 
revascularisation group and 32 of 75 participants in the control group needed a secondary 
revascularisation procedure.
Quality of life
Three studies assessed and reported disease-specific QoL. In two studies31,35 the VascuQol 
questionnaire was used, and in one study32 the Peripheral Artery Questionnaire (PAQ) 
was used. Pooled data from these studies (n = 301) produced a pooled SMD of 0.18 (95% 
CI -0.04 to 0.41; P = 0.11) showing no clear differences between study groups. There was 
little heterogeneity (I² = 0%) (Analysis 2.6).
Analysis 2.6. Endovasular revascularisation versus conservative therapy in form of supervised ex-
ercise, outcome: Quality of life (disease-specific).
Three studies assessed and reported general health-related QoL. Two studies31,35 
used one or more domains of Short Form-36, and one study32 used Short Form-12. We 
have provided a summary of their findings in Figure 4. None of the domains showed a 
clear difference between study groups.
PSM 20180914 Proefschrift Farzin Fakhry BW.indd   100 21-11-18   14:24
Endovascular revascularization versus conservative management for claudication
101
4
Figure 4. Health-related quality of life (mean differences between groups).
Procedure related complications
Three studies provided data on the number of minor complications following endovascular 
revascularisation (Table 1)29,32,35. Two studies29,35 reported one arterial perforation during 
the procedure, which needed surgical revision. One study32 stated that no major procedure 
related complications had occurred.
Table 1. Minor complications after endovascular revasuclarisation 
Study Groin haematoma Artery dissection
Creasy 1990 3/20 1/20
Fakhry 2015 5/106 2/106
Greenhalgh 2008 8/67 1/67
Murphy 2015 nr 2/46
Nordanstig 2014 1/52 nr
Spronk 2009 6/75 1/75
nr: not reported 
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Cardiovascular events
No study reported data on cardiovascular events during follow-up.
Non-treadmill functional performance measures
Two studies reported non-treadmill functional performance measures including self-
reported walking distance, hourly free-living steps measured with a pedometer, and 
functional status assessed with the walking impairment questionnaire (WIQ) and with 
PAQ31,32. One reported no clear differences in self-reported walking distance between 
the two study groups at one year of follow-up31. After six months’ follow-up, the second 
study found no clear differences between study arms for change in hourly free-living 
steps. Similarly in this study, at 18 months’ follow-up, PAQ and WIQ scores for all domains 
were comparable between groups, except for the PAQ physical limitation score and the 
PAQ summary score, both of which favoured the endovascular revascularisation group 
(P < 0.05)32.
Mortality
Five studies reported data on all-cause mortality29-32,35. During follow-up, 11 of 222 
participants in the endovascular revascularisation group and 12 of 213 participants in the 
supervised exercise therapy group had died (OR 0.84, 95% CI 0.35 to 2.00; P = 0.69). 
There was little heterogeneity (I² = 0%) (Analysis 2.7).
Analysis 2.7. Endovasular revascularisation versus conservative therapy in form of supervised ex-
ercise, outcome: Mortality. 
Subgroup analysis
Given the limited number of studies and fact that conservative therapy in all studies 
consisted of supervised exercise therapy, we performed no subgroup analysis.
Sensitivity analysis
In sensitivity analysis excluding two studies30,31, which reported only median (IQR) MWD 
or PFWD; or which measured walking distances on a treadmill during only five minutes, 
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which probably underestimated the treatment effect, results compared with the main 
analysis showed changes for the following outcome: At 6 to 12 months’ follow-up, pooled 
results for MWD from the three remaining studies29,32,35 (n = 232) showed higher MWD in 
the supervised exercise therapy group than in the endovascular revascularisation group, 
with SMD of -0.52 (95% CI -0.98 to -0.07; P = 0.024) (Analysis 2.8). For all other outcomes, 
results from sensitivity analysis did not differ substantially from results obtained by the 
main analysis.
We did not perform sensitivity analysis on the methodological quality of studies or on 
individual study effects owing to the limited number of included studies.
Analysis 2.8. Endovasular revascularisation versus conservative therapy in form of supervised ex-
ercise, outcome: Sensitivity analysis: maximum walking distance.
Comparison 3. Endovascular revascularisation plus conservative therapy versus conservative 
therapy
Data from three studies26,26,31 (n = 457) comparing endovascular revascularisation plus 
supervised exercise versus supervised exercise alone and data from two studies32,33 (n 
= 199) comparing endovascular revascularisation plus pharmacotherapy (i.e. cilostazol) 
versus pharmacotherapy for intermittent claudication were eligible for inclusion.
Maximum walking distance
After 6 to 12 months’ follow-up, use of a random-effects model and pooled data from 
three studies (n = 432) showed no clear differences in MWD between participants 
following combination therapy versus supervised exercise therapy alone (SMD 0.26, 95% 
CI -0.13 to 0.64; P = 0.19; Analysis 3.1). Heterogeneity was substantial (I² = 70%).
After 6 to 12 months’ follow-up, use of a random-effects model and pooled data 
from two studies (n = 186) showed that participants following combination therapy had 
a higher MWD than those given pharmacotherapy alone (Analysis 3.1), with an SMD of 
0.38 (95% CI 0.08 to 0.68; P = 0.014), which is equivalent to a small effect in favour of 
combination therapy. There was little heterogeneity (I² = 0%).
One study26 provided long-term data for MWD at two years’ follow-up for comparison 
of combination therapy versus supervised exercise therapy alone, which showed a higher 
MWD in the combination therapy group than in the supervised exercise therapy alone 
group (SMD 1.18, 95% CI 0.65 to 1.70; P < 0.0001; 106 participants; Analysis 3.2).
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One study32 provided long-term data for MWD at 18 months’ follow-up for comparison 
of combination therapy versus pharmacotherapy alone, which showed a higher MWD in 
the combination therapy group than in the pharmacotherapy alone group (SMD 0.72, 
95% CI 0.09 to 1.36; P = 0.02; 47 participants; Analysis 3.2).
Pain-free walking distance
After 6 to 12 months’ follow-up, use of a random-effects model and pooled data from 
two studies (n = 305) showed no clear differences in PFWD between participants following 
combination therapy and those given supervised exercise therapy alone (pooled SMD 
0.33, 95% CI -0.26 to 0.93; P = 0.27; Analysis 3.3). Heterogeneity was substantial (I² = 83%).
Analysis 3.1. Endovascular revascularisation plus conservative therapy versus conservative thera-
py, outcome: Maximum walking distance.
Analysis 3.2. Endovascular revascularisation plus conservative therapy versus conservative thera-
py, outcome: Maximum walking distance (long-term).
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Analysis 3.3. Endovascular revascularisation plus conservative therapy versus conservative thera-
py, outcome: Pain-free walking distance.
After 6 to 12 months’ follow-up, use of a random-effects model and pooled data 
from two studies (n = 186) showed that participants following the combination therapy 
had a higher PFWD than those given pharmacotherapy alone (Analysis 3.3), with SMD of 
0.63 (95% CI 0.33 to 0.94; P < 0.0001), which is equivalent to a moderate effect in favour 
of combination therapy. There was little heterogeneity (I² = 0%).
One study26 compared combination therapy versus supervised exercise therapy alone 
in two separate trials - the aortoiliac trial and the femoropopliteal trial - and reported 
data on long-term PFWD after two years’ follow-up. In the femoropopliteal trial, 63% 
of participants in the combination therapy group and 22% of those in the supervised 
exercise therapy group attained 200 metres without claudication pain, corresponding to 
an adjusted hazard ratio of 3.11 (95% CI 1.42 to 6.81; P < 0.01) in favour of combination 
therapy. Similarly, in the aortoiliac trial, 61% of participants in the combination therapy 
group and 25% of those in the supervised exercise therapy group attained 200 metres 
without claudication pain, corresponding to an adjusted hazard ratio of 3.6 (95% CI 1.0 to 
12.8; P = 0.05) in favour of combination therapy.
One study32 provided long-term data for PFWD at 18 months’ follow-up comparing 
combination therapy versus pharmacotherapy alone showing no clear differences between 
study groups (SMD 0.54, 95% CI -0.08 to 1.17; P = 0.09; 47 participants; Analysis 3.4).
Analysis 3.4. Endovascular revascularisation plus conservative therapy versus conservative thera-
py, outcome: Pain-free walking distance (long-term).
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Secondary invasive interventions
Three studies comparing combination therapy versus supervised exercise therapy alone 
reported data on the number of secondary invasive interventions during follow-up. During 
12 to 24 months’ follow-up, investigators performed a secondary invasive intervention in 
10 of 231 participants in the combination therapy group and in 37 of 226 participants in 
the supervised exercise therapy group (OR 0.27, 95% CI 0.13 to 0.55; P = 0.0003) (Analysis 
3.5). There was little heterogeneity (I² = 0%).
Two studies comparing combination therapy versus pharmacotherapy alone reported 
data on the number of secondary invasive interventions during follow-up. During 12 to 
18 months’ follow-up, researchers performed a secondary invasive intervention in 10 of 
98 participants in the combination therapy group and in 7 of 101 participants in the 
pharmacotherapy group (OR 1.83, 95% CI 0.49 to 6.83; P = 0.37) (Analysis 3.5). There was 
little heterogeneity (I² = 17%).
Analysis 3.5. Endovascular revascularisation plus conservative therapy versus conservative therapy, 
outcome: Secondary invasive interventions.
Quality of life
Four studies assessed and reported disease-specific QoL. Three of them25,31,33 used the 
VascuQol questionnaire, and one32 used the Peripheral Artery questionnaire.
Pooled data from two studies (n = 330) comparing combination therapy versus supervised 
exercise therapy alone produced a pooled SMD of 0.25 (95% CI -0.05 to 0.56; P = 0.10) 
(Analysis 3.6). Heterogeneity was moderate (I² = 45%).
Pooled data from two studies (n = 170) comparing combination therapy versus 
pharmacotherapy alone produced a pooled SMD of 0.59 (95% CI 0.27 to 0.91; P = 0.0003) 
(Analysis 3.6), which is equivalent to a small effect in favour of combination therapy. There 
was little heterogeneity (I² = 0%).
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Analysis 3.6. Endovascular revascularisation plus conservative therapy versus conservative therapy, 
outcome: Quality of life (disease-specific).
Five studies assessed and reported general health-related QoL using one or more 
domains of Short Form-36 or Short Form-1225,26,31-33. We have provided a summary 
of findings from these five studies in Figure 5. For domains assessed on the physical 
functioning scale, the physical role scale, and the bodily pain scale, data show statistically 
significant differences in favour of combination therapy.
Procedure related complications
Four studies provided data on the number of minor complications (Table 1) following 
endovascular revascularisation25,26,32,33. One study32 reported one arterial perforation 
during the procedure, which needed a surgical revision. One study33 reported an 
emergency surgical exploration due to access site bleeding and one study31 stated that 
no major procedure related complications had occurred.
Cardiovascular events
No study reported data on cardiovascular events during follow-up.
Non-treadmill functional performance measures
Three studies reported non-treadmill functional performance measures including self-
reported walking distance, hourly free-living steps measured with a pedometer, and 
functional status assessed with WIQ and PAQ31-33. At one year of follow-up, one study31 
reported no statistically significant difference in self-reported walking distance between 
study groups, and one study33 reported a significant difference in self-reported MWD in 
favour of combination therapy over pharmacotherapy alone (P < 0.01). After six months’ 
follow-up, one study32 reported no statistically significant differences between groups 
for change in hourly free-living steps. At 18 months’ follow-up, one study31 reported 
that for all domains of WIQ and PAQ summary score, a statistically significant greater 
improvement favoured combination therapy (P < 0.05) over pharmacotherapy alone.
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Mortality
Three studies comparing combination therapy versus supervised exercise therapy 
reported data on all-cause mortality showing that 5 of 231 participants in the combination 
therapy group and 7 of 226 participants in the supervised exercise therapy alone group 
had died (OR 0.67, 95% CI 0.20 to 2.21; P = 0.51) (Analysis 3.7) (25; 26; 31). There was little 
heterogeneity (I² = 0%).
A: Femoropoliteal trial.B: Aortoiliac trial.
1 In this study, the comparison was endovascular revascularisation plus supervised exercise versus supervised exercise.
2 In this study, the comparison was endovascular revascularisation plus pharmacotherapy with cilostazol versus cilostazol.
Figure 5. Health-related quality of life (mean differences between groups).
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Two studies comparing combination therapy versus pharmacotherapy reported data on 
all-cause mortality showing that 5 of 99 participants in the combination therapy group 
and 1 of 102 participants in the pharmacotherapy alone group had died (OR 1.30, 95% CI 
0.14 to 11.92; P = 0.82) (Analysis 3.7). There was little heterogeneity (I² = 8%).
Analysis 3.7. Endovascular revascularisation plus conservative therapy versus conservative therapy, 
outcome: Mortality.
Subgroup analysis
Given the limited number of studies, we performed no subgroup analysis.
Sensitivity analysis
In sensitivity analysis excluding one study31, which reported only median (IQR) MWD 
or PFWD and measured walking distances on a treadmill during only five minutes 
(probably underestimating the treatment effect), results compared with those of the main 
analysis showed changes in the following outcome: For the comparison of endovascular 
revascularisation plus supervised exercise versus supervised exercise alone, pooled 
results for MWD from the two remaining studies (n = 339) showed higher MWD in the 
combination therapy group than in the supervised exercise alone group, with SMD of 0.43 
(95% CI 0.21 to 0.65; P < 0.0001) (Analysis 3.8), which is equivalent to a moderate effect in 
favour of combination therapy. For PFWD, results from one study25 showed higher PFWD 
in the combination therapy group than in the supervised exercise alone group (SMD 0.62, 
95% CI 0.34 to 0.89; P = 0.0001; 212 participants) (Analysis 3.9).
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Analysis 3.8. Endovascular revascularisation plus conservative therapy versus conservative thera-
py, outcome: Sensitivity analysis: maximum walking distance.
Analysis 3.9. Endovascular revascularisation plus conservative therapy versus conservative thera-
py, outcome: Sensitivity analysis: pain-free walking distance.
DISCUSSION 
In this review, we included ten RCTs with a total of 1087 participants assessing the (added) 
effect of endovascular revascularisation in the management of patients with stable 
intermittent claudication. It should be stated that overall the studies included are relatively 
small and show considerable heterogeneity in outcome assessment and outcome 
reporting; therefore trial results must be interpreted with caution.
Summary of main results
After comparing endovascular revascularisation versus no therapy (except exercise 
advice) for intermittent claudication, three studies (n = 134) provided data showing a 
moderate to large effect on walking distances in favour of endovascular revascularisation 
in the short term up to 12 months. However, after long-term follow-up, this short-term 
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advantage of endovascular revascularisation was uncertain upon pooling of results from 
two studies. In addition, as reported in these two studies, quality of life (QoL) and the 
number of secondary invasive interventions during follow-up were not substantially 
different between study groups.
After comparing endovascular revascularisation versus supervised exercise for 
intermittent claudication, five studies (n = 412) provided data showing no specific 
preference for one of the two treatment options. Overall, participants in the supervised 
exercise therapy group tended to have higher walking distances, and participants in 
the endovascular revascularisation group tended to have better general and disease-
specific QoL, yet these differences were not statistically significant. Similarly, the number 
of secondary invasive interventions during follow-up was comparable between the 
two study groups. Sensitivity analysis excluding studies reporting only median walking 
distances and one study that measured walking distances on a treadmill during only five 
minutes, which probably underestimated the treatment effect, showed that participants 
following supervised exercise had a higher maximum walking distance (MWD) after 6 to 
12 months when compared with participants following endovascular revascularisation.
After comparing endovascular revascularisation plus conservative therapy versus 
conservative therapy alone for intermittent claudication, three studies (n = 457) comparing 
endovascular revascularisation plus supervised exercise versus supervised exercise alone 
provided data showing no clear difference in walking distances and in disease-specific 
QoL between groups up to 12 months’ follow-up, and one study reported better walking 
distances in favour of combination therapy at 24 months’ follow-up. In addition, participants 
following endovascular revascularisation plus supervised exercise tended to have higher 
general health-related QoL in favour of combination therapy for some of the Short Form 
(SF)-36 domains. Finally, the number of secondary invasive interventions during follow-up 
was significantly lower following combination therapy compared with supervised exercise 
alone. Sensitivity analysis excluding one study reporting only median walking distances 
and measuring walking distances on a treadmill during only five minutes, which probably 
underestimated the treatment effect, showed that participants following endovascular 
revascularisation plus supervised exercise had higher maximum walking distance (MWD) 
and pain-free walking distance (PFWD) after 6 to 12 months compared with participants 
following supervised exercise only.
When comparing endovascular revascularisation plus cilostazol versus cilostazol alone, 
two studies (n = 199) provided data showing a small to moderate effect on short- and 
long-term walking distances in favour of combination therapy. In addition, participants 
following combination therapy had higher disease-specific and general health-related 
QoL with differences favouring endovascular revascularisation plus cilostazol for some 
of the SF-36 domains. The number of secondary invasive interventions during follow-up 
was not different between participants in the combination therapy group and those in the 
cilostazol only group.
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Six studies with a total of 366 participants randomised to an endovascular 
revascularisation procedure provided data on the number of procedure related 
complications. Overall endovascular revascularisation for claudication seems to be 
a relatively ’safe’ procedure with an incidence of 8% (30/366) for minor procedure 
related complications (groin haematoma and artery dissection) requiring conservative 
management only. Three studies reported one arterial perforation each during the 
procedure that required a surgical revision. None of the studies reported any major 
procedure related complications leading to permanent disability or death. Yet, it should be 
noted that these data are based on complications within clinical studies, and complication 
rates in clinical practice might be much higher.
Overall completeness and applicability of evidence
In general, the ten included studies provided sufficient information on the predefined 
primary and secondary outcomes of this review, except for the number of cardiovascular 
events during follow-up, which was not reported by any of the studies.
Considerable heterogeneity in outcome assessment was evident between studies. The 
treadmill protocol (speed, grade, and time) used to assess primary outcome functional 
performance measures (i.e. MWD and PFWD) differed significantly between studies; 
therefore we used SMD as treatment effect for these outcomes to allow standardisation of 
study results to a uniform scale. In addition, some heterogeneity in outcome reporting was 
evident between studies, including three studies30,31,36 reporting only median (interquartile 
range (IQR)) MWD and PFWD. In sensitivity analysis excluding these studies and one 
study31 limiting treadmill time to assess MWD and PFWD to only five minutes, the main 
results changed significantly for three analyses as summarised above.
Given the limited number of studies included in this review, we were unable to perform 
all of the predefined subgroup analyses to investigate existing clinical heterogeneity 
between studies based on the selected population (femoropopliteal vs aortoiliac vs 
combined disease) or heterogeneity due to the endovascular revascularisation procedure 
performed (angioplasty vs stenting).
Given these restrictions, applicability of this review is limited to the general population 
of patients with intermittent claudication, and review findings do not allow robust 
conclusions for specific groups of participants or specific types of interventions given.
Quality of the evidence
We used GRADE criteria according to Schünemann48 and Atkins49 to assess the quality of 
evidence for the outcomes MWD, PFWD, secondary invasive interventions, and disease-
specific QoL. 
For the comparison endovascular revascularisation versus no specific therapy for 
intermittent claudication, we rated the quality of evidence as low (MWD and PFWD at 
long term) or moderate (MWD and PFWD at 6 to 12 months and secondary invasive 
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interventions). We downgraded the quality of evidence for this comparison mainly 
because of small study sample sizes and the possibility of serious risk of bias in two studies 
with three or more risk of bias domains labelled as having ’unclear’ risk.
For the comparison endovascular revascularisation versus conservative therapy (i.e. 
supervised exercise), quality assessment ranged from moderate (MWD and PFWD at 6 to 
12 months and at long term) to high (secondary invasive interventions and disease-spe-
cific QoL). We downgraded the quality of evidence for this comparison mainly owing to 
substantial heterogeneity between studies and high risk of attrition bias in one29 of the 
five studies included in the analysis. 
For the final comparison of combination therapy of endovascular revascularisation 
followed by conservative therapy versus conservative therapy alone, the quality assessment 
for the comparison combination therapy versus supervised exercise alone ranged from 
low (MWD at long term) to moderate (MWD and PFWD at 6 to 12 months and disease-
specific QoL) to high (number of secondary invasive interventions). We downgraded 
the quality of evidence for this comparison mainly owing to substantial heterogeneity 
between studies. We assessed quality for the comparison combination therapy versus 
pharmacotherapy alone as high (MWD and PFWD at 6 to 12 months, disease-specific 
QoL, and number of secondary invasive interventions).
The Cochrane Vascular Information Specialist conducted a comprehensive search 
to identify all relevant studies for inclusion in this review. In addition, review authors 
handsearched the reference lists of all eligible studies and reviews for additional relevant 
studies. Nevertheless, unpublished studies or data may have been missed. We had 
to exclude two eligible studies because one40 reported no outcome measures for the 
subgroup of participants receiving endovascular revascularisation, and one45 published 
only abstract data with incomplete results. We attempted to contact study authors to ask 
for relevant data but received no response. Study authors from one study33 provided data 
on the subgroup of participants receiving endovascular revascularisation, which allowed 
us to include this study in the quantitative analysis. However, it should be noted that this 
study was not powered to detect a difference in outcomes between the subgroup of 
participants receiving endovascular revascularisation and control group participants.
A potential bias that deserves attention is the limitation of maximum walking time on a 
treadmill test for assessment of the primary outcomes MWD and PFWD during follow-up, 
which varied between studies and ranged from 5 minutes to 30 minutes. Particularly in 
studies, which limited maximum walking time to only 5 minutes31, and to 10 minutes36, 
this may have caused serious underestimation of treatment effect, as participants might 
have been able to walk farther. This might explain the non-significant differences between 
treatment groups as reported by these studies31,36. In addition, to pool trial data, we 
assumed normal distribution for walking distances in three studies30,31,36 and used reported 
median values in the meta-analysis; this may have biased pooled results. In sensitivity 
analysis excluding these studies, the main results changed significantly for three analyses, 
as summarised above.
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Agreements and disagreements with other studies or reviews
Results of this review are in line with those of two previously published systematic 
reviews comparing treatment strategies for patients with intermittent claudication50,51. 
Both reviews concluded that endovascular revascularisation alone provides no significant 
benefit over supervised exercise therapy alone, and combination therapy of endovascular 
revascularisation plus supervised exercise therapy may be superior to supervised exercise 
therapy alone. Since then, results from three sizeable RCTs have been published and are 
included in this review25,32,33, overall confirming the conclusions provided by those two 
earlier systematic reviews.
AUTHOR’S CONCLUSIONS
Implications for practice
In the management of patients with intermittent claudication, endovascular revas-
cularisation does not provide significant benefits compared with supervised exercise 
therapy alone in terms of improvement in functional performance or quality of life. 
Although the number of studies is small with presence of some clinical heterogeneity, 
evidence suggests a possible synergetic effect when endovascular revascularisation is 
combined with a conservative therapy of supervised exercise or pharmacotherapy with 
cilostazol: the combination therapy seems to result in greater improvements in functional 
performance and quality of life scores when compared with conservative therapy alone.
Implications for research
More large (and long-term) studies assessing the added effect of endovascular 
revascularisation over and above supervised exercise therapy, or assessing the 
effectiveness of a stepped care approach with supervised exercise followed by 
endovascular revascularisation if needed, are required to define the optimal treatment 
strategy for the growing population of patients with intermittent claudication. In addition, 
health economic analyses of these combined treatment strategies are scarce and are 
urgently needed.
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CHARACTERISTICS OF STUDIES
Characteristics of included studies 
Creasy 1990
Methods Study design: parallel 2-arm RCT
Number of sites: 1
Sample size estimation: not reported
Follow-up: 3, 6, 9, 12, 15 months and 6 years
Participants Country and setting: United Kingdom, Oxford Regional Vascular Service
Inclusion criteria
- Stable unilateral claudication, with failure of conservative treatment for  
≥ 3 months
- Treadmill claudicating distance < 375 meters
- Angiographically significant lesion(s) suitable for treatment by angioplasty, as 
agreed upon by both surgeon and radiologist
Exclusion criteria: none
Number of participants assessed and randomised: 36 participants fulfilled the 
entry criteria and were randomised
Demographics
- Age (years): Group 1: mean 63.6 (SD 8.9); Group 2: mean 62.2 (SD 8.6)
- Gender (male): Group 1: 15 (75%); Group 2: 12 (75%)
Interventions Group 1: endovascular revascularisation without stenting, n = 20 (n = 30 at 6 
years’ follow-up)
Group 2: supervised exercise therapy for 6 months (2 sessions/week, 30 minutes/
session), n = 16 (n = 26 at 6 years’ follow-up)
Compliance with interventions
- Group 1: Two angioplasties were not successful
- Group 2: Mean attendance over 6 months of exercise therapy was 0.89 sessions/
week
Mortality
- Group 1: 4 participants after 6 years’ follow-up
- Group 2: 6 participants after 6 years’ follow-up
Loss to follow-up
- Group 1: 4 participants after 6 years’ follow-up
- Group 2: 5 participants after 6 years’ follow-up
Outcomes Maximum walking distance, pain-free walking distance, number of secondary 
interventions, procedure-related complications
Notes Source of funding: Oxford District Research Committee
Notes: New participants were added to the study after initial publication in 1990. 
Meta-analysis for long-term walking distances used numbers of participants at 6 
years’ follow-up.
Authors’ conclusion: “In patients with mild or moderate claudication, who do not 
require an immediate therapeutic response, supervised exercise therapy may 
ultimately produce greater symptomatic improvement than PTA.”
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Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Unclear risk “Simple randomisation” was performed according to trial 
authors; exact randomisation technique was not reported
Allocation concealment 
(selection bias)
Unclear risk No description of allocation concealment process
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
High risk Blinding of participants and personnel not possible given the 
nature of the intervention (endovascular revascularisation)
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Unclear risk Blinding of assessors not adequately discussed in the study
Incomplete outcome 
data (attrition bias) 
All outcomes
High risk Not analysed according to intention-to-treat principle; par-
ticipants who had technically unsuccessful angioplasties were 
excluded from analysis; at 1-year follow-up, walking distance in 
only 5 participants (25%) in the revascularisation group and in 7 
participants (44%) in the exercise group assessed; characteristics 
of withdrawals not adequately discussed; new participants added 
to study after 1 year of follow-up
Selective reporting 
(reporting bias)
Low risk All relevant outcome measures as specified in the methods 
section were reported
Other bias Unclear risk Sample size estimation not adequately discussed; low number 
of participants in whom primary endpoint was assessed (study 
underpowered)
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Fakhry 2015
Methods Study design: parallel 2-arm RCT
Number of sites: 10
Sample size estimation: 210 participants to detect 30% difference in maximum 
walking distance between the 2 treatment groups based on 90% power, type I 
error rate of 0.01, and anticipating 10% censoring
Follow-up: 1, 6, and 12 months
Participants Country and setting: Netherlands, university and non-university hospitals
Inclusion criteria
- Patients with stable intermittent claudication
- One or more vascular stenoses > 50% diameter reduction at the aortoiliac and/
or femoropopliteal level established by non-invasive vascular imaging
- Maximum walking distance between 100 and 500 meters as assessed on a 
graded treadmill
Exclusion criteria
- Targeted lesion deemed unsuitable for revascularisation
- Prior treatment for the targeted lesion (including exercise therapy)
- Limited life expectancy
- Limited ambulation due to any other condition than intermittent claudication 
not allowing participant to follow treadmill training
Number of participants assessed and randomised: 666 participants assessed, 212 
participants randomised to 1 of the treatment groups
Demographics
- Age (years): Group 1: mean 64 (SD 9); Group 2: mean 66 (SD 10)
- Gender (male): Group 1: 60 (57%); Group 2: 72 (68%)
Interventions Group 1: endovascular revascularisation with selective stenting plus supervised 
exercise therapy, n = 106
Group 2: supervised exercise therapy for 12 months (2 to 3 sessions/week 0 to 3 
months, 1 session/week 3 to 6 months, 1 session/mo 6 to 12 months, 60 minutes/
session), n = 106
Compliance with interventions
- Group 1: endovascular revascularisation technically successful in 102 (96%) par-
ticipants, on average per participant 30 sessions exercise followed
- Group 2: on average per participant 43 sessions exercise followed
Mortality
- Group 1: 1 participant
- Group 2: 3 participants
Loss to follow-up
- Group 1: 5 participants
- Group 2: 8 participants
Outcomes Maximum walking distance, pain-free walking distance, number of secondary 
interventions, procedure-related complications, SF-36 Physical Functioning, SF-36 
Physical Role, SF-36 Bodily Pain, SF-36 General Health, VascuQol
Notes Source of funding: grant from Netherlands organization for health research and 
development
Authors conclusion: “Among patients with intermittent claudication after 1 year 
of follow-up, a combination therapy of endovascular revascularization followed 
by supervised exercise resulted in significantly greater improvement in walking 
distances and health-related quality-of-life scores compared with supervised 
exercise only.”
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Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Low risk Randomisation using Web-based randomisation software based 
on minimisation method
Allocation concealment 
(selection bias)
Low risk Central Web-based allocation
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
High risk Blinding of participants and personnel not possible given the 
nature of the intervention (endovascular revascularisation)
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Low risk Independent outcome assessors
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk Analysis based on an intention-to-treat principle, censoring at 12 
months low (6%) and comparable between groups
Selective reporting 
(reporting bias)
Low risk All requested relevant outcome measures provided by study 
authors
Other bias Low risk No other forms of bias identified
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Greenhalgh 2008
Methods Study design: parallel 2-arm RCTs: (1) femoropopliteal disease trial; (2) aortoiliac 
disease trial
Number of sites: 9
Sample size estimation: 170 participants in each trial based on 90% power and 
significance level of 0.05 to detect a difference of 60 metre improvement in abso-
lute walking distance between groups
Follow-up: 6, 12, and 24 months
Participants Country and setting: United Kingdom, university and non-university hospitals
Inclusion criteria
- Positive outcome on the Edinburgh Claudication Questionnaire
- ABPI < 0.9 or > 0.9 with a positive stress test (fall of > 30 mmHg in Doppler 
blood pressure following a treadmill test at 4 km/h, 10 slope for 1 minute)
- Aortoiliac or femoropopliteal target lesion amenable to endovascular revascu-
larisation as demonstrated by duplex mapping or diagnostic arteriography
Exclusion criteria
- Symptoms too mild to consider angioplasty or so severe that intervention was 
mandatory
- Critical limb ischaemia (absolute Doppler blood pressure < 50 mmHg or pres-
ence of ulcers or gangrene with Doppler pressure > 50 mmHg)
- Concomitant disease such as musculoskeletal or cardiac that was prohibitive to 
exercise
Number of participants assessed and randomised: 144 participants assessed, 
127 participants randomised (93 participants in the femoropopliteal trial and 34 
participants in the aortoiliac trial)
Demographics
Femoropopliteal disease trial
- Age (years): Group 1: 63.9 (SD: 9.0); Group 2: 68.5 (SD: 9.4)
- Gender (male): Group 1: 33 (69%); Group 2: 26 (58%)
Aortoiliac disease trial
- Age (years): Group 1: mean 63.9 (SD 8.6); Group 2: mean 62.5 (SD 9.8)
- Gender (male): Group 1: 12 (62%); Group 2: 10 (67%)
Interventions Group 1: endovascular revascularisation with selective stenting plus supervised 
exercise therapy, n = 48 (femoropopliteal disease trial), and n = 19 (aortoiliac 
disease trial)
Group 2: supervised exercise therapy for 6 months (≥ 1 session/week, 30 minutes/
session), n = 45 (femoropopliteal disease trial), and n = 15 (aortoiliac disease trial)
Compliance with interventions
Femoropopliteal trial
- Group 1: in 11/44 participants, endovascular revascularisation recorded as failed, 
62% attended available weekly exercise classes
- Group 2: 61% attended available weekly exercise classes
Aortoiliac trial
- Group 1: in 2/19 participants, endovascular revascularisation recorded as failed, 
53% attended available weekly exercise classes
- Group 2: 48% attended available weekly exercise classes
Mortality
Femoropopliteal trial
- Group 1: 2 participants
- Group 2: 2 participants
Aortoiliac trial
- Group 1: 1 participants
- Group 2: 2 participants
Loss to follow-up
Femoropopliteal trial
- Group 1: 3 participants
- Group 2: 6 participants
Aortoiliac trial
- Group 1: 4 participants
- Group 2: 1 participants
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Outcomes Absolute walking distance, initial claudication distance, number of secondary 
interventions, SF-36 physical health score , SF-36 physical mental score, proce-
dure-related complications
Notes Source of funding: Camelia Botnar Arterial Research Foundation with independ-
ent educational grants from Bard Ltd., Boston Scientific Ltd., and Cook
Authors’ conclusion: “PTA confers adjuvant benefit over supervised exercise and 
best medical therapy in terms of walking distances and ABPI 24 months after PTA 
in patients with stable mild to moderate intermittent claudication.”
Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Low risk Adequate randomisation technique using “randomly permuted 
blocks of unequal size generated by Stata”
Allocation concealment 
(selection bias)
Low risk Central allocation, “performed by the trial manager via a laptop 
computer whilst on site at each centre”
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
High risk Blinding of participants and personnel not possible given the 
nature of the intervention (endovascular revascularisation)
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Unclear risk Blinding of assessors not adequately discussed in the study
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk Analysis based on an intention-to-treat principle, censoring at 24 
months moderate (17%) and comparable between groups
Selective reporting 
(reporting bias)
Unclear risk Prespecified maximum walking distance reported; for pain-
free walking distance, no absolute distances reported during 
follow-up
Other bias Unclear risk Intended recruitment based on power calculations 170 partic-
ipants in each trial, eventually including 93 participants in the 
femoropopliteal trial and 34 participants in the aortoiliac trial
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Hobbs 2006
Methods Study design: parallel 3-arm RCT
Number of sites: 4
Sample size estimation: 21 participants (7 per group) required to detect a 75% 
reduction in the thrombin antithrombin complex in treatment groups with 80% 
power and a P value of 0.05
Follow-up: 3 and 6 months
Participants Country and setting: United Kingdom, Department of Vascular Surgery at Univer-
sity of Birmingham
Inclusion criteria
- Confirmed mild to moderate intermittent claudication (defined as absolute clau-
dication distance (of 50 to 500 m on a treadmill) due to infrainguinal disease
- Suitable for unilateral infrainguinal endovascular revascularisation and participa-
tion in a supervised exercise programme
- 3 to 6 months stabilised on best medical therapy before consideration for study 
entry
Exclusion criteria
- Significant aortoiliac disease
- Equally severe bilateral symptoms (making them unsuitable for unilateral 
angioplasty)
- Previous ipsilateral infrainguinal intervention
- Unable to exercise to absolute claudication distance on treadmill
Number of participants assessed and randomised: 372 participants screened for 
entry; from them 23 participants randomised to 1 of 3 treatment arms
Demographics
- Age (years): Group 1: median 67 (IQR 57 to 77); Group 2: median 67 (IQR 58 to 
71); Group 3: median 67 (IQR 57 to 77)
- Gender (male): Group 1: 6 (67%); Group 2: 6 (86%); Group 3: 4 (57%)
Interventions Group 1: endovascular revascularisation without stenting plus best medical ther-
apy, n = 9
Group 2: supervised exercise therapy plus best medical therapy for 12 weeks (2 
sessions/week, 60 minutes/session), n = 7
Group 3: best medical therapy based on cardiovascular risk factor management, 
n = 7 (for analysis, this group was labelled as ‘no therapy’)
Compliance with interventions: not reported
Mortality
- Group 1: 0 participants
- Group 2: 0 participants
- Group 3: 0 participants
Loss to follow-up
- Group 1: 0 participants
- Group 2: 1 participant
- Group 3: 0 participants
Outcomes Maximum walking distance, pain-free walking distance
Notes Source of funding: Health Technology Assessment Grant
Authors’ conclusion: “The addition of lower limb revascularization by PTA to best 
medical therapy in patients with intermittent claudication due to infra-inguinal 
disease results in a medium-term improvement in the resting procoagulant and 
hypo fibrinolytic state.”
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Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Unclear risk Participants underwent “central randomisation”, yet exact rando-
misation technique not specified
Allocation concealment 
(selection bias)
Unclear risk Study did not address allocation concealment process
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
High risk Blinding of participants and personnel not possible given the 
nature of the intervention (endovascular revascularisation)
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Unclear risk Blinding of assessors not adequately discussed in the study
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk During 6-month follow-up, only 1 participant withdrew (4%) from 
the study
Selective reporting 
(reporting bias)
Low risk All relevant outcome measures as specified in the methods 
section were reported
Other bias Unclear risk Study was not powered to consider walking distances as primary 
endpoint; study was closed early including only 10% of required 
participants
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Mazari 2011
Methods Study design: parallel 3-arm RCT
Number of sites: 1
Sample size estimation: 60 participants in each treatment arm based on 80% 
power, α = 0.05, and anticipating a 20% dropout rate to detect a 20% difference 
between treatment arms in physical function domain of SF-36
Follow-up: 1,3, 6, and 12 months
Participants Country and setting: United Kingdom, Vascular Surgical Unit of a university 
hospital
Inclusion criteria
- Symptomatic unilateral intermittent claudication
- Femoropopliteal lesion amenable to angioplasty (as discussed in a multi-discipli-
nary meeting)
- Symptoms stable after 3 months on best medical therapy
Exclusion criteria
- Critical limb ischaemia
- Incapacitating systemic disease
- Inability to tolerate treadmill testing (unrelated to limb ischaemia)
- Significant Ischaemic changes on ECG during treadmill testing
- Ipsilateral vascular surgery or peripheral angioplasty within previous 6 months
Number of participants assessed and randomised: 1157 participants were assessed 
for inclusion; from them 178 participants were randomised to 1 of 3 treatment 
arms
Demographics
- Age (years): Group 1: median 69.5 (95% CI 64 to 79); Group 2: median 70 (95% 
CI 63 to 75); Group 3: median 69 (95% CI 63 to 76)
- Gender (male): Group 1: 33 (57%); Group 2: 37 (62%); Group 3: 37 (62%)
Interventions Group 1: endovascular revascularisation without stenting plus supervised exercise 
therapy, n = 58
Group 2: endovascular revascularisation without stenting, n = 60
Group 3: supervised exercise therapy for 12 weeks (3 sessions/week), n = 60
Compliance with interventions: not reported
Mortality
- Group 1: 1 participant
- Group 2: 0 participants
- Group 3: 0 participants
Loss to follow-up
- Group 1: 10 participants
- Group 2: 8 participants
- Group 3: 14 participants
Outcomes Maximum walking distance, pain-free walking distance, number of secondary 
interventions, SF-36 Physical Function, SF-36 Role Physical, SF-36 Bodily Pain, 
SF-36 General Health, SF-36 Vitality, SF-36 Social, SF-36 Emotional, SF-36 Mental, 
VascuQol, self-reported maximum walking distance
Notes Source of funding: BJS research bursary, European Society of Vascular Surgery 
research grant, and support from the Academic Vascular Surgical Unit, University 
of Hull
Authors’ conclusion: “For patients with intermittent claudication due to femo-
ropopliteal disease, PTA, supervised exercise and PTA plus supervised exercise 
were all equally effective in improving walking distance and quality of life after 12 
months.”
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Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Unclear risk Participants were “randomised into one of the three treatment 
arms”; exact sequence generation method not reported
Allocation concealment 
(selection bias)
Low risk Sealed envelopes were used
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
High risk Blinding of participants and personnel not possible given the 
nature of the intervention (endovascular revascularisation)
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Unclear risk Blinding of assessors not adequately discussed in the study
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk Sufficient number of participants (82%) analysed after 1 year of 
follow-up; censoring comparable between groups
Selective reporting 
(reporting bias)
Low risk All relevant outcome measures as specified in the methods 
section were reported
Other bias Low risk No other forms of bias identified
Murphy 2015
Methods Study design: parallel 4-arm RCT
Number of sites: 22
Sample size estimation: Allowing 30% premature withdrawal, 252 participants 
would be needed to have 80% power to detect relevant difference between 
supervised exercise and stenting groups. Sample size was adjusted to 217 after 
removal of stenting plus supervised exercise arm owing to slow enrolment.
Follow-up: 6 and 18 months
Participants Country and setting: United States, university and non-university hospitals
Inclusion criteria
- Symptoms of moderate to severe intermittent claudication (ability to walk 2 to 11 
minutes on a graded treadmill test)
- Objective evidence of a haemodynamically significant aortoiliac arterial stenosis 
established by non-invasive vascular testing
Exclusion criteria
- Critical limb ischaemia
- Comorbid conditions limiting participants’ walking ability
- More than 25% deviation between 2 treadmill tests at baseline
- Total aortoiliac occlusion from the level of the renal arteries to the inguinal 
ligaments
Number of participants assessed and randomised: 999 participants screened, 119 
participants randomised to 1 of 4 treatment arms
Demographics
- Age (years): Group 1: mean 65 (SD 10); Group 2: mean 64 (SD 10); Group 3: 
mean 62 (SD 8)
- Gender (male): Group 1: 32 (70%); Group 2: 21 (49%); Group 3: 16 (73%)
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Interventions Group 1: endovascular revascularisation with primary stenting plus claudication 
pharmacotherapy (cilostazol), n = 46
Group 2: supervised exercise therapy for 26 weeks (3 sessions/week, 1 hour/ses-
sion) supplemented by 12-month telephone-based (1 to 2 calls/mo) programme 
to adhere and maintain adherence plus claudication pharmacotherapy (cilosta-
zol), n = 43
Group 3: claudication pharmacotherapy, including cilostazol 100 mg twice daily 
and advice on home exercise and diet, n = 22
Group 4: endovascular revascularisation plus supervised exercise therapy and 
claudication pharmacotherapy (cilostazol), n = 8 (inclusion in this study arm 
stopped prematurely and study arm excluded from further analysis)
Compliance with interventions
- Group 1: 43 participants received assigned intervention, all procedures techni-
cally successful, > 90% adherence to cilostazol treatment
- Group 2: 29 (71%) participants attended at least 70% of 78 scheduled exercise 
sessions, > 90% adherence to cilostazol treatment
- Group 3: > 90% adherence to cilostazol treatment
Mortality
- Group 1: 0 participants
- Group 2: 1 participant
- Group 3: 0 participants
Loss to follow-up
- Group 1: 5 participants
- Group 2: 8 participants
- Group 3: 4 participants
Outcomes Maximum walking distance, pain-free walking distance, number of secondary 
interventions, procedure-related complications, SF-12 Physical, SF-12 Mental, 
Walking Impairment Questionnaire Score, Peripheral Artery Questionnaire Score, 
hourly free-living steps on pedometer
Notes Source of funding: grants from National Heart, Lung, and Blood Institute. Finan-
cial support from Cordis/Johnson & Johnson (Warren, NJ), eV3 (Plymouth,MN), 
and Boston Scientific (Natick, MA). Cilostazol was donated to all study participants 
by Otsuka America, Inc (San Francisco, CA). Pedometers were donated by Omron 
Healthcare, Inc (Lake Forest, IL). Krames Staywell (San Bruno, CA) donated print 
materials on exercise and diet.
Notes: The endovascular revascularisation plus supervised exercise therapy treat-
ment arm was stopped after including 8 participants owing to slow enrolment.
Authors’ conclusion: “Both supervised exercise and endovascular revasculariza-
tion had better 18-month outcomes than medical treatment. Both treatments 
provided comparable durable improvement in functional status and in quality of 
life up to 18 months. The durability of claudication exercise interventions merits its 
consideration as a primary claudication treatment.”
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Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Low risk A real-time Web-based randomisation programme was used to 
randomise participants
Allocation concealment 
(selection bias)
Low risk Central Web-based allocation concealment
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
High risk Blinding of participants and personnel not possible given the 
nature of the intervention (endovascular revascularisation)
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Low risk Study reported to be an “observer-blinded” randomised trial
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk All analyses according to intention-to-treat principle; censoring 
was moderate (10%) after 6 months’ follow-up and was well 
balanced between treatment groups
Selective reporting 
(reporting bias)
Low risk All relevant outcome measures as specified in the methods 
section were reported
Other bias Unclear risk Intended recruitment based on power calculations was 252 par-
ticipants; eventually 119 participants were included in the study
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Nordanstig 2014
Methods Study design: parallel 2-arm RCT
Number of sites: 1
Sample size estimation: From power calculations, a total sample size of 158 partic-
ipants was needed with the assumption of a maximum dropout rate of 25% and 
80% power to detect relevant differences between the 2 groups.
Follow-up: 6 and 12 months
Participants Country and setting: Sweden, Department of Vascular Surgery at university 
hospital
Inclusion criteria
- Stable (≥ 6 months) intermittent claudication, without any other important 
activity-limiting medical condition
- Aged ≤ 80 years
Exclusion criteria
- Very mild claudication symptoms
- Severe claudication symptoms making invasive treatment mandatory
- Weight > 120 kg
- ≥ 2 previously failed ipsilateral vascular interventions
- Inability to understand the Swedish language
Number of participants assessed and randomised: 464 participants screened for 
inclusion; of these, 205 participants were eligible, and eventually 158 participants 
were randomised in the trial
Demographics
- Age (years): Group 1: mean 68 (SD 7); Group 2: mean 68 (SD 6)
- Gender (male): Group 1: 41 (52%); Group 2: 38 (48%)
Interventions Group 1: invasive vascular procedure including open surgery or endovascular 
revascularisation with primary stenting in the aortoiliac segment and selective 
stenting in the femoropopliteal segment plus claudication pharmacotherapy 
(cilostazol 100 mg twice daily), home-based exercise training advice, and cardi-
ovascular risk factor management, n = 79 (of these, 52 participants received an 
endovascular revascularisation procedure)
Group 2: non-invasive management including claudication pharmacotherapy 
(cilostazol 100 mg twice daily), home-based exercise training advice, and cardio-
vascular risk factor management, n = 79
Compliance with interventions
- Group 1: 70 participants received invasive treatment; from them, 52 participants 
received an endovascular intervention, 60% adherence to cilostazol treatment at 
12 months, no data on exercise adherence
- Group 2: 60% adherence to cilostazol treatment at 12 months; no data on 
exercise adherence
Mortality
- Group 1: 1 participant of the 52 participants receiving endovascular 
revascularisation
- Group 2: 0 participants
Lost to follow up:
- Group 1: 2 participants of 52 participants receiving endovascular 
revascularisation
- Group 2: 3 participants
Outcomes Maximum walking distance, intermittent claudication distance, number of sec-
ondary interventions, procedure-related complications, SF-36 Physical Function, 
SF-36 Role Physical, SF-36 Bodily Pain, SF-36 General Health, SF-36 Vitality, SF-36 
Social, SF-36 Emotional, SF-36 Mental Health, and VascuQol
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Notes Source of funding: Study was funded by the Fred G. and Emma E. Kanolds 
Foundation/Gothenburg Medical Society; Helena Ahlin Foundation; Odd Fellow, 
Karlstad, Sweden; Swedish Heart and Lung Foundation; and Hjalmar Svensson 
Foundation.
Notes: Outcome data from the subgroup of 52 participants who received an 
endovascular revascularisation at baseline in the invasive treatment group were 
provided by study authors and were included in the analyses in this systematic 
review.
Authors’ conclusion: “An invasive treatment strategy improves health-related 
quality of life and intermittent claudication distance after 1 year in patients with 
stable lifestyle-limiting claudication receiving current medical management. 
Long-term follow-up data and health-economic assessments are warranted to 
further establish the role for revascularization in intermittent claudication.”
Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Low risk Randomisation was performed via computerised randomisation 
software based on minimisation method
Allocation concealment 
(selection bias)
Low risk Allocation sequence was concealed using computerised rando-
misation software
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
High risk Blinding of participants and personnel not possible given the 
nature of the intervention (endovascular revascularisation)
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Unclear risk Blinding of assessors not adequately discussed in the study
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk All analysis performed by intention-to-treat principle; censoring 
during 12-month follow-up low and well balanced between 
treatment groups
Selective reporting 
(reporting bias)
Low risk All relevant outcome measures as specified in the methods sec-
tion were reported in the results section
Other bias Low risk No other forms of bias identified
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Nylaende 2007
Methods Study design: parallel 2-arm RCT
Number of sites: 1
Sample size estimation: approximately 100 participants in each group; thus a total 
of 200 participants to detect a difference of 20% in QoL between groups assum-
ing type I error of 5% and power of 80%
Follow-up: 3, 12, and 24 months
Participants Country and setting: Norway, Centre of Vascular Surgery at university hospital
Inclusion criteria
- < 80 years of age
- Symptomatic IC > 3 months
- Ankle brachial index < 0.9 without pain at rest and/or ischaemic skin changes
- Lesion feasible for angioplasty evaluated by angiography
- Subjective pain-free walking distance < 400 metres
- Ability to exercise on a treadmill
Exclusion criteria
- Previous vascular or endovascular surgery
- Diabetic skin ulceration
- Renal insufficiency (defined as serum creatinine > 150 mmol/L)
- Oral anticoagulant medication
- Suffering from a physical or mental disorder expected to impede compliance
Number of participants assessed and randomised: 826 participants were assessed 
for inclusion; finally 56 participants could be included and randomised to 1 of 2 
treatment groups.
Demographics
- Age (years): Group 1: median 68 (25 to 75 percentiles: 56 to 72); Group 2: 
median 69 (25 to 75 percentiles: 61 to 75)
- Gender (male): Group 1: 16 (57%); Group 2: 15 (54%)
Interventions Group 1: endovascular revascularisation with primary stenting for iliac occlusions 
and selective stenting for iliac stenoses plusoptimal medical treatment, n = 28
Group 2: optimal medical treatment including active smoking cessation, advice on 
home-based exercise therapy, individual nutritional advice, and acetylsalicylic acid 
160 mg daily to all participants and cardiovascular risk factor management, n = 28 
(for analysis, this group was labelled as ‘no therapy’)
Compliance with interventions
- Group 1: All procedures were technically successful.
- Group 2: No data were provided on home-based exercise therapy compliance.
Mortality
- Group 1: 1 participant
- Group 2: 0 participants
Loss to follow-up
- Group 1: 1 participant
- Group 2: 4 participants
Outcomes Maximum walking distance, pain-free walking distance, number of secondary 
interventions, SF-36 Physical Function, SF-36 Role Physical, SF-36 Bodily Pain, 
SF-36 General Health, SF-36 Vitality, SF-36 Social, SF-36 Emotional, SF-36 Mental, 
SF-36 Health Transition, Claudication Score (5 domains), visual analogue scale
Notes Source of funding: unrestricted grants from Pfizer AS, Norway
Authors conclusion: “Early intervention with PTA in addition to optimal medical 
treatment seems to have a generally more positive effect compared to optimal 
medical treatment only, on haemodynamic, functional as well as quality of life 
aspects during the first 2 years in patients with intermittent claudication.”
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Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Low risk A “computerized randomisation list” was used
Allocation concealment 
(selection bias)
Low risk Sealed envelopes were used
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
High risk Blinding of participants and personnel not possible given the 
nature of the intervention (endovascular revascularisation)
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Unclear risk Blinding of assessors not adequately discussed in the study
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk All relevant outcome measures as specified in the methods 
section were reported
Selective reporting 
(reporting bias)
Low risk Censoring during 12-month follow-up minimal (9%) and well 
balanced between groups
Other bias Unclear risk Intended recruitment based on power calculations was 200 par-
ticipants; eventually 56 participants were included in the study,
Source of funding: unrestricted grants from Pfizer AS, Norway
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Spronk 2009
Methods Study design: parallel 2-arm RCT
Number of sites: 1
Sample size estimation: 68 participants in each arm based on 80% power and 
significance level of 0.05 to detect 25% difference in improvement in physical 
functioning dimension of SF-36 between the 2 groups
Follow up: 1, 6, 12 months and 7 years
Participants Country and setting: Netherlands, outpatient clinic at a non-university hospital
Inclusion criteria
- Rutherford category 1, 2, or 3 claudication with duration ≥ 3 months
- Maximum pain-free walking distance < 350 metres
- Ankle-brachial index < 0.9 at rest or decreasing by more than 0.15 after the 
treadmill test
- ≥ 1 vascular stenoses of > 50% diameter reduction at the iliac or femoropop-
liteal level on magnetic resonance angiography
Exclusion criteria
- Abdominal aortic aneurysm, life-incapacitating cardiac disease (New York Heart 
Association Class III and higher)
- Multi-level disease (i.e. same-side stenoses at both iliac and femoral levels, 
requiring multiple revascularisation procedures)
- Isolated tibial artery disease
- Lesions deemed unsuitable for revascularisation
- Prior treatment for the lesion (including exercise therapy)
Number of participants assessed and randomised: 293 participants assessed, 151 
participants randomised to 1 of 2 treatment groups
Demographics
- Age (years): Group 1: mean 65 (SD 11); Group 2: mean 66 (SD 9)
- Gender (male): Group 1: 44 (59%); Group 2: 39 (52%)
Interventions Group 1: endovascular revascularisation with selective stenting, n = 76
Group 2: supervised exercise therapy for 24 weeks (2 sessions/week, 30 minutes/
session), n = 75
Compliance with interventions
- Group 1: In 4 participants, revascularisation failed technically
- Group 2: Per participant, on average 33 (SD 10) sessions of exercise followed
Mortality
- Group 1: 5 participants (after 7 years: 15)
- Group 2: 3 participants (after 7 years: 17)
Loss to follow-up
- Group 1: 2 participants (after 7 years: 14)
- Group 2: 0 participants (after 7 years: 22)
Outcomes Maximum walking distance, pain-free walking distance, number of secondary 
interventions, procedure-related complications, SF-36 Physical Functioning, SF-36 
Physical Role, SF-36 Bodily Pain, SF-36 General Health, VascuQol
Notes Source of funding: not applicable
Authors conclusion: “After 6 and 12 months, patients with intermittent claudica-
tion benefited equally from either endovascular revascularization or supervised 
exercise.”
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Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Low risk A “computer generated block-randomized list” was used, pre-
pared in advance by an independent statistician
Allocation concealment 
(selection bias)
Low risk Allocation was “sealed for every particular participant.”
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
High risk Blinding of participants and personnel not possible given the 
nature of the intervention (endovascular revascularisation)
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Low risk Walking distance evaluated by an independent assessor blinded 
to assigned treatment
Incomplete outcome 
data (attrition bias) 
All outcomes
Low risk All analysis according to intention-to-treat principle; after 12 
months’ follow-up, censoring minimal (7%) and well balanced 
between the 2 groups
Selective reporting 
(reporting bias)
Low risk All relevant outcome measures as specified in the methods 
section were reported
Other bias Low risk No other forms of bias identified
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Whyman 1996
Methods Study design: parallel 2-arm RCT
Number of sites: 1
Sample size estimation: 54 participants based on 90% power and significance 
level of 0.05 to detect 40% difference in number of participants with symptomatic 
improvement between intervention and control groups
Follow-up: 3, 6, and 24 months
Participants Country and setting: United Kingdom, outpatient department of a university 
hospital
Inclusion criteria
- Predominantly unilateral intermittent claudication
- Lesion suitable for endovascular revascularisation
Exclusion criteria
- Previous angioplasty or arterial surgery to the symptomatic leg
- Iliac occlusion or > 10 cm length femoropopliteal occlusion, multiple stenoses or 
diffuse disease with long stenoses
- Participants taking oral anticoagulants
- Duration of symptoms < 1 month
- Inability to manage the treadmill examination
- Any psychiatric illness or other reason making follow-up difficult.
Number of participants assessed and randomised: 425 participants assessed, 62 
participants randomised
Demographics
- Age (years): Group 1: mean 60.6 (range 44 to 73); Group 2: mean 62.6 (range 45 
to 78)
- Gender (male): Group 1: 23 (77%); Group 2: 28 (88%)
Interventions Group 1: endovascular revascularisation without stenting, n = 30
Group 2: conventional medical treatment including low-dose aspirin plus advice 
on smoking and exercise, n = 32 (for analysis, this group was labelled as ‘no 
therapy’)
Compliance with interventions: not reported
Mortality
- Group 1: 0 participants
- Group 2: 2 participants
Loss to follow-up
- Group 1: 1 participant
- Group 2: 2 participants
Outcomes Maximum walking distance, pain-free walking distance, number of secondary 
interventions, Nottingham health profile scores, self-reported maximum walking 
distance
Notes Source of funding: grant from the Scottish Home and Health Department, cost of 
balloon catheters from Meadox, UK
Authors’ conclusion: “Two years after PTA, patients had less extensive disease 
than medically treated patients, but this did not translate into a significant advan-
tage in terms of improved walking or quality of life.”
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Risk of bias
Bias Authors’ 
judgement
Support for judgement
Random sequence 
generation (selection 
bias)
Low risk Randomisation was carried out via a computerised random 
allocation system
Allocation concealment 
(selection bias)
Low risk Allocation was carried out via a computerised random allocation 
system
Blinding of participants 
and personnel (perfor-
mance bias) 
All outcomes
High risk Blinding of participants and personnel not possible given the 
nature of the intervention (endovascular revascularisation)
Blinding of outcome 
assessment (detection 
bias) 
All outcomes
Unclear risk Blinding of assessors not adequately discussed in the study
Incomplete outcome 
data (attrition bias) 
All outcomes
Unclear risk Censoring minimal (5%) and comparable between groups, yet 
participants in the control group who underwent angioplasty or 
surgery excluded from analysis
Selective reporting 
(reporting bias)
Low risk All relevant outcome measures as specified in the methods 
section were reported
Other bias Unclear risk Source of funding: cost of balloon catheters from Meadox, UK
ABI: ankle brachial pressure index.
IC: intermittent claudication.
IQR: interquartile range.
PTA: percutaneous transluminal angioplasty.
QoL: quality of life.
RCT: randomised controlled trial.
SD: standard deviation.
SF-36: Short Form-36.
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Characteristics of excluded studies 
Study Reason for exclusion
Bo 2013 All participants received endovascular revascularisation
Brodmann 2013 Two endovascular revascularisation techniques were compared; no non-interven-
tional treatment group was included
Gabrielli 2012 Two endovascular revascularisation techniques were compared; no non-interven-
tional treatment group was included
Gelin 2001 Intervention group included participants with open and endovascular revascu-
larisation; no data could be provided for the subgroup of participants receiving 
endovascular revascularisation
Giugliano 2013 Participant assignment to a specific group of treatment was not randomised
Heider 2009 Participants were followed up to 4 weeks. No relevant outcome measures for this 
systematic review were reported
Husmann 2008 Walking distances were recorded only up to 1 month follow-up; no long-term 
data were provided. In addition, no other relevant outcome measures for this 
systematic review were reported
Kruidenier 2011 All participants received endovascular revascularisation
Thomson 1999 Abstract data only with incomplete results; no additional data could be provided
Characteristics of ongoing studies 
Frans 2012a
Trial name or title SUPERvised Exercise Therapy or Immediate PTA for Intermittent Claudication in 
Participants With an Iliac Artery Obstruction
Methods Study design: multi-centre randomised controlled trial
Sites: 15 Dutch hospitals
Sample size estimation: 400 participants to detect a clinically relevant difference 
in quality-adjusted life-years between the 2 groups based on 90% power and 2-
sided significance level of 0.05
Follow up: 1 week, 1, 6, and 12 months
Participants Consecutive outpatients with intermittent claudication due to aortoiliac disease 
with a walking distance between 100 and 300 metres on a treadmill at 3.2 km/h 
and 10% incline. All participants must have an iliac artery obstruction with a diam-
eter reduction ≥ 50%
Interventions Group 1: endovascular revascularisation with selective stenting
Group 2: supervised exercise therapy for 6 months
Outcomes Maximum walking distance, pain-free walking distance, complications, treatment 
failures, additional interventions, costs, AMC linear disability score, VascuQol, 
Short-Form 36, EuroQol
Starting date Inclusion started in September 2011
Contact information m.j.koelemaij@amc.uva.nl
Notes Owing to slow enrolment, inclusion stopped prematurely (241 participants 
included per May 2015; www.superstudie.nl).
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NCT01230229
Trial name or title Primary Stenting vs Conservative Treatment in Claudicants - A Study on Quality of 
Life (NCT01230229)
Methods Study design: randomised controlled trial
Estimated enrolment: 100 participants
Follow-up: 12 and 24 months
Participants Patients with stable intermittent claudication (Fontaine IIa and IIb) due to superfi-
cial femoral artery disease
Interventions Group 1: endovascular revascularisation with primary stenting (self-expanding 
stent)
Group 2: best medical treatment including an exercise programme
Outcomes Primary: improvement in quality of life scores (Short Form-36 and EuroQol-5D 
surveys)
Secondary: ABI, walking distances, cost parameters
Starting date January 2010
Contact information Hans Lindgren, MD; e-mail: hanslindgren@gmail.com
Notes Planned recruitment and randomisation of 100 participants; estimated 
study completion date June 2017 (https://clinicaltrials.gov/ct2/show/study/
NCT01230229?term=endovascular+and+claudication#desc)
ABI: ankle brachial pressure index.
AMC: academic medical centre.
PTA: percutaneous transluminal angioplasty.
QoL: quality of life.
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ABSTRACT
Background
Long-term comparisons of supervised exercise and endovascular revascularization for 
patients with intermittent claudication are scarce. The long-term clinical effectiveness of 
supervised exercise therapy and endovascular revascularization was assessed in patients 
from a randomized trial.
Methods 
Consenting patients with intermittent claudication were assigned randomly to either 
supervised exercise therapy or endovascular revascularization. Outcome measures on 
functional performance (pain-free and maximum walking distance, ankle : brachial 
pressure index), quality of life (QoL) and number of secondary interventions were measured 
at baseline and after approximately 7 years of follow-up. Repeated-measurement and 
Kaplan–Meier methods were used to analyse the data on an intention-to treat-basis.
Results
A total of 151 patients were randomized initially to either supervised exercise therapy 
or endovascular revascularization. After 7 years, functional performance (P <0·001) and 
QoL (P ≤0·005) had improved after both supervised exercise therapy and endovascular 
revascularization. Long-term comparison showed no differences between the two 
treatments, except in the secondary intervention rate, which was significantly higher after 
supervised exercise therapy (P=0.001). Nevertheless, the total number of endovascular 
and surgical interventions (primary and secondary) remained higher after endovascular 
revascularization (P <0·001).
Conclusions
In the longer term, supervised exercise therapy-first or endovascular revascularization-
first treatment strategies were equally effective in improving functional performance and 
QoL in patients with intermittent claudication. The substantially higher number of invasive 
interventions in the endovascular revascularization-first group supports a supervised 
exercise therapy-first treatment strategy for intermittent claudication. Registration 
number: NTR199 (http://www.trialregister.nl). 
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Intermittent claudication, Rutherford categories 1–31, is the classical symptom of 
peripheral arterial disease (PAD). intermittent claudication affects about 2 per cent of 
the population aged 40–44 years, increasing to 8 per cent in people aged 70–74 years2. 
Patients with intermittent claudication have significant functional disability due to their 
impairedwalking3, and suffer reduced quality of life (QoL), which is comparable to the 
situation in other forms of cardiovascular disease4. Previous studies have established 
both supervised exercise therapy and endovascular revascularization to be effective in 
improving walking performance and QoL in patients with intermittent claudication5,6. 
Consequently both strategies are recommended as treatment options by the TransAtlantic 
Inter-Society Consensus (TASC) II and the American College of Cardiology/American 
Heart Association Practice guidelines for the management of patients with PAD2,7. 
supervised exercise therapy has the advantage of being a safe non-invasive treatment, 
whereas endovascular revascularization is attractive because of its immediate effect, if 
successful. Direct comparison of these two options in the long term can help determine 
which treatment is more durable and should be offered as initial therapy for intermittent 
claudication. 
Controlled trials comparing supervised exercise therapy and endovascular 
revascularization, especially in the long term, are scarce. Previously, the Comparing 
Exercise Therapy with Angioplasty for Claudication (CETAC) trial8 and a systematic review, 
with results from three other controlled trials comparing supervised exercise therapy and 
endovascular revascularization for intermittent claudication9, concluded that the clinical 
effectiveness of supervised exercise therapy and endovascular revascularization was 
equivalent after 12 months. However, owing to lack of long-term data, it remains unclear 
whether the improvements gained in the first 12 months are sustained. 
This study was a late evaluation of patients from the CETAC trial. The aim was to 
compare the long-term clinical effectiveness of a supervised exercise therapy-first or 
an endovascular revascularization-first treatment strategy in patients with intermittent 
claudication. 
METHODS
The study design and methods of the CETAC trial have been published previously8. The 
CETAC trial was a single-centre randomized trial comparing the clinical effectiveness of 
supervised exercise therapy versus endovascular revascularization as initial treatment 
for patients with intermittent claudication. The study was approved by the institutional 
review board and guidelines of Good Clinical Practice and the Consolidated Standards 
of Reporting Trials were followed10. The study was registered as an international standard 
randomized controlled trial (ISRCTN 64443682)11. 
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Study patients and randomization 
In brief, patients with stable intermittent claudication visiting the outpatient clinic were 
considered for inclusion in the trial if they were suitable candidates for both supervised 
exercise therapy and endovascular revascularization, and agreed to participate in the 
trial. Inclusion and exclusion criteria have been published previously8. Patients with both 
iliac and femoropopliteal disease diagnosed on magnetic resonance angiography were 
included. After providing informed consent, patients were randomized to either supervised 
exercise therapy or endovascular revascularization using a computer-generated block-
randomized list. For the purposes of the present study, participants in the CETAC trial 
were contacted again, and those willing to be reinvestigated signed a new consent form. 
Those who could not attend the clinic were contacted by telephone, and asked to fill in a 
QoL questionnaire and return it by mail.
Interventions
At baseline, patients with one or more risk factors for cardiovascular disease were referred 
to an internal medicine physician for secondary prevention according to the European 
Society of Cardiology guidelines on cardiovascular risk factor management in clinical 
practice8,12. 
The supervised exercise therapy programme consisted of 24-weeks of supervised 
treadmill exercise, two sessions per week, each lasting 30 min8. In addition, patients were 
encouraged to walk for at least 30min three times a week at home and to continue 
walking for at least 1 h per day after completing the 24-week programme. 
Endovascular revascularization was performed by an experienced interventional 
radiologist. For iliac revasculari zation, a self-expanding nitinol stent was placed if the 
initial balloon angioplasty was not technically successful. For femoral revascularization, a 
self-expanding nitinol stent was placed if the residual lumen diameter was less than 50 
per cent after the initial balloon angioplasty. After the procedure all the patients were 
given general recommendations concerning lifestyle changes and were strongly advised 
to walk regularly.
Outcome measures and assessments
Consenting patients attended for a standard treadmill walking test (speed 3·5 km/h, 
no graded incline) to assess functional performance, which included maximum walking 
distance (MWD), pain-free walking distance (PFWD), and ankle : brachial index (ABI) at 
rest and after the treadmill walking test. They also completed a patientreported QoL 
questionnaire. 
The questionnaire consisted of the rating scale13, Short Form 36 (SF-36; QualityMetric, 
Lincoln, Rhode Island, USA)14 and the PAD-specific vascular QoL score (VascuQoL)15 
instruments. As physical functioning, role functioning limitations due to physical problems, 
bodily pain and general health domains of the SF-36 instrument are the most relevant for 
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describing the health status of patients with PAD8,16, the present analysis was restricted to 
these four domains. For all reported QoL instruments, higher scores correspond to better 
QoL as perceived by the patient.
Secondary interventions and outcomes
To gather information on the type, date and cause of any subsequent secondary 
intervention following initial randomization, the patients’ medical records were reviewed 
by two authors independently. Disagreements were resolved by consensus. A secondary 
intervention was defined as an additional invasive treatment offered to the patient during 
follow-up as a result of primary randomized treatment failure. This included any surgical 
or endovascular intervention. The number of patients who required leg amputations as a 
consequence of limb ischaemia was registered for each treatment group. If a patient had 
died during follow-up, the hospital records were searched and, if necessary, the patient’s 
general practitioner was contacted to determine the exact date and cause of death.
Statistical analysis
The main analyses were conducted according to the intention-to-treat principle. 
Completeness of long-term follow-up in each treatment group was calculated as the 
ratio of the total observed person-time of follow up to the potential maximum17. For 
the continuous outcome measures of physical performance and QoL, the significance 
of mean change within and between each treatment group at follow-up compared with 
baseline was analysed using mixed models for repeated measures. The significance of 
differences between the two treatment groups regarding survival and having one or more 
secondary intervention(s) was evaluated using Fisher’s exact test, Kaplan–Meier methods, 
and Cox regression analysis to calculate hazard ratios (HRs) with 95 percent confidence 
intervals (c.i.). In the Kaplan–Meier analysis for secondary interventions, patients without 
a secondary intervention were censored at death, loss to follow-up or at the end of 
the study. The log rank test was used to compare the Kaplan–Meier curves. Post hoc 
perprotocol analyses were performed, which included data from patients who completed 
the allocated treatment and finished the study without any secondary intervention.
Furthermore, a sensitivity analysis excluding patients with missing values in the long 
term was performed (completecase analysis) to determine whether this might affect the 
main results. For all analyses a significance level of 0.050 (two-sided) was considered 
statistically significant. Analyses were carried out using SPSS version 17 software (IBM, 
Armonk, New York, USA) and SAS version 9.2 (SAS Institute, Cary, North Carolina,USA). 
RESULTS
A total of 151 patients were initially assigned randomly to supervised exercise therapy 
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(75) or endovascular revascularization (76). In the endovascular revascularization group 
one patient refused further participation after randomization, but before undergoing 
the intervention and baseline data collection; this patient was therefore excluded from 
further analysis. There were no significant differences in baseline characteristics regarding 
demographic data and co-morbidities between the supervised exercise therapy and 
endovascular revascularization groups8. Baseline functional performance measures and 
QoL scores were also comparable between groups, except for PFWD (P=0.043)8. Similarly, 
baseline characteristics of the patients available for long-term follow-up were comparable 
in the supervised exercise therapy and endovascular revascularization groups, except for 
PFWD (P =0.024). 
In the supervised exercise therapy group, adherence to the supervised exercise therapy 
programme was good, with a mean(s.d.) of 33(10) sessions followed. In the endovascular 
revascularization group, revascularization failed technically in four patients. Therefore, 
two patients underwent a surgical procedure as initial intervention, and two were offered 
a home-based exercise programme.
After a median follow-up of approximately 7 (range 0.07–9.17) years, 17 patients in the 
supervised exercise therapy group and 15 in the endovascular revascularization group had 
died. Completeness of long-term follow-up was 70.9 per cent (236 of 333 weeks) and 83.8 
per cent (279 of 333 weeks) respectively. Thirtysix patients were available for review in the 
supervised exercise therapy group and 47 in the endovascular revascularization group. 
Sixtyfive patients agreed to attend for treadmill testing; the remaining 18 (7 supervised 
exercise therapy, 11 Endovascular revascularization) were interviewed by telephone on 
their general health and returned a completed QoL questionnaire by mail.
Functional performance
In both the supervised exercise therapy and endovascular revascularization groups, MWD 
and PFWD had increased significantly after 7 years compared with baseline values (P 
<0.001). The mean long-term improvement in the supervised exercise therapy group was 
975 (95 percent c.i. 772 to 1177)m for MWD and 700 (461 to 941)m for PFWD. Similarly, 
in the endovascular revascularization group the improvement in MWD and PFWD was 
sustained after 7 years, with a mean increase of 1074 (881 to 1267) and 940 ( 710 to 1171)
m respectively compared with baseline (Table 1). There were no significant differences 
in MWD and PFWD between the groups after 7 years. The ABI, both at rest and after 
exercise, increased significantly after 7 years in both groups compared with baseline 
values (P <0.001). There were no significant differences in ABI between the groups after 7 
years of follow-up (Table 1).
Quality of life 
In both groups the VascuQoL score increased significantly after approximately 7 years. 
The mean long-term improvement was 0.6 (95 percent c.i. 0.2 to 1.1) in the supervised 
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Table 1. Baseline scores and mean changes within, and difference between, the treatment groups 
in measures of functional performance. 
Supervised 
Exercise 
(n=75)
Endovascular 
Revascularization
 (n=75)
Mean 
Difference
(between groups)
 
P†
Maximum Walking Distance (m)
Baseline  186 (164 ; 208) 174 (157 ; 191)
1 year 1041 (892 ; 1189)* 829 (674 ; 984)* 212 (-4 ; 426) 0.063
7 years  975 (772 ; 1177)* 1074 (881 ; 1267)* -99 (-379 ; 180) 0.481
Pain Free Walking Distance (m)
Baseline 104 (89 ; 119) 82 (71 ; 93)
1 year 916 (743 ; 1090)* 784 (599 ; 968)* 133 (-121 ; 386) 0.302
7 years 700 (461 ; 941)* 940 (710 ; 1171)*  -240 (-573 ; 93) 0.156
Ankle Brachial Index (at rest)
Baseline 0.62 (0.58 ; 0.66) 0.63 (0.59 ; 0.67)
1 year 0.05 (0.01 ; 0.09)* 0.18 (0.14 ;0.23)* -0.14 (-0.19 ; -0.08) 0.000
7 years 0.20 (0.12 ; 0.27)* 0.21 (0.14 ; 0.28)* -0.01 (-0.12 ; 0.09) 0.809
Ankle Brachial Index (post- exercise)
Baseline 0.42 (0.37 ; 0.47) 0.41 (0.36 ; 0.46)
1 year 0.17 (0.11 ; 0.23)* 0.32 (0.26 ; 0.38)* -0.15 (-0.24 ; -0.07) 0.001
7 years 0.22 (0.14 ; 0.30)*  0.31 (0.23 ; 0.38)* -0.09 (-0.19 ; 0.02) 0.123
Data are presented as mean improvement compared to baseline (95 per cent confidence interval), Measures of functional 
performance after 7 years assessed in 29 out of 36 patients in the supervised exercise group and in 36 out of 47 patients in 
the endovascular revascularization group.
* P <0.050 (mean change versus baseline, Fisher’s least significant difference test from mixed model).
† Wald test for fixed effects in mixed model
exercise therapy group (P =0.005) and 0.9 (0.5 to 1.3) in the endovascular revascularization 
group (P <0.001), with no significant difference between the two treatments (Table 2). The 
rating score did not improve significantly in either group after 7 years of follow-up, and 
there were no significant differences between the groups (Table 2). Some of the SF-36 
health domain scores showed significant improvement after 7 years of follow-up in both 
groups. Nonetheless, there were no significant differences in SF-36 scores between the 
groups (Table 2).
Survival and secondary interventions
During follow-up, 17 patients in the supervised exercise therapy group and 15 in the 
endovascular revascularization group died. The cumulative survival probability for 7 years 
after randomization was 68 percent in the supervised exercise therapy group and 74 
percent in the endovascular revascularization group; the survival rates were not significantly 
different between the two groups (HR 1.35, 95 percent c.i. 0.67 to 2.70; P =0.402). 
Seven years after randomization, the proportion of patients who had not needed a 
secondary intervention (endovascular or surgery) was 47 percent in the supervised exercise 
therapy group and 73 percent in the endovascular revascularization group (Figure 1); the 
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secondary intervention rate was significantly higher in the supervised exercise therapy 
group (HR 2.56, 1.41 to 4.63; P =0.001). Nevertheless, the total number of endovascular 
and surgical procedures performed at baseline (primary) plus those performed during 
followup (secondary) were significantly higher in the endovascular revascularization group 
(P <0.001) (Table 3)
Thirty-two patients in the supervised exercise therapy group underwent one or more 
secondary intervention(s) during follow-up. In the majority of patients (27 of 32) this 
was intervention for a pre-existing lesion that had already been identified at baseline; in 
only five patients was the intervention for a new atherosclerotic lesion. The secondary 
interventions were endovascular in 20 of 32 patients and the majority (19 of 32) were 
done for stenosis in the aortoiliac segment. Seventeen patients in the endovascular 
Table 2. Baseline scores and mean changes within, and difference between, the treatment groups 
in measures of quality of life.
Supervised
Exercise
(n=75)
Endovascular
Revascularization
 (n=75)
Mean
Difference
(between groups)
 
P†
Vascular Qol score (1-7)
Baseline 4.3 (4.0 ; 4.6) 4.2 (4.0 ; 4.4)
1 year  0.6 (0.2 ; 1.0 )*  0.7 (0.4 ; 1.1)* -0.1 (-0.6 ; 0.4) 0.634
7 years  0.6 (0.2 ; 1.1)*  0.9 (0.5 ; 1.3)* -0.3 (-0.9 ; 0.3) 0.290
Rating Score (0-100)
Baseline 65.4 (61.3 ; 69.5) 62.3 (58.4 ; 66.2)
1 year  6.5 (2.0 ; 11.0)*  4.5 (0.0 ; 8.9)* 2.0 (-4.3 ; 8.3) 0.527
7 years  -0.3 (-6.8 ; 6.0) 4.3 (-1.6 ; 10.2) -4.6 (-13.3 ; 4.0) 0.292
SF-36 Physical Functioning (0-100)
Baseline 49.4 (44.8 ; 54.0) 42.0 (36.1 ; 47.9)
1 year 12.7 (7.6 ; 17.8)*  17.1 (12.0 ; 22.1)* -4.4 (-11.6 ; 2.8) 0.228
7 years 4.9 (-3.7 ; 13.4)  11.1 ( 3.2 ; 18.9)* -6.2 (-17.8 ; 5.3) 0.287
SF-36 Role Physical Score (0-100)
Baseline 49.0 (38.7 ; 59.3) 36.7 (24.9 ; 48.5)
1 year 5.9 (-4.9 ; 16.8) 20.7 (9.8 ; 31.5)* -14.7 (-30.0 ; 0.6) 0.059
7 years -2.5 (-13.5 ; 18.5) 18.0 (3.1 ; 32.9)* -20.5 (-42.3 ; 1.3) 0.065
SF-36 Bodily Pain (0-100)
Baseline 54.8 (50.0 ; 59.9) 50.1 (45.4 ; 54.7)
1 year  9.7 (3.6 ; 15.7)* 11.3 (5.3 ; 17.3)* -1.7 (-10.2 ; 6.9) 0.702
7 years 6.3 (-1.5 ; 14.2) 10.6 (3.3 ; 18.0)* -4.3 (-15.0 ; 6.5) 0.431
SF-36 General Health (0-100)
Baseline 53.8 (49.4 ; 58.2) 53.1 (48.0 ; 58.2)
1 year 4.9 (0.4 ; 9.4)* 2.1 (-2.5 ; 6.6) 2.8 (-3.6 ; 9.2) 0.384
7 years  -6.9 (-12.4 ; -1.4)* -3.2 ( -8.5 ; 2.0) -3.7 (-11.3 ; 3.9) 0.341
Data are presented as mean improvement compared to baseline (95 per cent confidence interval), QoL, Quality of Life; SF-36, 
Short-Form 36; Measures of Quality of Life after 7 years reported by 34 out of 36 patients in the supervised exercise group 
and by 43 out of 47 patients in the endovascular revascularization group.  
* P <0.050 (mean change versus baseline, Fisher’s least significant difference test from mixed model).
† Wald test for fixed effects in mixed model  
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Table 3. Secondary endovascular or surgical interventions.
Supervised
Exercise
(n=75)
Endovascular
Revasculari zation
(n=75)
 
P ‡
No. of patients with one or more secondary 
intervention(s) 32 17 0.01
Secondary intervention lesion 
Intervention on pre-existing lesion 
Intervention on new lesion 
Secondary intervention segment 
Aortoiliac segment 
Femoropopliteal segment
Secondary intervention procedure
Endovascular procedure
 Surgical procedure
Average number of secondary interventions*  
Total no. of interventions (primary and secondary)†
No. of patients with amputation
Minor amputation 
Major amputation
27 
 5 
19 
13 
20 
12 
2.0 (1 – 6)
64
2 
-
13 
  4 
7 
10 
  
8 
9 
2.8 (1 - 7)
121
- 
3 
0.70
0.25
0.37
0.10§
<0.01
1.00
*Mean (range) number of secondary interventions (endovascular or surgical procedure) during follow-up once a patient 
needed a secondary intervention. †Total number of endovascular and surgical procedures at baseline (primary) and during 
follow-up (secondary). ‡Fisher’s exact test, except §Student’s t test.
Figure 1. Kaplan–Meier estimates of the proportion of patients without secondary intervention 
during follow-up in supervised exercise and endovascular revascularization groups. P <0.001 (log 
rank test)
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revascularization group required one or more secondary endovascular or surgical 
intervention(s), including 13 who had reintervention for a previously treated lesion and 
four who underwent intervention for a new lesion. The secondary interventions in the 
endovascular revascularization group were endovascular in eight of 17 patients and the 
majority (10 of 17) were for (re)stenosis in the femoropopliteal segment (Table 3). 
Although there was no significant difference in amputation rates between the two 
groups, the severity of the amputations differed; there were two minor amputations in 
the supervised exercise therapy group and three major amputations in the endovascular 
revascularization group (Table 3).
The per-protocol analysis, which included data from patients who completed the 
allocated treatment and finished  the study without having any secondary intervention, 
did not change the results regarding mean difference between the groups in functional 
performance measures and QoL scores compared with the results of the main analysis. 
Similarly, the complete-case analysis, which excluded patients with missing values in the 
long term, yielded similar results to the main analysis in terms of mean difference in 
functional performance measures and QoL scores.
DISCUSSION
This report examined the long-term clinical effectiveness of supervised exercise therapy 
and endovascular revascularization as initial treatment for patients with intermittent 
claudication due to aortoiliac or femoropopliteal disease. After a median follow-up of 
approximately 7 years, supervised exercise therapy-first treatment was equivalent to 
endovascular revascularization-first treatment in achieving improvements in functional 
performance and QoL.
 Long-term benefits in functional performance have been demonstrated previously 
for supervised exercise therapy18-20, as well as for endovascular revascularization21,22, 
in cohort studies; the only randomized clinical trial (RCT) published so far found no 
significant difference in walking capacity between supervised exercise therapy and 
endovascular revascularization23. However, that study did not show any increase in MWD 
or PFWD after approximately 6 years, possibly due to the limited number of patients. In 
addition to a persistent increase in walking distance, the present study also demonstrated 
a sustained improvement in QoL after both supervised exercise therapy and endovascular 
revascularization. In contrast to the VascuQoL, the SF-36 instrument failed to demonstrate 
(sustained) improvements, especially after supervised exercise therapy. VascuQoL is a 
disease-specific instrument that was developed and validated in patients with intermittent 
claudication15, and may be better for detecting disease-related QoL improvement.
Another interesting observation was that ABI values at rest and after exercise in 
the supervised exercise therapy group were significantly higher after 7 years than at 
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baseline, which resulted in the similar ABI improvements in the two treatment groups 
after 7 years; this contrasts with the 12-month results8. This significant improvement in ABI 
after supervised exercise therapy was not the result of the supervised exercise therapy 
programme itself, and was explained by the appreciable number of patients in the 
supervised exercise therapy group who received a secondary intervention (endovascular 
or surgical revascularization) during follow-up. Although the high crossover rate to 
endovascular revascularization is not desirable in a clinical study, it does reflect real-world 
clinical practice. Per-protocol analysis, including only data from patients who completed 
their allocated treatment without crossover, did not affect the conclusion of the main 
intention-to-treat analysis.
A positive finding of this study was that, after 7 years, almost half of the patients with 
intermittent claudication randomized to supervised exercise therapy initially had sustained 
improvement in functional performance and QoL without the need for any secondary 
intervention. The mean number of subsequent interventions after the initial treatment 
failure tended to be higher in the endovascular revascularization group, and the long-
term prognosis for the leg seemed poorer, with three major amputations compared with 
only two minor amputations in the supervised exercise therapy group. These findings 
support the conservative supervised exercise therapy-first approach, without exposing 
patients to invasive endovascular or surgical treatments and their complications24,25. 
With respect to the level of disease, ten of 20 patients in the endovascular 
revascularization group with one or more lesions in the femoropopliteal segment required 
secondary intervention in this arterial segment, whereas seven of 55 patients with aortoiliac 
disease underwent a secondary intervention for restenosis in the aortoiliac segment 
during follow-up. This finding is expected, confirming a higher long-term patency rate 
for endovascular revascularization of aortoiliac compared with femoropopliteal lesions2,24. 
Given the high patency rate and relative ease of endovascular aortoiliac procedures, 
patients with aortoiliac disease may be considered for endovascular revascularization-first 
treatment, yet in the supervised exercise therapy group almost two thirds of the patients 
with intermittent claudication due to aortoiliac disease did not require a secondary 
intervention during follow up. The 6-month results of the Claudication: Exercise Versus 
Endoluminal Revascularization (CLEVER) trial, a multicentre RCT comparing supervised 
exercise therapy and endovascular revascularization for patients with intermittent 
claudication due to aortoiliac disease, demonstrated that supervised exercise therapy 
resulted in better walking performance than endovascular revascularization26. Another 
RCT, comparing supervised exercise therapy, endovascular revascularization or both for 
patients with intermittent claudication due to femoropopliteal disease, concluded that 
all treatment regimens were equally effective in improving walking distance and QoL27. 
Results from these two recent trials combined with the present data justify supervised 
exercise therapy-first treatment for patients with intermittent claudication due to both 
aortoiliac and femoropopliteal disease.
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The present study had some limitations. First, not all patients were available for long-
term follow-up, which might have caused bias. However, baseline characteristics, functional 
performance and QoL measures were similar after 12 months in patients who withdrew 
and those who completed the long-term follow-up. Second, a high mortality and attrition 
rate among patients in the study decreased its power to detect small significant differences 
between the supervised exercise therapy and endovascular revascularization groups. 
Third, to avoid multiple revascularization procedures, patients with ipsilateral multilevel 
disease (stenoses at both iliac and femoral levels) were excluded from the present study. 
It is not known whether the findings of the present study are generalizable to this group. 
Finally, there was no information from participants on regular exercise performance after 
the trial. Therefore, only endovascular and surgical procedures, but not exercise, were 
considered as secondary interventions.
One year cost-effectiveness analysis, comparing supervised exercise therapy and 
endovascular revascularization for intermittent claudication, based on data from the 
present study has shown that, from a societal perspective and using a willingness-to-pay 
threshold of  €50.000 per quality adjusted life year, supervised exercise therapy is cost-
effective compared with endovascular revascularization28. Given the higher baseline costs 
for an endovascular revascularization-first approach compared with supervised exercise 
therapy28, and the relatively large number of patients in the endovascular revascularization 
group who had a secondary surgical procedure, it is likely that supervised exercise therapy 
remains cost-effective in the long term. 
This study suggests that in the long-term supervised exercise therapy-first or 
endovascular revascularization-first treatment strategies are equivalent in improving 
functional performance and QoL in patients with intermittent claudication. Although the 
secondary intervention rate was higher in patients who had supervised exercise therapy 
as initial treatment, the total number of invasive interventions (primary and secondary) 
remained substantially lower, and hence this study supports the use of a supervised 
exercise therapy-first approach for patients with intermittent claudication.
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Chapter 6
Long-term effects of structured home-based exercise 
program on functional capacity and quality of life in 
patients with intermittent claudication
Fakhry F, Spronk S, de Ridder M, Hoed PT, Hunink MGM.
Arch Phys Med Rehabil. 2011 Jul; 92(7):1066-73
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ABSTRACT
Objectives:
To evaluate effects of a structured home-based exercise program on functional capacity 
and quality of life in patients with intermittent claudication after 1-year follow-up, and 
to compare these results with those from a concurrent control group who received 
supervised exercise therapy.
Design: Comparative longitudinal cohort study.
Setting: Referral center.
Participants: Patients (N=142) with intermittent claudication.
Interventions: Structured home-based exercise therapy or supervised exercise therapy.
Main Outcome Measures: 
The maximum- and pain-free walking distance and the ankle-brachial index (at rest and 
postexercise) were measured at baseline and after 6 and 12 months’ follow-up. Additionally, 
quality of life was evaluated using a self-administered questionnaire consisting of the 
Euroqol-5D (scale 0 –1), rating scale (scale 0 –100), Short-Form Health Survey (SF-36; scale 
0 –100), and the Vascular Quality of Life Questionnaire (VascuQol; scale 1–7). Comparison 
of the groups was performed with adjustment for the nonrandomized setting using 
propensity scoring.
Results
One hundred forty-two patients with intermittent claudication started the structured 
home-based exercise program, of whom 95 (67%) completed 12 months’ follow-up. 
The mean relative improvement compared with baseline was statistically significant after 
12 months’ follow-up for the maximum- and pain-free walking distance (342%, 95% 
confidence interval [CI], 169–516; P=0.01 and 338%, 95% CI, 42–635; P=0.03, respectively) 
and for the ankle-brachial index post exercise (mean change, 0.06; 95% CI,0 .01–0.10; 
P=.02). For the quality of life outcomes, the improvement compared with baseline was 
statistically significant after 12 months for the VascuQol (mean change, 0.42; 95% CI, 
0.20 –0.65; P<0.01) and for the SF-36 physical functioning (mean change, 5.17; 95% CI, 
.77–9.56; P=0.02). Compared with the structured home-based exercise program, patients 
in the control group showed significantly better results in the mean relative improvement 
of maximum- and pain-free walking distance and change in the ankle-brachial index at 
rest after 12 months’ follow-up.
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Conclusions
Structured home-based exercise training is effective in improving both functional capacity 
and quality of life in patients with intermittent claudication and may be considered as a 
feasible and valuable alternative to supervised exercise therapy, since supervised exercise 
programs are not often available. 
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Pripheral arterial disease a chronic atherosclerotic occlusive disease of the lower 
extremities. The classic symptom in patients with PAD is intermittent claudication (ie, 
Rutherford category 1, 2, or 3)1, affecting approximately 275,000 people older than 
50 years in The Netherlands alone. Of these, half will have a cardiovascular event within 
10 years (19% fatal, 27% nonfatal), resulting in more than 2500 deaths each year2. Patients 
with intermittent claudication have functional limitations because of impaired walking 
ability3, and diminished quality of life (QoL)4.
The treatment goals for patients with intermittent claudication are to relieve 
symptoms and improve daily functional abilities and QoL. Previous studies have shown 
that exercise training should have a central role in the management of intermittent 
claudication by significantly improving the MWD5-7 and QoL8. A Cochrane review and 
a recent systematic review showed that supervised exercise therapy is more effective 
than “go home and walk” advice9,10. Furthermore, the American College of Cardiology 
and American Heart Association guidelines recommend supervised exercise therapy 
as the initial treatment modality for patients with intermittent claudication11. In clinical 
practice, however, supervised exercise therapy programs have a limited capacity in 
many centers12. In addition, reimbursement for supervised exercise sessions depends on 
the patient’s health insurance. Because of these limitations, many physicians in routine 
practice still advise their patients with intermittent claudication to “go home and walk.” 
This approach, however, has many shortcomings including a high dropout rate and 
inadequate exercise as a result of minimal instruction. A better alternative to this simple 
“go home and walk” advice may be a structured home-based exercise program in which 
additional instructions, encouragement, and motivation are offered to the patient during 
the program. Since the patient can exercise in a self-chosen environment, a structured 
homebased exercise program does not require the infrastructure and the logistics of 
supervised exercise programs and thus, if efficacious, may be implemented in current 
practice more easily.
The objective of this study was to evaluate the effectiveness of a structured home-
based exercise program on both functional capacity and QoL in patients with intermittent 
claudication after 6 and 12 months’ follow-up, and to compare these results with those for 
a concurrent control group who received supervised exercise therapy.
METHODS
Study Design and Participants
This study was a comparative longitudinal cohort study following up patients with 
intermittent claudication (Rutherford category 1, 2, or 3) for a period of 12 months. All 
patients with intermittent claudication referred to the Department of Vascular Surgery 
by their general practitioner were considered for recruitment. Patients met the following 
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inclusion criteria for a structured home-based exercise program: (1) older than 18 years; 
(2) Rutherford category (1, 2, or 3); (3) ankle-brachial index (ABI) less than 0.9 at rest, 
or ABI with a decrease of more than 30% after the treadmill test; (4) pain-free walking 
distance (PFWD) less than 350m during a treadmill test; (5) and informed consent. 
Exclusion criteria were (1) patient eligible for concurrent RCT13,14; (2)life-incapacitating 
cardiac disease; and (3) inability to complete a treadmill walking test for reasons other 
than claudication.
Patients who were eligible for a concurrent randomized controlled trial (RCT) and 
were allocated to supervised exercise therapy served as controls. In this RCT, which was 
performed at the same hospital, results of supervised exercise therapy and endovascular 
revascularization for patients with intermittent claudication were compared after 
12 months of follow-up13,14. Inclusion criteria of this RCT were (1) Rutherford category 1, 
2, or 3, with a duration of 3 months or more; (2) PFWD less than 350m; (3) ABI less than 
0.9 at rest, or ABI decreasing by greater than .15 after the treadmill test; (4) 1 or more 
vascular stenoses of greater than 50% diameter reduction at the iliac or femoropopliteal 
level; and (5) informed consent. Exclusion criteria were (1) abdominal aortic aneurysm; 
(2) life-incapacitating cardiac disease (New York Heart Association classification  II and 
higher); (3) multilevel disease (ie, same-side stenoses at both the iliac and femoral levels, 
requiring multiple revascularization procedures); (4) isolated tibial artery disease; (5) 
lesions deemed unsuitable for revascularization (iliac or femoropopliteal Trans-Atlantic 
Inter-Society Consensus for the Management of PAD (TASC) type D and some TASC type 
B and/or C lesions24); and (6) prior treatment for the lesion (including exercise training). 
Institutional review board approval was obtained, and all patients gave written informed 
consent.
Risk Factor Modification
Before starting either a structured home-based exercise program or a supervised exercise 
program, baseline data were obtained for all patients including cardiovascular risk factors, 
concomitant diseases, medical therapy use, previous vascular interventions, and a self-
administered QoL assessment by questionnaire. Patients with one or more risk factors for 
cardiovascular disease were referred to a physician for secondary prevention according 
to the European Society of Cardiology guidelines on cardiovascular disease prevention in 
clinical practice15 .
Interventions
Structured home-based exercise program
Before initiating the exercise program, a treadmill test at the vascular laboratory 
established patients’ initial PFWD and maximum walking distance (MWD). The patients 
were instructed to accomplish daily exercise sessions, at least 1 session daily, during 24 
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weeks in a self-chosen environment. In addition, patients were advised to include regular 
walks in their daily routine. Each subject received an information sheet with instructions 
regarding the exercise regimen, which consisted of approximately 30 minutes of walking 
during each exercise session, started with the initial walking speed, and involved walking 
near-maximum claudication pain, alternated with 1 minute of walking at a very low pace 
until the pain abated16. Evaluation of the walking distance took place after 2, 8, 16, and 24 
weeks at the vascular laboratory by a vascular technologist. During these 1-hour individual 
follow-up sessions, the patient’s progress was assessed by establishing the patient’s 
MWD and PFWD, and discussing the approximate number of sessions and duration of 
each exercise session the patient had performed. New targets regarding walking speed, 
walking distance, and compliance were given to the patient. Problems experienced by the 
patient during the exercise program were discussed, and additional instruction on exercise 
performance was given. Education about the treatment of intermittent claudication 
and the presently known results and advantages of exercise training on intermittent 
claudication and atherosclerotic risk factors was given to the patients every session. The 
patients were also strongly encouraged to keep up the recommended exercise program 
and to perform at least ome exercise session daily. After completion of the 24-week 
program, patients were advised to include home-based exercise training in their daily 
routine.
Control group
All patients in the nonrandomized control group started with supervised exercise therapy 
for a period of 24 weeks, 2 sessions weekly. The exercise session consisted of 30 minutes 
of walking on a treadmill at a workload of 3.5km/h without a graded incline and was 
supervised by a vascular technologist. Patients walked to near-maximum claudication 
pain, then decreased the workload and continued exercising at this reduced workload 
until the pain subsided, after which the workload was increased again13. After completion 
of the 24-week supervised program, these patients were also advised to walk on a daily 
basis.
Outcomes
The outcome variable was effectiveness, which was defined as improvement compared 
with baseline in both functional capacity and QoL after 6- and 12-month follow-up. 
Improvement in functional capacity was assessed by MWD and PFWD after treadmill 
walking (speed 3.5 km/h, no graded incline), and by the ABI at rest and postexercise 
determined by Doppler pressure measurements. Trained vascular technicians assessed 
these parameters. For practical reasons the maximum walking time was 30 minutes. 
Improvement in QoL was assessed by a self-administered questionnaire. This patient-
reported questionnaire consisted of the Euroqol-5D, rating scale, Medical Outcomes 
Study 36-Item Short-Form Health Survey (SF-36), and the Vascular Quality of Life 
PSM 20180914 Proefschrift Farzin Fakhry BW.indd   166 21-11-18   14:24
Long-term effects of structured home-based exercise for claudication
167
6
Questionnaire (VascuQol) instruments. The Euroqol-5D instrument assesses QoL values 
from the societal perspective and classifies patients into a health-state. It covers 5 QoL 
dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression17. 
We used the Dutch scoring algorithm, which was derived from the general population, 
to value each health state between 0 and 1, where 0 indicates death and 1 indicates 
maximum health18. The rating scale instrument asked the patients to rate their overall 
health on a scale from 0 to 100, where 0 represents death and 100 perfect health19. 
The SF-36 instrument contains 36 questions and evaluates the general health and well-
being of patients through 8 different health domains20. Previous studies demonstrated 
that only physical functioning, role-functioning limitations caused by physical problems, 
bodily pain, and general health are the most relevant health domains to describe the 
health status of patients with peripheral arterial disease (PAD)14,21, so we restricted this 
analysis to these 4 domains. The SF-36 was valued on a 0- to 100-point scale; 0 reflected 
worst health, and 100 indicated maximum health. The VascuQol instrument consists of 25 
questions22. For each question there is a 7-point response scale, with 1reflecting the worst 
possible QoL and 7 the best possible QoL.
Statistical Analysis
Continuous data are presented as means and SDs. Discrete data are given as numbers and 
percentages. Changes in the outcome measures are expressed as mean improvements 
compared with baseline and 95% CIs, except for the dependent variables MWD and the 
PFWD which are given as mean relative improvements due to the skewness of these 
data13.
To assess the differences in baseline characteristics between the patients who 
received the structured home-based exercise program and the control group, we used 
the unpaired t test or the Mann-Whitney U test, as appropriate, whereas dichotomous 
outcomes were assessed with the chi-square test. Significance of change in the outcome 
measures was assessed with mixed effects models for repeated measures. An advantage 
of this repeated-measures approach is that it allows for inclusion of patients with missing 
follow-up data, due to random withdrawal, in the analysis. Where applicable, a linear 
mixed model was applied to the original outcome. Otherwise, in case of the MWD and 
the PFWD, we used a transformation to a relative improvement compared with baseline. 
We adjusted the model for the following potential confounders, based on clinical 
judgment and the literature: sex, age, smoking, hypertension, diabetes mellitus, and 
hyperlipidemia24. 
To compare the differences in outcome measures between the structured home-
based exercise program and the control group, we performed a propensity score–
adjusted repeated measures analysis. We first computed a propensity score by using a 
multivariable logistic regression analysis with treatment group as the dependent variable 
and baseline characteristics related to the outcome as independent variables25. We then 
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entered the propensity score into a linear mixed model as a continuous variable to adjust 
for all observed potential imbalance between the two treatment groups. In our modeling 
approach, we first assumed a general model for the mean structure, and sought the 
simplification of the variance-covariance matrix structure. After all possible dependencies 
were eliminated, we proceeded with an elimination of the mean structure parameters.
A significance level of 0.05 (2-sided) was considered statistically significant. Calculations 
were performed with SPSS 14.0 for Windows and SAS 9.2.
RESULTS
Patients
A total of 298 patients with intermittent claudication were referred to the Department of 
Surgery. One hundred fifty-one patients were excluded based on the exclusion criteria. 
Five patients never started the structured home-based exercise program for various 
reasons and were therefore also excluded from further analysis. Thus, the final study 
population consisted of 142 patients. Ninety-five of the 142 patients (67%) completed 12 
months’ follow-up. The remaining 47 patients discontinued the study for various reasons 
(Figure 1). 
The baseline characteristics of the patients are presented in Table 1. There were no 
statistical significant differences in baseline characteristics between patients from the 
structured home-based exercise program group and patients from the control group, 
except for smoking and level of disease (Table 1).
Outcomes
The adjusted mean relative improvement in MWD compared with baseline after 6 months 
of structured home-based exercise was 364% (95% confidence interval [CI], 200–528; 
P<0.01) and was statistically significant (Table 2). After 12 months’ follow-up, this adjusted 
relative improvement was still statistically significant (improvement 342%; 95% CI, 169–
516; P<0.01). The adjusted mean relative improvement in PFWD after 6 months compared 
with baseline was 269% (95% CI, –60 to 597; P=0.10), which was not statistically significant. 
After 12 months’ follow-up, this adjusted mean relative improvement was statistically 
significant with an improvement of 338% (95% CI, 42–635; P=0.03) (Table 2). Although 
there were no significant differences in the ABI at rest after 6 and 12 months’ follow-up, 
the mean change in ABI after exercise was significantly better after follow-up compared 
with baseline. After 6 months, the mean change was 0.04 (95% CI, 0.00 –0.07; P=.04). 
After 12 months, this improvement was still statistically significant and increased to 0.06 
(95% CI, 0.01–0.10; P=.02).
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Figure 1. Flow chart of the total population eligible for structured home-based exercise program. 
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Table 1. Baseline patient characteristics 
Characteristic
Structured Home‐Based 
Exercise (n=142)
Control group,
Supervised Exercise (n=75)
P
Age (years) 68.1 +/- 10.1 66.9 +/- 8.9 NS
Body Mass Index (kg/m2) 26.8 +/-  5.6 25.5 +/- 4.6 NS
Male sex 91/142 (64) 44/75 (59) NS
Arterial hypertension 67/134 (50) 30/75 (40) NS
Diabetes Mellitus 44/142 (31) 14/75 (19) NS
Hyperlipidemia 66/128 (52) 43/75 (57) NS
History of ischemic heart disease 44/142 (31) 22/75 (29) NS
History of cerebrovascular disease 23/141 (16) 5/75 ( 7) NS
Pulmonary disease 17/142 (12) 9/75 (12) NS
Renal disease 4/140 ( 3) 4/74 ( 5) NS
Osteoarthritis of lower limb 21/139 (15) 5/75 ( 7) NS
Smoking
Never
Current/Former
11/139 ( 8)
128/139 (95)
37/75 (49)
38/75 (51)
< 0.01
Level of disease
AortoiIiac
Femoropopliteal
Infrapopliteal 
23/139 (17)
98/139 (71)
18/139 (12)
34/69 (49)
35/69 (51)
0/69 (  0)
< 0.01
Rutherford classification
1 or 2
3
79/142  (56)
63/142  (44)
33/73  (45)
40/73  (55)
NS
Pain-free walking distance (m) 106  (+/- 88.2) 
 n=120
108 (+/- 69) 
n=71
NS
Maximum walking distance (m) 201  (+/- 177) 
n=123
191  (+/- 97) 
n=71
NS
Ankle Brachial Index
at rest
after exercise
0.62 (+/- 0.20) n=139
0.42 (+/- 0.22) n=125
0.62 (+/- 0.18) n=75
0.42 (+/- 0.20) n=75
NS
SF-36 quality of life score#
Physical functioning
Physical role functioning
Bodily pain
General health
48 (+/- 21) n=137
45 (+/- 42) n=134
56 (+/- 22) n=140
53 (+/- 19) n=140
49 (+/- 20) n=75
51 (+/- 43) n=75
55 (+/- 22) n=75
54 (+/- 19) n=75
NS
EuroQol total score** 0.70 (+/- 0.20) n=140 0.68 (+/- 0.21) n=75 NS
Rating scale total score# 62  (+/- 18) n=128 64  (+/- 18) n=74 NS
VascuQol total score& 4.3 (+/- 1.16) n=142 4.2 (+/- 1.26) n=75 NS
Values are mean ± SD or n (%) unless otherwise indicated.
Abbreviation: SF-36= Short Form-36; NS, not significant.
*Score, 0 to 100 (worst-best) scale.
†Score, 0 to 1 (worst-best) scale.
‡Score, 1 to 7 (worst-best) scale.
# Score= 0-100 (worst-best) scale
** Score= 0-1 (worst-best) scale 
& Score=1-7 (worst-best) scale
PSM 20180914 Proefschrift Farzin Fakhry BW.indd   170 21-11-18   14:24
Long-term effects of structured home-based exercise for claudication
171
6
Table 2. Mean change in measures of functional capacity, 6 and 12 months compared with base-
line, after a structured home-based exercise program (n=142)
Measure of functional capacity Adjusted mean change
(95% CI)**
Adjusted
p-value**
Maximum walking distance (%)*
After 6 months
After 12 months
364 (200 to 528)
342 (169 to 516)
< 0.01
< 0.01
Pain-free walking distance (%)*
After 6 months
After 12 months
269 (-60 to 597)
338 ( 42 to 635)
NS
0.03
ABI at rest
After 6 months
After 12 months
0.001 (-0.03 to 0.03)
-0.001  (-0.04 to 0.04)
NS
NS
ABI after exercise 
After 6 months
After 12 months
0.04 (0.00 to 0.07)
0.06 (0.01 to 0.10)
0.04
0.02
Abbreviation: CI=Confidence Interval; ABI=Ankle Brachial Index; NS= Not Significant
* Presented as mean relative improvement 
** Adjusted for sex, age, smoking, hypertension, hyperlipidemia, and diabetes mellitus. 
The adjusted mean change in QoL after 6 months compared with baseline was statistically 
significant for the VascuQol (scale 1–7) with a mean change of 0.37 (95% CI, 0.17–0.56; 
P<0.01), and for the SF-36 physical functioning scores (scale 0–100) with a mean change 
of 5.96 (95% CI, 2.04 –9.87; P<0.01). After 12 months, this improvement was still statistically 
significant for the VascuQol (mean change, 0.42; 95% CI, 0.20 –0.65; P<0.01) and for the 
SF-36 physical functioning score (mean change, 5.17; 95% CI, 0.77–9.56; P=0.02) (Table 3).
Comparison of Groups
After adjustment for potential confounders, the patients in the control group showed 
significantly better results in functional capacity outcomes except for ABI after exercise 
(Table 4). However, after adjustment, there were no significant differences in the QoL 
scores between the 2 groups at 6 or 12 months’ follow-up, except for SF-36 general health 
domain (P=0.03) and rating scale (P<0.01) at 6 months’ follow-up (Table 5).
Table 4 and 5
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Table 3. Mean change in measures of quality of life, 6 and 12 months compared to baseline, after 
a structured home-based exercise program (n=142)
Measure of quality of life Adjusted mean change 
(95% CI)*
Adjusted P *
VascuQol total score& 
After 6 months
After 12 months
0.37 (0.17 to 0.56)
0.42 (0.20 to 0.65)
< 0.01
< 0.01
SF-36 Physical functioning# 
After 6 months
After 12 months
5.96 (2.04 to 9.87)
5.17 (0.77 to 9.56)
< 0.01
0.02
SF-36 Physical role functioning#
After 6 months
After 12 months
0.07 (-0.09 to 1.84)
0.09 ( 0.04 to 2.12)
NS
0.04
SF-36 Bodily pain#
After 6 months
After 12 months
2.31 (-1.88 to 6.50)
4.10 (-0.93 to 9.11)
NS
NS
SF-36 General health# 
After 6 months
After 12 months
-1.53 (-4.53 to 1.47)
-0.99 (-4.24 to 2.24)
NS
NS
Rating scale total score# 
After 6 months
After 12 months
-0.38 (-4.06 to 3.29)
2.38 (-0.93 to 5.69)
NS
NS
EuroQol total score**  
After 6 months
After 12 months
-0.00 (-0.21 to 0.20)
0.04 (-0.02 to 0.44)
NS
NS
Abbreviation: NS= Not Significant; CI= Confidence Interval; SF-36= Short Form-36
* Adjusted for sex, age, smoking, hypertension, hyperlipidaemia, and diabetes mellitus.
& Score=1-7 (worst-best) scale
# Score= 0-100 (worst-best) scale
**  Score= 0-1 (worst-best) scale
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DISCUSSION
The objective of this study was to evaluate the effectiveness of a structured home-based 
exercise program for patients with intermittent claudication and to compare these results 
with those for a concurrent control group who received supervised exercise therapy. 
We determined the improvement in both functional capacity and QoL after 6 and 12 
months’ follow-up and showed that a structured home-based exercise program was 
of significant benefit in improving MWD, PFWD, the ABI postexercise, and the QoL in 
patients with intermittent claudication. The improvement achieved in MWD and PFWD 
can also be considered clinically relevant, as patients improved their pre-training adjusted 
MWD and PFWD by 342% and 338%, respectively, after 12 months’ follow-up, This is 
comparable with walking an additional 6 to 7 blocks until maximum claudication pain and 
can be considered as substantial improvement for patients with intermittent claudication. 
However, compared with a supervised exercise program, the structured home-based 
exercise program was inferior in improving functional capacity.
Studies evaluating both functional capacity and QoL after structured home-based 
exercise program are scarce, and to our knowledge this is the first study that evaluated all 
these outcomes by using an unsupervised but structured approach. There are no meta-
analyses on the effectiveness of structured home-based exercise programs. However, our 
results were consistent with those from previous RCTs, in which minimal supervision was 
added to their home-based exercise training group26,27. The results from the literature 
evaluating the effectiveness of the simple “go home and walk” advice are not comparable 
with our results because of the supportive element in our study. The improvement 
achieved in MWD after 12 months was larger in our study compared with studies 
evaluating the simple “go home and walk” advice28,29. An explanation for this difference 
is probably that our home-based exercise program was structured by intervening visits 
during the program in which we evaluated patients’ progress, offered patients additional 
instructions, and motivated them to continue. Patients who follow the “go home and walk” 
advice but do not get any form of supervision and encouragement are more likely to stop 
the program than patients who get supervised exercise therapy30. The dropout rate in 
our study (33%) was low and comparable with the dropout rates from RCTs evaluating 
supervised exercise therapy31-33. An explanation for this “good” compliance might be that 
in our structured home-based exercise program the patient could perform the exercise 
sessions in a self-chosen environment and time, which might facilitate continuation of the 
program.
Study Limitations
Although we demonstrated significant improvement in functional capacity and QoL, there 
were some limitations of our study, which could have affected our results. First, our study 
sample was relatively small, which may limit the level of evidence of our study. Second, 
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our study was a single-center study, nonblinded and nonrandomized. To adjust for the 
effect of nonrandomization we used a propensity score–adjusted analysis to compare the 
structured home-based exercise group with a control group. Although propensity score 
risk adjustment controls for the observed imbalance on background covariates between 
the treatment and control group, it does not take into account nonmeasured confounding 
variables that may have still caused a treatment selection bias. Next, we excluded the 
patients eligible for a concurrent RCT, which might have established an inherent bias 
in the selection of patients. However, at baseline, there were no statistically significant 
differences in severity of disease, functional capacity, and QoL outcomes between the 
patients in our study and patients from the concurrent RCT. 
Furthermore, we did not ask the patients to keep daily programrecords of their 
exercise sessions, and because the patients were not completely supervised, there could 
be a level of uncertainty about their exercise compliance. Because exercise compliance 
in an unsupervised exercise therapy program is very important but difficult to measure, 
a suggestion for future studies might be to use devices such as pedometers to monitor 
patients’ activity. Since patients in a structured home-based exercise program have the 
freedom to exercise in the convenience of their home setting, the patient compliance 
and QoL can be favorably influenced. For many patients it is difficult to attend regular 
activities that are outside their daily routine. Many patients with intermittent claudication 
are physically inactive, which could reduce a patient’s motivation to participate in a 
supervised exercise therapy program, and emphasizes the need to explore the most 
convenient and feasible program in daily practice. Next, our analyses were limited to only 
those who completed the study. To deal with this limitation we included all patients in the 
analyses and used a repeatedmeasures approach, which has the advantage of allowing 
for the inclusion of patients with random missing follow-up data because of withdrawal. 
Still the possibility that those who withdrew from the study would have responded less 
favorably to exercise cannot be ruled out. 
Furthermore, at the time of the study protocol, a graded treadmill test was not 
available, and instead we used a speed of 3.5 km/h with a maximum of 30 minutes for 
practical reasons. However, a significant number of patients were able to walk longer than 
the limited 30 minutes, and the demonstrated improvement in the MWD after 6 and 12 
months’ follow-up may have been underestimated. Whereas patients in the control group 
exercised on a treadmill, patients in the structured home-based exercise program did not. 
This might have caused a familiarization for treadmill walking in the control group with 
a subsequent better performance when they were tested during follow-up, which could 
have led to overestimation of the difference in MWD and PFWD between the 2 groups in 
favor of the control group.
It is important to emphasize that our study was not designed to compare the 
effectiveness of a structured home-based exercise training group with a supervised 
exercise therapy group. Our goal was to evaluate a structured home-based exercise 
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program when a supervised program is not available. Implementing supervised exercise 
therapy for intermittent claudication in daily practice can be complicated. Many vascular 
surgeons do not have access to a rehabilitation center for carrying out supervised exercise 
therapy because of limited capacity at the centers. A recent published study showed that 
despite all the recommendations from the TASC, and the American College of Cardiology 
and the American Heart Association guidelines to use supervised exercise therapy in 
the management of intermittent claudication11,24,only 24% of surgeons have access to 
supervised exercise therapy12. Furthermore, patients are often limited in their transport to 
the hospital or rehabilitation center in terms of costs and time. These limitations force the 
current practice of care for most patients to still consist of advice to “go home and walk.”
Economic evaluation of (structured) home-based exercise training versus supervised 
exercise therapy is important but still relatively rare. A recent article from van Asselt et al 
evaluating the cost-effectiveness of supervised exercise therapy compared with “go home 
and walk” advice concluded that at a willingness-to-pay threshold of €40.000 per quality-
adjusted life year, supervised exercise therapy is likely to be a costeffective therapeutic 
option34. However, in this study, supervised exercise therapy was compared with advice 
to “go home and walk” and not with a structured home-based exercise program as we 
described. Although one would expect the structured home-based exercise to be less 
expensive, additional treatment costs after failure of a structured home-based exercise 
program need to be taken into account and could raise the costs. Therefore, further 
research with a full economic evaluation that includes consideration of all costs and 
consequences is needed.
To improve current practice, we showed that a structured home-based exercise 
program can be clinically more effective than the simple “go home and walk“ advice 
and should be used instead. We suggest that all patients with symptoms of intermittent 
claudication should be treated with a supervised exercise therapy program. If a supervised 
exercise therapy program is not feasible, a structured home-based exercise program 
should be considered instead of the “go home and walk” advice.
CONCLUSIONS
A structured home-based exercise program is effective in improving both functional 
capacity and QoL in patients with intermittent claudication and may be considered 
as a feasible and valuable alternative to a supervised exercise therapy program, since 
supervised exercise programs are not often available in clinical practice.
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ABSTRACT
Importance 
Supervised exercise is recommended as a first-line treatment for intermittent claudication. 
Combination therapy of endovascular revascularization plus supervised exercise may be 
more promising but few data comparing the 2 therapies are available.
Objective
To assess the effectiveness of endovascular revascularization plus supervised exercise for 
intermittent claudication compared with supervised exercise only.
Design, setting and participants
randomized clinical trial of 212 patients allocated to either endovascular revascularization 
plus supervised exercise or supervised exercise only. Data were collected between May 
17, 2010, and February 16, 2013, in the Netherlands at 10 sites. Patients were followed up 
for 12 months and the data were analyzed according to the intention-to-treat principle.
Interventions
A combination of endovascular revascularization (selective stenting) plus supervised 
exercise (n = 106) or supervised exercise only (n = 106).
Main outcomes and measures 
The primary end pointwas the difference in maximum treadmill walking distance at 12 
months between the groups. Secondary end points included treadmill pain-free walking 
distance, vascular quality of life (VascuQol) score (1 [worst outcome] to 7 [best outcome]), 
and 36-item Short-Form Health Survey (SF-36) domain scores for physical functioning, 
physical role functioning, bodily pain, and general health perceptions (0 [severe limitation] 
to 100 [no limitation]).
Results
Endovascular revascularization plus supervised exercise (combination therapy) was 
associated with significantly greater improvement in maximum walking distance (from 
264m to 1501m for an improvement of 1237m) compared with the supervised exercise only 
group (from 285m to 1240mfor improvement of 955 m) (mean difference between groups, 
282m; 99% CI, 60-505 m) and in pain-free walking distance (from 117m to 1237m for an 
improvement of 1120m vs from 135m to 847m for improvement of 712m, respectively) 
(mean difference, 408 m; 99%CI, 195-622 m). Similarly, the combination therapy group 
demonstrated significantly greater improvement in the disease-specific VascuQol score 
(1.34 [99% CI, 1.04-1.64] in the combination therapy group vs 0.73 [99% CI, 0.43-1.03] 
in the exercise group; mean difference, 0.62 [99%CI, 0.20-1.03]) and in the score for the 
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SF-36 physical functioning (22.4 [99%CI, 16.3-28.5] vs 12.6 [99%CI, 6.3-18.9], respectively; 
mean difference, 9.8 [99% CI, 1.4-18.2]). No significant differences were found for the 
SF-36 domains of physical role functioning, bodily pain, and general health perceptions.
Conclusions and relevance
Among patients with intermittent claudication after 1 year of follow-up, a combination 
therapy of endovascular revascularization followed by supervised exercise resulted in 
significantly greater improvement in walking distances and health-related quality-of-life 
scores compared with supervised exercise only.
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Intermittent claudication is the classic symptomatic form of peripheral artery disease, 
affecting approximately 20 to 40 million people worldwide and is increasing rapidly with 
the aging world population1. Patients with claudication experience significant functional 
disability resulting in a sedentary lifestyle and reduced quality of life2-4.
Supervised exercise is an effective first-line treatment for claudication5 and is 
recommended by international guidelines as the standard of care6-9. Yet, in clinical practice, 
its value remains uncertain because supervised exercise programs are underused due to 
limited access in most countries, reimbursement issues, and poor patient compliance5,10. 
As a consequence, endovascular revascularization is an increasingly attractive first-line 
alternative due to its immediate effect and potential to prevent disability11. Studies have 
suggested that endovascular revascularization is not significantly different from supervised 
exercise for improving functional performance and quality of life12,13. Hence, to date, the 
optimal first-line treatment in clinical practice for the increasing population of patients 
with claudication remains uncertain.
A combination therapy of early endovascular revascularization followed by supervised 
exercise seems promising because it combines the immediate improvement in claudication 
symptoms after revascularization with the added longterm benefits of exercise therapy. 
Two systematic reviews on this topic concluded that combination therapy might be 
superior to supervised exercise or endovascular revascularization alone12,13. However, this 
conclusion was based on limited data and needed to be confirmed in a larger randomized 
clinical trial (RCT). To address this question, the Endovascular Revascularization And 
Supervised Exercise (ERASE) RCT was designed to compare both the effectiveness and 
costeffectiveness of endovascular revascularization plus supervised exercise in patients 
with intermittent claudication with supervised exercise only. The outcomes on effectiveness 
are reported in this article. The cost-effectiveness analysis will be presented in the future.
METHODS
Study Design
The ERASE study was a parallel-design RCT conducted in the Netherlands at 10 sites 
between May 17, 2010, and February 16, 2013, comparing endovascular revascularization 
plus supervised exercise for intermittent claudication with supervised exercise only. The 
institutional review board at each participating center approved the trial protocol and 
written informed consent was obtained from all patients.
Participants
Patients with peripheral artery disease and stable claudication (≥3 months) referred to the 
outpatient clinic in the participating centers were potentially eligible. Patients were included 
if they had a resting ankle brachial index (ABI) of 0.90 or less or if their ABI decreased by 
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more than 0.15 after treadmill testing regardless of their ABI at rest. All participants also 
had 1 or more vascular stenoses at the aortoiliac level, the femoropopliteal level, or both, 
as established by noninvasive vascular imaging. Furthermore, their maximum walking 
distance had to be between 100 m and 500 m as assessed on a graded treadmill using the 
protocol by Gardner et al.14 Patients were excluded if their target lesions were unsuitable 
for revascularization or if they had received prior treatment for the target lesions. Patients 
with limited life expectancy or ambulation due to a condition other than peripheral artery 
disease also were excluded.
Randomization
Eligible patients were assigned in a 1:1 ratio to either endovascular revascularization 
plus supervised exercise or supervised exercise only. Randomization and allocation 
was performed using web-based randomization software (TenALEA, Amsterdam, the 
Netherlands) based on the Pocock and Simon minimization method.15,16
Intervention
Supervised Exercise
Exercise was provided to the patients by trained physiotherapists in a network of 
physiotherapy clinics in each patient’s neighborhood or at the physiotherapy center of the 
participating site. All physiotherapists were required to have completed a 2-day course 
on supervised exercise for claudication certified by the Royal Dutch Society for Physical 
Therapy and follow the society’s guideline on treatment of claudication.17 Most of the 
selected physiotherapists (82%) also participated in ClaudicatioNet, a national network of 
integrated care to improve the quality and accessibility of supervised exercise for patients 
with claudication in which the participating physiotherapists receive regular training 
and monitoring.18 The exercise program consisted primarily of treadmill walking to near-
maximum claudication pain. The physiotherapists were advised to start with a frequency 
of 2 to 3 sessions every week and approximately 30 to 45 minutes per session during the 
first 3 months. After this phase, the frequency was reduced to at least 1 session per week 
between months 3 and 6 and then to a frequency of 1 session per 4 weeks at 12 months, 
depending on patients’ progress and preference.
Endovascular Revascularization Plus Supervised Exercise
Endovascular revascularization was performed by an experienced interventional radiologist 
or vascular surgeon following the latest standards in accordance with the normal practice 
of the participating site. For iliac and femoral revascularizations, a stent was used only if 
the initial balloon angioplasty was not successful (selective stenting). In addition, within 2 
to 4 weeks after the procedure, patients were enrolled in the supervised exercise program 
described above.
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Outcomes and Assessment
Outcome assessment was performed at baseline and at the 1-, 6-, and 12-month 
follow-up visits. Baseline medical history and demographic data, including sex and race, 
were obtained by patient report to allow external generalizability of the study results. In 
addition, lipid profile, weight, height, and waist circumference were measured at the study 
visit and patient reported smoking and physical activity level were recorded. Physical 
activity was patient reported as number of hours physical activity (walking, running, 
bicycling, or other form of physical activity) performed per week. Vascular imaging, 
assessment of treadmill walking distances, ABI, and patientreported quality of life also 
were recorded.
The primary outcome was maximum walking distance at 12 months assessed during a 
graded treadmill test14 (maximum duration, 30 minutes). To ensure blinded outcome 
assessment, the treadmill test was overseen by an independent person, who was unaware 
of the specific treatment assigned, and patients were advised not to discuss their assigned 
treatment.
Secondary outcomes included pain-free walking distance, ABI (at rest and after 
exercise), and additional interventions (defined as any surgical or endovascular 
revascularization procedure, or both) offered to the patient during follow-up as a result of 
primary randomized treatment failure, number of leg amputations, and recurrent stenosis 
detected at 12 months by duplex ultrasonography in the endovascular revascularization 
plus supervised exercise group. Patientreported generic quality of life was obtained using 
the Rating score, which is based on a single question in which patients rate their health 
state on a scale from 0 (worst imaginable) to 100 (best imaginable),19 and the 36-item 
Short-Form Health Survey domain scores for physical functioning, physical role function 
(ie, limitations due to physical problems), bodily pain, and general health perceptions 
on a scale from 0 (severe limitation) to 100 (no limitation)20; these are the most relevant 
health domains to describe the health status of patients with peripheral artery disease.21 In 
addition, disease-specific quality of life was measured using the VascuQol questionnaire, 
which consists of the following 5 domains of activities, symptoms, pain, emotional, and 
social scored on a scale from 1 (worst outcome) to 7 (best outcome).22
Statistical Analysis
Based on previous studies, a mean difference of 30% to 35% in treadmill maximum 
walking distance (corresponding to an approximately 150 m difference after 12 months) 
between the 2 groups was considered as a relevant effect size.23-25 The power calculations 
proposed that 210 patients would be needed to achieve a 90% power to detect a 30% 
difference in maximum walking distance between the groups, with a 2-sided type I error 
rate of 0.01 and anticipating a 10% loss to follow-up. The main analyses were conducted 
according to the intention-to-treat principle. 
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Completeness of follow-up in each group was calculated as the ratio of total observed 
persontime of follow-up to the potential maximum persontime of follow-up.26 Continuous 
variables at baseline are presented as means and standard deviations and categorical 
variables as proportions. Multiple imputation to replace the missing baseline variables 
(5.2% [range, 0%-13%] of the baseline values were missing) was performed by combining 
the results from 5 imputed data sets in which regression modeling was used to predict 
the missing values based on the existing baseline variables.27 Between-group differences 
for the continuous outcome measures were compared using mixed models for repeated 
measures with random-effects adjustment for center effects.
A significant number of patients reached the maximum of 30 minutes of walking on 
the treadmill during follow-up, causing a nonnormal distribution for walking distances. To 
address this ceiling effect and account for the correlations in the repeated measurements 
for each patient, we used the Tobit mixed-effects model.28 The computations were 
performed in SAS procedure NLMIXED using the general likelihood option. Between-
group differences for additional interventions during follow-up were compared using 
Kaplan-Meier methods and Cox proportional hazards models. The proportional hazards 
assumptions were evaluated and met to estimate hazard ratios with corresponding 99% 
confidence intervals. To account for multiple testing, we used a stringent significance level 
of 0.01 (2-sided) as statistically significant for all analyses. The statistical analyses were 
performed using SPSS version 21 (SPSS Inc) and SAS version 9.3 (SAS Institute Inc).
RESULTS
A total of 666 patients were screened for inclusion. Of these, 212 patients were randomly 
assigned to supervised exercise (n = 106) or endovascular revascularization plus supervised 
exercise (n = 106; combination therapy group) (Figure 1). The 2 groups were well matched 
at baseline (Table 1). The mean (SD) age was 65 (10) years, 132 patients (62%) were 
men, and noninvasive imaging identified 112 (53%) patients with predominant aortoiliac 
disease and 100 (47%) patients with predominant femoropopliteal disease. The types of 
noninvasive imaging used were duplex ultrasonography (n = 155), magnetic resonance 
angiography (n = 8), and computed tomography angiography (n = 49).
In the combination therapy group, endovascular revascularization at baseline was 
technically successful in 102 patients (96%). Procedure-related minor complications 
occurred in 7 patients (7%), including groin hematoma (n = 5) and localized arterial 
dissection (n = 2); however, no major complications were recorded. Of the 4 patients in 
whom endovascular revascularization technically failed, 3 underwent an open surgical 
procedure, including endarterectomy (n = 2) and bypass (n = 1) procedures, and 1 received 
only supervised exercise.Among the 102 patients with technically successful endovascular 
revascularization, balloon angioplasty was followed by selective stent placement in 63 
patients (62%). 
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Table 1. Baseline characteristics of the study population according to treatment group
Baseline Characteristics Supervised Exercise
(n= 106)
Endovacular Revascularization 
plus Supervised Exercise
(n= 106)
Age (years) 66 (10) 64 (9)
Gender (male) 72 (68%) 60 (57%)
Ethnicity
White
Black
Other
98 (92%)
2 (2%)
6 (6%)
102 (96%)
2 (2%)
2 (2%)
Smoking
Current
Former
55 (52%)
42 (40%)
65 (61%)
33 (31%)
Lipids (mg/dL)
Total cholesterol
LDL-C
HDL-C
Triglycerides
189 (46)
108 (43)
50 (23)
195 (133)
193 (58)
112 (50)
54 (31)
168 (133)
Hyperlipidemiaa   44 (42%) 47 (44%)
BMI (kg/m2) 26.2 (4.4) 27.0 (4.1)
Waist size (cm) 102 (18) 102 (14)
Hypertension 66 (62%) 62 (58%)
Diabetes 27 (26%) 17 (16%)
History of ischemic cardiac disease 42 (40%) 35 (33%)
History of cerebrovascular disease 14 (13%) 11 (10%)
Pulmonary disease 17 (16%) 15 (14%)
Renal insufficiency 7 (7%) 7 (7%)
Lower limb osteoarthritis 12 (11%) 11 (10%)
Physical activity (hours/week)b 4.0 (1.0-8.0) 4.0 (1.0-9.0)
Duration IC (months)b 12.0 (6.0-24.0) 12.0 (5.0-24.0)
Fontaine classificationc
IIa
IIb
24 (23%)
82 (77%)
18 (17%)
88 (83%)
Dominant lesion
Aortoiliac
Femoropopliteal
54 (51%)
52 (49%)
58 (55%)
48 (45%)
Maximum Walking Distance (m) 285 (165) 264 (145)
Pain Free Walking Distance (m) 135 (88) 117 (83)
Ankle Brachial Indexd 
At rest 0.68 (0.16) 0.71 (0.18)
Post exercise 0.40 (0.24) 0.43 (0.21)
VascuQol scoree 4.51 (1.02) 4.48 (0.92)
Rating scoref 64.9 (17.8) 67.9 (17.8)
SF36- Physical Functioningg 52.7 (21.0) 51.4 (16.4)
SF36- Role Physical Scoreg 53.4 (40.9) 59.2 (40.2)
SF36- Bodily Paing  53.1 (20.7) 52.7 (17.6)
SF36- General Healthg 53.9 (20.3) 59.3 (15.4)
Data are presented as number of patients (%) or means (standard deviations)
Abbreviations: SE, supervised exercise; ER, endovascular revascularization; LDL-C low density lipoprotein- cholesterol; 
HDL-C, high density lipoprotein- cholesterol; BMI, body mass index; IC, intermittent claudication; VascuQol, vascular quality 
of life questionnaire score; SF-36, the 36-item short form health survey score
a: Defined as total cholesterol level  ≥ 193 mg/d
b: Data presented as median (interquartile range)
c: Fontaine stage IIa is defined as pain-free walking distance >200 meters, Fontaine stage IIb is defined as pain- free walking 
distance ≤200 meters
d: Minimum value of those for right and left legs
e:The VascuQol consists of 25 questions on five domains including activities, symptoms, pain, emotional and social domain, 
scored on a 1 (worst outcome) and 7 (best outcome) scale. 
f:Rating score consists of a single question in which patients score their health state on a 0 (worst imaginable health state)  to 
100 (best imaginable health state)  point scale.
g: In this study the SF-36 questionnaire consists of four separate domain scores, which are the weighted sums of the questions 
in each domain. Each domain score is expressed on a 0 (severe limitation) to 100 (no limitation) scale.
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The average number of completed exercise sessions in the combination therapy group 
was 30 sessions compared with the recommended 46 to 59 sessions during the 1-year 
follow-up. In the supervised exercise group, the average number of completed exercise 
sessions was 43 sessions compared with the recommended 46 to 59 sessions during the 
1-year follow-up. The completeness of 1-year follow up was 96% (5211/5438 person-
weeks) in the exercise group and 97% (5329/5518 person-weeks) in the combination 
therapy group (Figure 1).
Figure 1. Flow of Patients in the Endovascular Revascularization and Supervised Exercise Trial
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Table 2. Mean changes compared to baseline and mean difference between the treatment groups 
for measures of functional performance 
Functional Perfor‐
mance Measures
Supervised  
Exercise 
(n=106)
Endovascular 
Revascularization
 plus Supervised 
Exercise
 (n=106)
Between‐Group 
Difference P Valuea
Maximum Walking Distance (meters)
Baseline 285 (244 ; 326) 264 (228 ; 300)
1 month 438 (282 ; 595) 1004 (835 ; 1174) 566 (358 ; 774)  <0.001
6 months 851 (683 ; 1018) 1260 (1076 ; 1444) 409 (183 ; 636) <0.001
12 months 955 (786 ; 1124) 1237 (1058 ; 1418) 282 (60 ; 505)  0.001
Pain Free Walking Distance (meters)
Baseline 135 (113 ; 157) 117 (96 ; 138)
1 month 181 ( 23 ; 339) 724 (561 ; 886) 543 (340 ; 744) <0.001
6 months 542 (378 ; 707) 1071 (900 ; 1243) 529 (315 ; 743) <0.001
12 months 712 (549 ; 876) 1120 (948 ; 1293) 408 (195 ; 622) <0.001
Ankle Brachial Indexb (at rest)
Baseline 0.68 (0.64 ; 0.72) 0.71 (0.67 ; 0.76)
1 month -0.02 (-0.07 ; 0.02) 0.19 (0.15 ; 0.23) 0.21 (0.15 ; 0.27)  <0.001
6 months 0.04 (-0.01 ; 0.09) 0.16 (0.11 ; 0.20) 0.12 (0.05 ; 0.17) <0.001
12 months 0.03 (-0.02 ; 0.08) 0.16 (0.11 ; 0.21) 0.13 (0.06 ; 0.19) <0.001
Ankle Brachial Indexb (post- exercise)
Baseline 0.40 (0.34 ; 0.46) 0.43 (0.38 ; 0.48)
1 month 0.03 (-0.02 ; 0.09) 0.36 (0.30 ; 0.42) 0.33 (0.25 ; 0.40) <0.001
6 months 0.12 (0.06 ; 0.18) 0.33 (0.27 ; 0.39) 0.21 (0.13 ; 0.29) <0.001
12 months 0.11 (0.05 ; 0.18) 0.33 (0.27 ; 0.40) 0.22 (0.13 ; 0.31) <0.001
Data are presented as mean improvement compared to baseline (99% confidence intervals) 
a: P values represent the difference between the two treatment groups for functional performance measures 
b: Minimum value for right and left legs 
Primary Outcome
During follow-up, the maximum treadmill walking distance improved significantly in 
both the supervised exercise only group and in the endovascular revascularization plus 
supervised exercise group. Compared with the supervised exercise only group, the 
improvement was significantly greater in the combination therapy group with a mean 
difference of 566 m (99% CI, 358-774 m) at 1 month, 409 m (99% CI, 183-636 m) at 6 
months, and 282 m (99% CI, 60-505 m) at 12 months (Table 2).
Secondary Outcomes
One year after randomization, endovascular revascularization plus supervised exercise led 
to greater improvement in pain-free walking distance compared with supervised exercise 
only with a mean between-group difference of 408 m (99% CI, 195-622 m). Similarly, ABI 
at rest and after exercise showed significantly greater improvement in the combination 
therapy group (Table 2).
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During the 1-year follow up, 2 patients (2%) in the supervised exercise group and none in 
the combination therapy group underwent a minor amputation due to deterioration of 
claudication to progressive lower limb ischemia. Twentythree patients (22%) in the supervised 
exercise group needed an intervention during follow-up due to deterioration of symptoms 
or persisting disabling symptoms, including 21 patients who required an endovascular 
revascularization procedure and 2 patients who required an open revascularization 
procedure. In the combination therapy group, 8 patients (8%) required a secondary 
intervention, including 3 patients who underwent an endovascular revascularization 
procedure and 5 patients who underwent an open revascularization procedure. This 
resulted in a significantly higher proportion of patients without an additional intervention 
after 1 year of follow-up in the combination therapy group (92%) compared with the 
supervised exercise group (77%) (hazard ratio, 3.2 [99% CI, 1.1-9.2]; P = .005; Figure 2).
At 1 year, 73 of the 100 patients available for follow-up in the endovascular 
revascularization plus supervised exercise group received duplex ultrasonography 
to assess restenosis of the revascularized dominant lesion. In this group, significant 
restenosis was identified in 23 patients (32%), including 17 (74%) with significant restenosis 
in the femoropopliteal segment and 6 (26%) with significant restenosis in the aortoiliac 
segment. In the group with a significant restenosis, 4 patients (17%) required a secondary 
revascularization procedure due to deterioration of claudication during the 1-year 
follow-up.
Figure 2. Kaplan-Meier Estimates of the Proportion of Patients Without Additional Intervention 
During Follow-up
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One year after randomization, the disease-specific VascuQol score significantly improved 
in both groups. The improvement was significantly greater for the combination therapy 
group with a mean between-group difference of 0.62 (99% CI, 0.20-1.03). Similarly, at 
1-year follow-up, the Rating score was significantly greater in the combination therapy 
group (Table 3). For the 36-item Short-Form Health Survey domains, only physical 
functioning was significantly greater at 12 months in the combination therapy group 
(Table 3).
DISCUSSION
The ERASE trial was designed to examine whether endovascular revascularization plus 
supervised exercise compared with supervised exercise only would further improve 
functional and quality of life outcomes in patients with intermittent claudication. After 
1 year, patients in both groups improved significantly; however, patients receiving the 
combination therapy had more rapid and significantly greater improvements in their 
walking performance and disease-specific quality of life.
To our knowledge, the ERASE trial is the first adequately powered RCT assessing the 
effectiveness of a combination therapy of endovascular revascularization plus supervised 
exercise vs supervised exercise only in patients with aortoiliac and femoropopliteal 
peripheral artery disease. In the Claudication: Exercise vs Endoluminal Revascularization 
trial,30,31 which was funded by the National Institutes of Health and assessed the 
effectiveness of treatment strategies for aortoiliac disease, the fourth treatment group 
combining endovascular revascularization plus supervised exercise was prematurely 
stopped and removed from the analysis due to slow enrollment. Similarly, in the Mild 
to Moderate Intermittent Claudication trial23 that assessed the adjuvant benefit of 
endovascular revascularization above supervised exercise, recruitment was stopped 
prematurely due to slow enrollment. The authors included 67 patients in the combination 
therapy group and demonstrated that after 24 months of follow-up, patients in the 
endovascular revascularization plus supervised exercise group had significantly higher 
maximum walking distance compared with the patients in the exercise only group. A more 
recent trial by Mazari et al32 that assessed the effectiveness of a combination therapy of 
endovascular revascularization plus supervised exercise compared with a monotherapy 
of endovascular revascularization or supervised exercise in patients with femoropopliteal 
disease showed that the combination therapy was not different after 1 year regarding 
improvement in walking distance and quality of life. The lack of a statistically significant 
difference in walking distance between the groups might have been due to a ceiling effect 
because the treadmill test duration was limited to only 5 minutes (215 m).
The present study reopens the debate for revascularization in patients with 
claudication, in particular in terms of an approach using endovascular revascularization 
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Table 3. Mean changes compared to baseline and mean difference between the treatment groups 
for measures of quality of life
Quality of Life 
Measures 
Supervised Exercise 
(n=106)
Endovascular 
Revascularization
 plus Supervised 
Exercise
 (n=106)
Between‐Group 
Difference
 
P Valuea
VascuQol scoreb 
Baseline 4.51 (4.25 ; 4.77) 4.48 (4.25 ; 4.71)
1 month 0.27 (0.04 ; 0.50) 1.52 (1.29 ; 1.76) 1.25 (0.94 ; 1.56) <0.001
6 months 0.62 (0.37 ; 0.88) 1.41 (1.16 ; 1.66) 0.79 (0.45 ; 1.13) <0.001
12 months 0.73 (0.43 ; 1.03) 1.34 (1.04 ; 1.64) 0.62 (0.20 ; 1.03) <0.001
Rating scorec 
Baeline 64.9 (60.4 ; 69.4) 67.9 (63.4 ; 72.4)
1 month 1.1 (-3.9 ; 6.2) 9.9 (5.1 ; 14.7) 8.7 (2.4 ; 15.1) <0.001
6 months -0.5 (-5.5 ; 4.5) 10.1 (5.2 ; 15.0) 10.6 (4.3 ; 17.0) <0.001
12 months -1.4 (-3.5 ; 6.3) 7.9 (3.0 ; 12.8) 6.5 (0.2 ; 12.7)  0.008
SF-36 Physical Functioningd 
Baseline 52.7 (47.4 ; 58.0) 51.4 (47.3 ; 55.5)
1 month 4.0 (-0.7 ; 8.6) 27.3 (22.7 ; 31.8) 23.3 (17.3 ; 29.4) <0.001
6 months  12.7 (7.7 ; 17.7) 27.2 (22.3 ; 32.2) 14.6 (7.9 ; 21.2) <0.001
12 months  12.6 (6.3 ; 18.9) 22.4 (16.3 ; 28.5) 9.8 (1.4 ; 18.2)  0.002
SF-36 Role Physical Scored 
Baseline 53.4 (43.2 ; 63.7) 59.2 (49.1 ; 69.3)
1 month 2.6 (-7.2 ; 12.3) 19.7 (10.0 ; 29.4) 17.1 (4.5 ; 29.7) <0.001
6 months 5.9 (-4.4 ; 16.1)  18.9 (8.8 ; 28.9) 13.0 (-0.1 ; 26.1)  0.011
12 months 5.0 (-6.4 ; 16.5)  19.0 (7.8 ; 30.2) 14.0 (-0.8 ; 28.7)  0.015
SF-36 Bodily Paind 
Baseline 53.1 (47.9 ; 58.3) 52.7 (48.3 ; 57.1)
1 month -3.1 (-8.1 ; 2.0) 22.7 (17.7 ; 27.8) 25.8 (19.2 ; 32.4) <0.001
6 months  6.6 (1.2 ; 11.9) 21.0 (15.7 ; 26.3) 14.4 (7.4 ; 21.5) <0.001
12 months 10.4 (4.3 ; 16.5) 17.9 (12.0 ; 23.9) 7.6 (-0.6 ; 15.7)  0.017
SF-36 General Healthd 
Baseline 53.9 (48.9 ; 59.0) 59.3 (55.4 ; 63.2)
1 month -0.6 (-4.7 ; 3.5)  5.0 (0.8 ; 9.1) 5.6 (0.1 ; 11.0)  0.009
6 months 1.6 (-2.8 ; 5.9) 5.8 (1.5 ; 10.1) 4.2 (-1.6 ; 9.9)  0.061
12 months -2.4 (-7.3 ; 2.5)  1.7 (-3.1 ; 6.5) 4.1 (-2.4 ; 10.6)  0.106
Data are presented as mean improvement compared to baseline (99% confidence intervals) Abbreviations: VascuQol, vascu-
lar quality of life questionnaire score; SF-36, the 36-item short form health survey score 
a: P values represent the difference between the two treatment groups for quality of life measures
b: The VascuQol consists of 25 questions on five domains including activities, symptoms, pain, emotional and social domain, 
scored on a 1 (worst outcome) and 7 (best outcome) scale. The minimal clinically important difference for VascuQol has been 
established to be > 0.36 to 0.48 points39
c: Rating score consists of a single question in which patients score their health state on a 0 (worst imaginable health state)  to 
100 (best imaginable health state)  point scale. For patients with peripheral arterial disease the minimum clinically important 
difference for rating score has not been established yet.
d: In this study the SF-36 questionnaire consists of four separate domain scores, which are the weighted sums of the questions 
in each domain. Each domain score is expressed on a 0 (severe limitation) - 100 (no limitation) scale. The minimal clinically 
important difference for the SF-36 score is suggested to be >2 to 2.5 points29
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first. By improving lower extremity blood flow, early percutaneous revascularization of the 
target lesion gives an impulse to patient mobility and quality of life in the short-term. This, 
in turn, facilitates subsequent exercising and allows the patient to profit from the long-
term benefits of an additional supervised exercise program. Even though almost one-
third of the patients in the combination therapy group showed a restenosis of their initially 
revascularized lesion at 1-year follow-up, only 4% required a secondary intervention 
because of recurrent claudication symptoms. This suggests that the addition of a 
supervised exercise program may prevent deterioration despite restenosis or progression 
of atherosclerotic lesions. Similarly, Mazari et al.32 found a sustained clinical improvement 
after combination therapy with none of the patients reporting deterioration or requiring 
reintervention by 1 year. An important condition to achieve this synergetic effect is to have 
a wellestablished standardized and accessible supervised exercise program for patients to 
follow after the endovascular revascularization procedure, as was the case in the ERASE 
trial.
In addition to demonstrating benefits of a combination therapy, this study also 
confirmed the beneficial effects of exercise in the management of claudication with 
significant improvements in walking distances and quality of life in patients receiving 
supervised exercise only with the majority requiring no revascularization procedure up 
to 1 year. A cost-effectiveness analysis based on the ERASE results is required and is 
under way to address the question of whether the incremental benefit of the combination 
therapy as demonstrated in this study will also be cost-effective given the substantially 
higher costs of endovascular revascularization compared with supervised exercise.33-35
In clinical practice, especially in the United States, endovascular revascularization alone 
is being performed more frequently than the recommended care of supervised exercise. 
This is mainly due to reimbursement issues and unavailability of supervised exercise. 
Previous studies have shown exercise alone to be no different than24,32 or even superior 
to endovascular revascularization alone.30,31 Thus, in the ERASE trial we chose to study the 
treatment strategy of combining supervised exercise and endovascular revascularization. 
We believe this was the most relevant comparison from a scientific point of view and 
also the most relevant comparison in the context of recommended clinical practice as 
formulated in the guidelines.6-9
The ERASE study has several limitations. First, the results are only generalizable to 
patients with stable claudication meeting our eligibility criteria. Second, an adequate 
screening log for all eligible patients was only stored at the largest center. Due to an 
absence of screening logs at the other centers, some patients might have been eligible for 
inclusion but were not screened or might have been excluded based on the preference 
of physicians. Yet, no indication for such bias exists and the baseline characteristics of 
the population included in this study are comparable with previously published RCTs of 
patients with claudication.23,24,32,36
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Third, due to an absence of a well-defined and validated value for a clinically relevant 
difference in treadmill walking distance,37 it remains uncertain to what extent the significant 
difference in treadmill walking distance will affect the patients daily mobility. Fourth, 
the study follow-up was limited to 1 year and, given the decreasing mean difference 
in maximum walking distance between the 2 groups, the long-term effects of the 
combination therapy beyond 1 year remains unanswered and warrants further research. 
The exact reason for the decreasing mean difference in walking distance between the 
groups over time is unknown. Table 2 shows that the improvement in walking distance is 
sustained between 6 and 12 months with combination therapy, whereas with supervised 
exercise alone walking distance continues to improve during this period. This suggests 
that improvement in walking distance may take longer to develop with exercise alone 
because collateral circulation needs to develop and muscle metabolism needs to change. 
Alternatively, this may be explained by the revascularization interventions in the supervised 
exercise group, which were performed for deterioration of symptoms.
Fifth, the number of supervised exercise sessions followed by the patients was lower 
compared with the number of sessions as recommended by the guideline,7 which might 
have resulted in a less effective supervised exercise. Nonetheless, significant improvement 
was demonstrated in walking distance and quality of life in the supervised exercise 
group, which was comparable or even superior to previously published RCTs assessing 
the effectiveness of supervised exercise.23,24,30,32,36,38 In addition, the optimal number of 
supervised exercise sessions to complete remains unknown.5 The supervised exercise 
program in the ERASE study was in accordance with the single RCT on this issue, which 
suggests an important role for intensive training offered during the first 2 months of 
supervised exercise.39
CONCLUSIONS
Among patients with intermittent claudication after 1 year of follow-up, a combination 
therapy of endovascular revascularization followed by supervised exercise resulted in 
significantly greater improvement in walking distances and healthrelated quality of life 
scores compared with supervised exercise only.
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ABSTRACT
Background
Current guidelines recommend supervised exercise therapy as the preferred initial 
treatment for patients with intermittent claudication. The availability of supervised 
exercise therapy programmes is, however, limited and such programmes are often not 
reimbursed. Evidence for the long-term cost-effectiveness of supervised exercise therapy 
compared with endovascular revascularization as primary treatment for intermittent 
claudication might aid widespread adoption in clinical practice.
Methods 
A Markov model was constructed to determine the incremental costs, incremental quality 
adjusted life years (QALYs) and incremental cost-effectiveness ratio of supervised exercise 
therapy versus endovascular revascularization for a hypothetical cohort of patients with 
newly diagnosed intermittent claudication, from the Dutch healthcare payer’s perspective. 
In the event of primary treatment failure, possible secondary interventions were repeat 
endovascular revascularization, open revascularization or major amputation. Data sources 
for model parameters included original data from two RCTs, as well as evidence from the 
medical literature. The robustness of the results was tested with probabilistic and one-way 
sensitivity analysis.
Results
Considering a 5-year time horizon, probabilistic sensitivity analysis revealed that 
supervised exercise therapy was associated with cost savings compared with endovascular 
revascularization (− €6412, 95 percent credibility interval (CrI) – €11874 to – €1939). 
The mean difference in effectiveness was −0.07 (95 percent CrI −0.27 to 0.16) QALYs. 
Endovascular revascularization was associated with an additional €91600 per QALY gained 
compared with supervised exercise therapy. One-way sensitivity analysis indicated more 
favourable cost-effectiveness for endovascular revascularization in subsets of patients 
with low quality of life scores at baseline.
Conclusions
supervised exercise therapy is a more cost-effective primary treatment for intermittent 
claudication than endovascular revascularization. These results support implementation 
of supervised exercise programmes in clinical practice.
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Intermittent claudication is the most common manifestation of peripheral arterial disease 
(PAD). Its prevalence is around 2 percent in the population aged 40–44 years, increasing 
to 8 per cent at 70–74 years1. With the ageing population in Western societies, the 
prevalence of intermittent claudication is increasing2  and it will place a growing burden 
on healthcare resources. Treatment of intermittent claudication aims to improve quality 
of life (QoL) and walking distance. Over the past decade, several studies have compared 
supervised exercise therapy, endovascular revascularization or a combination of these 
treatments. In general, most studies found no difference between supervised exercise 
therapy and endovascular revascularization with respect to walking distance or QoL, even 
after 7 years of follow-up3-8. Supervised exercise therapy is a relatively safe, non-invasive 
treatment9. Accordingly, current international guidelines recommend supervised exercise 
therapy as the primary treatment in the management of intermittent claudication1,10–12. 
However, access to adequate supervised exercise therapy programmes worldwide is 
limited13,14. Furthermore, in contrast to endovascular revascularization they are often not, 
or only partially, reimbursed by insurance plans15,6. As a result, supervised exercise therapy 
remains underutilized in the treatment of intermittent claudication.
Considering the equal effectiveness of supervised exercise therapy and endovascular 
revascularization, other aspects such as costs, mortality and morbidity of the intervention 
can play a decisive role in choosing the initial treatment strategy. Previous cost-effectiveness 
studies17-19 found a supervised exercise therapy-first approach to be less expensive than 
endovascular revascularization, and equally effective. Implementation of a supervised 
exercise therapy-first approach in the treatment of intermittent claudication could lead 
to significant savings in terms of healthcare resources16. However, these studies either 
considered a limited time horizon of 12–15 months18,19, or did not include effectiveness16,17.
A clinical decision model, such as a Markov model, incorporates existing scientific 
evidence to analyse the clinical outcome of a disease20. It can be used to evaluate the 
cost-effectiveness of different treatment strategies over an extended period of time. A 
comprehensive Markov model, using contemporary evidence from multiple sources, is 
necessary to facilitate the optimal allocation of available healthcare resources. 
The purpose of the present study was to incorporate current evidence on the costs 
and effectiveness of supervised exercise therapy and endovascular revascularization into 
a clinical decision model, and to evaluate the cost-effectiveness of a supervised exercise 
therapy-first strategy (with endovascular revascularization in the event of supervised 
exercise therapy failure) compared with an endovascular revascularization-first strategy 
for the management of intermittent claudication.
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METHODS
Study design
A Markov model was developed using Microsoft Excel 2010 (Microsoft Corporation, 
Redmond,Washington,USA) to assess the cost-effectiveness, from the perspective of the 
Dutch healthcare payer, of supervised exercise therapy and endovascular revascularization 
for patients with newly diagnosed intermittent claudication (PAD Fontaine II, Rutherford 
1–3). The model was designed to simulate the effect of both treatment strategies on the 
clinical course of a hypothetical cohort of patients. It consisted of seven health states: 
asymptomatic PAD, mild claudication, moderate claudication, severe claudication, critical 
limb ischaemia (CLI), post major amputation and death (Fig. 1).
All patients started with an intervention, either supervised exercise therapy or 
endovascular revascularization. With each cycle, representing 3 months, transition 
probabilities determined whether patients would relocate to a different health state or 
remain in the same state. The decision model kept track of costs, time spent in each 
health state and impact on QoL. Subsequent analysis over a 5-year time horizon (20 
cycles) provided results regarding the cost-effectiveness of supervised exercise therapy 
and endovascular revascularization. Outcomes of interest were total quality adjusted life 
years (QALYs), total costs (reported in euros) and the incremental cost-effectiveness ratio 
(ICER).
Treatment strategies
Two primary treatment strategies were analysed: supervised exercise therapy and 
endovascular revascularization. supervised exercise therapy, lasting 1 year, was performed 
by a physiotherapist trained in supervised exercise therapy according to the guidelines of 
the Royal Dutch Society for Physical Therapy21. A typical session included interval training 
to near-maximal pain, as well as strength and endurance training, and focused on risk 
factor modification and improving self-management. endovascular revascularization 
comprised a percutaneous transluminal angioplasty followed by a stent when balloon 
dilatation was inadequate.
All patients received cardiovascular risk factor management according to present 
guidelines, including cholesterol-lowering medication and antiplatelet therapy1,10-12. In 
the event of failure of primary treatment (supervised exercise therapy or endovascular 
revascularization), secondary interventions were either open revascularization (OR), 
(repeated) endovascular revascularization or major amputation.
Model input sources
Costs, utilities and transition probabilities were derived from the existing medical 
literature18,19,22-36 and original patient data from two sources: the EXITPAD (Exercise 
Therapy in Peripheral Arterial Disease) trial37 and the CETAC (Comparing Exercise Training 
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Figure 1. Simplified diagram of the Markov structure. Patients start the cycle in one of the inter-
mittent claudication health states and will receive primarily either supervised exercise therapy (SET) 
or endovascular revascularization (ER). The shaded boxes represent a health state. The oval boxes 
represent a possible secondary intervention: major amputation, open revascularization (OR) or 
ER. The arrows indicate possible transitions between health states. Transition probabilities define 
how patients may move during a cycle. Both the supervised exercise therapy and ER groups have 
distinct transition probabilities. For clarity, simplifications have been made. The intermittent clau-
dication health states are represented in a single box. In the model, intermittent claudication was 
split into three groups (mild, moderate, severe) based on symptom severity as defined by quality 
of life. Each health state had possible transitions to itself not shown in the figure. 
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with Angioplasty for Claudication) study3. The EXITPAD study was a multicentre RCT 
that included 304 patients from 11 outpatient vascular surgery clinics throughout the 
Netherlands. Patients were randomized to either verbal walking advice or supervised 
exercise therapy performed by a local physiotherapist. The CETAC study was a single-
centre RCT; 151 consecutive patients who presented with symptoms of intermittent 
claudication due to iliac or femoropopliteal arterial stenosis were included. Patients with 
lesions unsuitable for revascularization were excluded. Patients were assigned randomly 
to either hospital-based supervised exercise therapy or endovascular revascularization. 
Further details of trial methodology were published previously3,37.
The baseline and 12-month follow-up data from the supervised exercise therapy 
treatment arms of the EXITPAD study (159 patients), and both the endovascular 
revascularization and supervised exercise therapy arms of the CETAC study (150 patients), 
were used. A comparison of baseline characteristics can be found in Table S1 (supporting 
information online). Their respective institutional review boards approved both trials and 
all patients gave written informed consent. The authors of both trials approved use of 
their data in the present study.
Health states
The starting health state was either mild, moderate or severe claudication. In the cycles 
after the initial intervention patients could either: recover completely (asymptomatic PAD); 
stay in the same health state; transit to any of the other intermittent claudication states; 
develop CLI (PAD Fontaine III and IV, Rutherford 4–6); possibly require an amputation 
(post major amputation); or die (death). Patients requiring secondary revascularization 
had the same possible health state transitions afterwards, but with different transition 
probabilities (Table S2, supporting information online). 
The health states mild, moderate and severe claudication were defined using the 
tertile values for the EuroQol 5 Dimension (EQ-5D™; EuroQol Group, Rotterdam, The 
Netherlands) score in the combined EXITPAD and CETAC data as thresholds to form the 
three distinct health states. At the start of the simulation, the virtual cohort was divided 
over these health states based on the initial distribution in the combined database (ratio 
mild :moderate : severe was 34 : 44 : 22).
Input parameters
Transition probabilities
Tables S2 and S3 (supporting information online) show the input transition probabilities 
with their corresponding sources and ranges used for probabilistic sensitivity analysis. 
Some assumptions had to be made where data sources were insufficient, as described 
below.
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Both mortality and progression to CLI were rare events in the EXITPAD and CETAC 
trials. Therefore, annual mortality23 and CLI incidence22 for health states mild, moderate 
and severe claudication were derived from the literature. 
The model structure allowed for only one type of secondary intervention. To be 
able to incorporate outcome and costs for both endovascular revascularization and OR, 
weighted averages of cost and effectiveness outcomes were calculated, and the results 
combined based on observed ratios of OR:ER (10 : 29316 for intermittent claudication and 
10 : 2729 for CLI).
Transitions for a patient in the CLI health state differed depending on type of treatment 
received. A study by Frans and colleagues29 found that, of 150 consecutive patients with 
CLI, 7.3 percent received conservative treatment, 3.3 percent required a major amputation, 
24.1 percent were treated with OR and 65.3 per cent with endovascular revascularization. 
Accordingly, different transition probabilities, from different sources, were used for 
patients with CLI who had conservative treatment (wound care and pharmacotherapy 
alone)25, after endovascular revascularization or OR26 and after amputation28 (Tables S2 
and S3, supporting information online).
Costs
All costs (Table 1) were established from a Dutch healthcare payer’s perspective. The 
costs of supervised exercise therapy were calculated assuming a physiotherapist’s fee 
of €30.00 per half-hour training session and 48 training sessions in 12 months16. Costs 
for the initial endovascular revascularization treatment strategy were taken from the 
CETAC database, and included the procedure, follow-up and overhead costs19. The costs 
for the initial outpatient consultation and diagnostic evaluation were considered to be 
equal for supervised exercise therapy and endovascular revascularization, and were 
therefore not included in the analysis. Costs for secondary interventions were determined 
for endovascular revascularization19, OR31 and major amputation35 separately. The costs 
of being in the health state CLI were derived from Stockl et al.33, considering wound 
care for patients with diabetic ulcers. The cost of being in the mild, moderate or severe 
claudication health state was calculated based on one yearly outpatient follow-up visit38 
and medication costs39. The cost of asymptomatic PAD was based on medication costs 
only.
Cost input derived from American sources was converted to the Dutch healthcare 
system using the healthcare-specific purchasing power parity of the USA relative to the 
average of a group of developed countries40. All costs were updated to September 2014 
euros with the Dutch and US inflation indices (http://statline.cbs.nl and http://www.bls.
gov/data/inflationcal _culator.htm ).
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Quality of life
To assess the effect of treatment on QoL, utility scores were assigned to each health state 
(Table 1). A utility is the valuation of a person’s health ranging from 0 (worst possible) to 1 
(perfect). Utility scores for mild, moderate and severe claudication as well as asymptomatic 
PAD were derived from the EXITPAD and CETAC data by calculating median EQ-5D™ 
values for these states. Utilities for post major amputation41 and CLI26 were drawn from 
the literature.
Analysis
Validation
The internal validity of the model was tested by comparing the health state distribution 
after 1 simulated year with the distribution in the observed data from the EXITPAD and 
CETAC studies. The external validity was verified by comparing important simulated 
Table 1. Utilities and Costs With Distribution Used in Probabilistic Sensitivity Analysis
Model parameters Value* (standard error) Distribution Source
Health state utilities
  Asymptomatic PAD 0.81 (0.002) Beta EXITPAD/CETAC
  Mild claudication 0.78 (0.006) Beta EXITPAD/CETAC
  Moderate claudication 0.65 (0.002) Beta EXITPAD/CETAC
  Severe claudication 0.54 (0.020) Beta EXITPAD/CETAC
  Critical limb ischemia 0.42 (0.144)† Beta 26
  Post major amputation 0.54 (0.076)† Beta 26
Health state costs (€, 2014)
  Asymptomatic PAD 16 (4)‡ Gamma 39
  Mild claudication 93 (20)‡ Gamma 39, 39
  Moderate claudication 93 (20)‡ Gamma 38, 39
  Severe claudication 93 (20)‡ Gamma 38, 39
  Critical limb ischemia 13 881 (6000)‡ Gamma 26, 33
  Post major amputation 2777 (437) Gamma 34
Costs of interventions (€, 2014)
Primary treatment:
  SET 1440 (1260) Gamma See text
  ER 7530 (1530) Gamma 19
Secondary interventions
  ER/OR for IC 7552§ (1534) Gamma 19, 31
  ER/OR for CLI 12 559§ (3000)‡ Gamma 31
  Major amputation 14 917 (1817) Gamma 35
Values in parentheses are standard errors. *All values are presented per year. They were converted into 3-monthly values to 
fit the cycle length of the model. †Based on a range of values from different studies reported by Barshes et al.26 ‡Estimated 
standard error owing to lack of published data. §Cost of secondary intervention endovascular revascularization (ER)/open 
revascularization (OR) was calculated by combining separate costs, assuming an OR:ER ratio of 10 : 29316 for intermittent 
claudication and 10 : 2729 for critical leg ischaemia. PAD, peripheral arterial disease; SET, supervised exercise therapy.
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outcome parameters with values described in the practice guidelines from the Society 
for Vascular Surgery12.
Base-case analysis
All probabilities, costs and utilities were calculated to 3-month values, the cycle length 
of this Markov model. The age at the start of the simulation was set at 66 years (mean 
age in the combined EXITPAD and CETAC database). Future costs and outcomes were 
discounted at the rates of 4 and 1.5 percent respectively, following the Dutch Guidelines 
for Pharmaco-Economic Research42. Total QALYs were calculated by multiplying the 
time a patient remained in a certain health state by the associated utility, and the results 
were summed across health states. Incremental costs and QALYs were determined by 
subtracting total costs and QALYs for the endovascular revascularization-first arm from 
their respective supervised exercise therapy-first counterparts. A strategy was considered 
dominant if both effectiveness increased and costs decreased compared with the other 
strategy. To calculate the ICER for non-dominant situations, incremental costs were 
divided by incremental effectiveness (as measured by QALYs).
Uncertainty
To account for the uncertainty of the model outcome, a probabilistic sensitivity analysis 
was performed using Monte Carlo simulation. A probability distribution was derived for 
each parameter, from either reported standard errors, confidence intervals, alternative 
probabilities found in the literature or expert opinion (Table 1; Tables S2 and S3, supporting 
information online). The simulation ran 1000 times for a hypothetical cohort of 100 000 
patients for each treatment strategy. Each time, the value for each parameter differed 
based on random selection from their respective distributions. The mean costs and QALYs 
from the 1000 simulations were reported, along with their 95 percent credibility interval 
(CrI). The CrI is the Bayesian statistics equivalent of a confidence interval. 
The probability of supervised exercise therapy or endovascular revascularization 
being cost-effective at different willingness-to-pay (WTP) thresholds was presented in 
cost-effectiveness acceptability curves (CEACs). There is no consensus on an appropriate 
threshold for the costs society is willing to pay per QALY gained. In the Netherlands a 
WTP threshold range of €20 000 – €80 000/QALY has been suggested43. A threshold 
WTP for a QALY of €40 000 was used as this is close to the commonly used threshold 
of €50 000/QALY44. Various one-way sensitivity analyses were performed to evaluate the 
effect of alternative inputs and assumptions on the outcomes of the model. In particular, 
sensitivity analyses were carried out by varying the time horizon, using alternative discount 
rates, varying the age of the patients, alternating the frequency of supervised exercise 
therapy sessions (according to National Institute for Health and Care Excellence guideline 
recommendations11), using different costs or secondary intervention rates, applying 
cardiovascular health benefits after supervised exercise therapy45, and isolating patients 
with mild, moderate or severe disease (as defined by EQ-5D™ scores).
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RESULTS
The outcome of 1000 Monte Carlo Markov model simulations of a hypothetical cohort 
of 100000 patients with intermittent claudication was calculated (Figure 2). Over a 5-year 
time horizon, the mean total costs of supervised exercise therapy and endovascular 
revascularization were €10219 and €16631 respectively. Mean total QALYs were 2.78 for 
supervised exercise therapy and 2.85 for endovascular revascularization. The distribution 
of virtual patients across health states after 5 years is shown in Table S4 (supporting 
information online). Probabilistic sensitivity analysis showed that supervised exercise 
therapy saved costs compared with endovascular revascularization (−€6412, 95 percent 
CrI −€11874 to −€1939). There was no statistically significant difference in effectiveness 
(−0.07 (95 percent CrI −0.27 to 0.16) QALYs). Endovascular revascularization was 
associated with an additional €91600 per QALY gained compared with supervised exercise 
therapy. This exceeds the Dutch WTP threshold of €20 000–80 000/QALY. There were no 
statistically significant differences in the number of secondary interventions (endovascular 
revascularization/OR and major amputations) between supervised exercise therapy and 
endovascular revascularization.
Figure 3: shows the CEACs for the supervised exercise therapy-first and endovas-
cular revascularization-first treatment strategies. The probability of endovascular 
revascularization being cost-effective increased with a rising WTP threshold. Even so, with 
WTP thresholds of up to €100 000, the probability that endovascular revascularization was 
the optimal primary treatment choice did not exceed 53 percent.
One‐way sensitivity analysis
The supervised exercise therapy-first approach would remain the most cost-effective 
option, given a hypothetical WTP threshold of €40 000, in all one-way sensitivity analyses, 
except one alternative scenario in which all patients started in the severe claudication 
health state (Table 2). Alternative input values regarding cost estimations for endovascular 
revascularization and secondary intervention rates, as well as applying cardiovascular 
health benefits to the supervised exercise therapy-first treatment arm, markedly improved 
the cost-effectiveness of supervised exercise therapy. Changing the time horizon to lifetime 
decreased the probability that supervised exercise therapy was cost-effective compared 
with the base case (Fig. S1,supporting information online). However, this would assume a 
continued treatment effect of the initial intervention well beyond the follow-up time span 
of available trial data, increasing the uncertainty concerning incremental QALYs. This is 
illustrated by the wide spread of simulation results on the incremental cost-effectiveness 
plane of lifetime analysis (Fig. S2, supporting information online).
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Figure 2. Incremental cost-effectiveness plane for supervised exercise therapy versus endovascu-
lar revascularization (ER). The x-axis shows the incremental quality-adjusted life-years (QALYs), and 
the y-axis the incremental costs, for supervised exercise therapy compared with ER. The differences 
in costs (incremental costs) and QALYs (incremental QALYS) are calculated for each of the 100 000 
hypothetical patients and represented as a dot. The diagonal line represents a €40 000 willing-
ness-to-pay threshold. Supervised exercise therapy was the preferable treatment in all samples 
below this line, constituting 73 per cent of the 1000 simulations
Figure 3. Cost-effectiveness acceptability curves for a range of willingness-to-pay (WTP) thresh-
olds for the treatment of intermittent claudication. The x-axis shows different WTP thresholds that 
society may be willing to pay to gain 1 quality-adjusted life-year. The y-axis shows the proportion 
of samples that demonstrated cost-effectiveness for supervised exercise therapy and endovascular 
revascularization (ER)
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Validation
The model adequately predicted the health state distributions after 1 simulated year as 
observed in the EXITPAD and CETAC studies, and after 5 simulated years compared with 
outcomes presented by Conte and colleagues12 (Table S5, supporting information online).
DISCUSSION
This cost-effectiveness analysis, comparing supervised exercise therapy and endovascular 
revascularization as primary treatment in patients with newly diagnosed intermittent 
claudication, showed that supervised exercise therapy is more cost-effective than 
endovascular revascularization. The mean costs of a supervised exercise therapy-first 
treatment strategy over a 5-year interval were lower per patient, but there was no 
statistically significant difference in effectiveness. Submitting a new patient with intermittent 
Table 2. Input and outcomes of one-way sensitivity analyses
Parameters Incremental costs (€)* Incremental QALYs* CEP†
Base case analysis -6412 (-11 874;-1939) -0.07 (-0.27;0.16) 73%
Cost of ER
  €12 51231 -11 353 (-16 098;-6624) -0.07 (-0.27;0.14) 93%
Cost of SET
  24 sessions (2/week for 3 mo)48 -6832 (-12 058;-1848) -0.07 (-0.27;0.14) 76%
  2x 1-h session/wk for 3 mo11‡ -6084 (-14 522;2572) -0.07 (-0.53, 0.36) 72%
Discount rates 
  Costs 3%, outcome 3% -6619 (-11 744;-1827) -0.06 (-0.26;0.15) 77%
  Costs 5%, outcome 5% -6462 (-11 606;-1963) -0.07 (-0.26;0.12) 75%
Age
  55 years -6445 (-12 166;-1387) -0.07 (-0.31;0.17) 72%
  75 years -6637 (-11 662;-2334) -0.06 (-0.23;0.10) 81%
Time horizon
  Lifetime horizon -6341 (-13 707;424) -0.09 (-0.54;0.35) 61%
  10 years -6220 (-12 570;62) -0.10(-0.44;0.26) 59%
Secondary intervention rate
  SET 6.4%, ER 35.2%16 -8207 (-14 371;-2848) -0.09 (-0.30;0.14) 78%
Cardiovascular health benefits SET
  52% mortality reduction45 -6036 (-11 029;-1649) 0.01 (-0.19;0.23) 87%
Starting health state
  Mild Claudication -8051 (-13 219;-2380) 0.04(-0.18;0.26) 93%
  Moderate Claudication -6193 (-12 603;-735) -0.08 (-0.30;0.17) 63%
  Severe Claudication -4618 (-10 319;1250) -0.23 (-0.55;0.14) 29%
Value in parentheses are 95 per cent credibility intervals. *Incremental values are shown for supervised exercise therapy (SET) 
minus endovascular revascularization (ER). †Cost-effectiveness probability (CEP): the probability that supervised exercise 
therapy is cost-effective compared with ER considering a willingness-to-pay threshold of €40 000. ‡National Institute for 
Health and Care Excellence guidelines. QALY, quality-adjusted life-year; PAD, peripheral arterial disease.
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claudication to endovascular revascularization as opposed to supervised exercise therapy 
would cost an additional €91600 per QALY gained. This exceeds most international WTP 
thresholds. These results, therefore, support a supervised exercise therapy-first approach 
in the treatment of intermittent claudication.
The outcome of this model-based cost-effectiveness analysis is in line with previous 
economic evaluations. Reynolds and co-workers46 used a Markov model to extrapolate 
the results of a recent trial comparing supervised exercise therapy, stenting and optimal 
medical care for intermittent claudication. Data from one trial, containing a small sample 
of patients, were used. Consequently, comparisons between supervised exercise therapy 
and endovascular stenting lacked statistical power to detect small differences. Furthermore, 
their model did not include PAD progression to CLI and secondary interventions such 
as repeated endovascular revascularization,OR or amputation. In their analysis, stenting 
demonstrated an ICER of US $122600 per QALY gained (€109754; exchange rate 1 June 
2016) compared with supervised exercise therapy. These results are analogous to the ICER 
for endovascular revascularization versus supervised exercise therapy of €91600 found 
in the present study (US $102322), despite differences in setting and scope between the 
two studies. Likewise, a previous study16 used invoice data from a large Dutch health 
insurance company and demonstrated that implementation of supervised exercise 
therapy as initial treatment would amount to yearly cost savings of up to €6677 per 
patient. Two trial-based economic analyses18,19 found supervised exercise therapy to be 
as effective as endovascular revascularization and less costly. A retrospective analysis of 
costs by O’Brien-Irr and colleagues17 showed that a trial of supervised exercise therapywas 
cost-effective, even if 80 percent of patients still required endovascular revascularization 
afterwards. Thus, the present study confirms the findings of previous cost-effectiveness 
research on supervised exercise therapy versus endovascular revascularization. Moreover, 
it adds that potential cost savings can be achieved over an extended time horizon and 
without a detrimental effect on QoL, secondary intervention rate or mortality.
An advantage of Markov modelling is the possibility of testing the effect of separate 
clinical scenarios on cost-effectiveness. Indeed, several one-way sensitivity analyses yielded 
interesting results. Notably, the cost-effectiveness of endovascular revascularization 
became more favourable when all virtual patients started in the severe claudication 
health state, defined based on QoL scores assessed by the EQ-5D™ questionnaire. In 
daily practice these patients may be difficult to identify, as objective variables such as 
ankle : brachial index and lesion characteristics on imaging correlate poorly with QoL12. 
Nonetheless, these results warrant further research on the relationship between a patient’s 
perception of impairment and the threshold for invasive treatment.
Four international guidelines recommend supervised exercise therapy as primary 
treatment for intermittent claudication1,10-12. However, in practice there are several important 
impediments to routine implementation of supervised exercise therapy. First, availability 
of supervised exercise therapy programmes is lacking13. This study again supports the 
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implementation of a network of trained supervised exercise therapy providers to improve 
accessibility. Moreover, it indicates that the initial investment required to develop the 
necessary infrastructure for a supervised exercise therapy programme will be compensated 
by the economic benefits supervised exercise therapy yields. Second, insurance coverage 
is poor for supervised exercise therapy, as opposed to endovascular revascularization15,16.
The present results, in accordance with previous analyses16-19,46, advocate the allocation of 
healthcare resources to support reimbursement by health insurers.
Finally, it has been postulated that patients with intermittent claudication generally 
favour endovascular revascularization, as it provides a ‘quick fix’15.However, others have 
reported that supervised exercise therapy improves patients’ walking capacity rapidly in 
the first 2 months47, achieving maximal effectiveness at 3 months48. Emphasizing these 
short-term benefits could help motivate patients for supervised exercise therapy. In 
addition, the costs of supervised exercise therapy decrease when fewer training sessions 
are required to achieve the same effectiveness.
As it is inherent for a model to make simplifying assumptions about clinical reality, this 
study had several limitations. First, it was conducted from the perspective of the Dutch 
population and healthcare setting, and both costs and health effects are influenced by 
such situational factors. Second, EQ-5D™ QoL scores were used to quantify effectiveness 
instead of more conventional outcome measurements such as walking distance or 
theWalking Impairment Questionnaire. Dividing the study population over three distinct 
health states using these traditional outcome measurements provided no distinct QoL 
values for each state. Notably, the appropriate outcome measurement in intermittent 
claudication is still under debate. 
Third, treatment arms were compared using combined data from two different 
studies. Although baseline characteristics were generally similar, significant differences 
between baseline walking distances and smoking status were found. This could be a cause 
of heterogeneity. Fourth,most input parameters were based on data spanning 1 year. 
In the present model, a continued effect from both endovascular revascularization and 
supervised exercise therapy up to 5 years was assumed, as opposed to lifetime analysis. 
Sensitivity analysis using a lifetime horizon, assuming a continuous effect of treatment, 
showed this assumption had a moderate effect on outcome. Fifth, a recent trial49 showed 
a greater improvement in walking distances and health-related QoL after endovascular 
revascularization followed by supervised exercise therapy compared with supervised 
exercise therapy alone. These results raise the question of whether the observed improved 
effectiveness of combined treatment is associated with an acceptable increase in costs. 
The present analysis does not address this. 
Finally, owing to lack of sound evidence, the benefits of exercise on cardiovascular 
health and QoL were not included in the base-case model. The effect on outcome of 
a 52 percent reduction in cardiovascular mortality after 12 weeks of supervised exercise 
therapy45 was investigated in one-way sensitivity analysis. This provided an expected 
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dramatic increase in the relative cost-effectiveness of supervised exercise therapy. Future 
research should further clarify the potentially beneficial effect supervised exercise therapy 
provides on general cardiovascular health in this patient population.
This study has shown that supervised exercise therapy is a more cost-effective primary 
treatment for intermittent claudication than endovascular revascularization. These results 
add to an impressive body of evidence and consequent guideline recommendations 
advocating a supervised exercise therapy-first approach in the treatment of intermittent 
claudication. Policymakers’ efforts and further research should focus on realizing 
implementation of supervised exercise therapy in clinical practice.
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Endovascular revascularization plus supervised exercise 
versus supervised exercise only in patients with 
peripheral artery disease and intermittent claudication: 
a cost-effectiveness analysis
Fakhry F, Rouwet EV, Spillenaar Bilgen R, van der Laan L, Wever JJ, Teijink JAW, Hoff-
mann WH, Smits TM, van Brussel JP, Stultiens GNM, Derom A, den Hoed PT, Ho GH, 
van Dijk LC, Verhofstad N, Orsini M, van Petersen A, Woltman K, Hulst I, van Sambeek 
MRHM, Rizopoulos D, Moelker A, Spronk S, Hunink MGM.
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ABSTRACT
Background 
The ERASE study showed that for intermittent claudication a combination therapy of 
endovascular revascularization followed by supervised exercise as compared to standard 
care of supervised exercise only resulted in greater improvement of walking distance 
and QoL. The cost-effectiveness of the combination therapy as compared to supervised 
exercise is not well known.
Objectives
This study assessed the cost-effectiveness of endovascular revascularization plus 
supervised exercise versus supervised exercise only for intermittent claudication.
Methods
212 patients were randomized to the combination therapy (n=106) or supervised exercise 
only (n=106) and had a 12-month follow-up. Cumulative costs per patient were collected 
using the in-hospital resource utilization data and cost-questionnaires. QALYs were 
estimated using the EuroQol-5D questionnaire. ICERs were calculated from both the 
societal and healthcare perspective. The associated uncertainty was determined using 
bootstrap techniques and acceptability curves. 
Results
As compared with supervised exercise, the combination therapy cost an additional € 1.462 
(99% CI, 388 to 3862) from the healthcare perspective and € 161 (99% CI, -2286 to 3106) 
from the societal perspective. Accumulated QALYs during 12 months were 0.042 (99% 
CI, -0.009 to 0.118) higher in the combination therapy group. The corresponding ICERs 
were € 34.810 from the healthcare perspective and € 3.833 from the societal perspective. 
At a WTP of € 80.000 per QALY, the probability of the combination therapy being cost-
effective was 87% and 95% from the healthcare and societal perspective, respectively. 
From subgroup-analysis in males, patients with femoropopliteal disease and >65 years 
the probability of the combination therapy being cost-effective was less certain.
Conclusions
Combination therapy of endovascular revascularization followed by supervised exercise is 
clinically and economically a more attractive approach than supervised exercise only for 
intermittent claudication at 12-month follow-up. Yet in subgroup-analysis males, elderly 
and patients with femoropopliteal disease might benefit more from a supervised exercise 
only strategy. 
PSM 20180914 Proefschrift Farzin Fakhry BW.indd   222 21-11-18   14:24
Cost-effectiveness of endovascular revascularization plus supervised exercise 
223
9
Intermittent claudication is the classical symptomatic presentation of peripheral artery 
disease (PAD) affecting approximately 20-40 million people worldwide with its prevalence 
increasing significantly as the population ages1. Patients with symptomatic PAD experience 
functional disability resulting in substantial morbidity and loss of quality of life (QoL)2. In 
addition to the clinical burden, PAD is associated with a significant economic burden and 
impact on healthcare services3,4.    
Supervised exercise has been established as an effective first-line treatment in the 
management of intermittent claudication and is being recommended as standard 
care by the guidelines2,5-7. Yet, in clinical practice endovascular revascularization is 
being performed more commonly due to limited access to exercise programs in 
most countries, reimbursement issues and prevention of unnecessary disability with 
immediate revascularization8-10. Some studies suggest that combining early endovascular 
revascularization, which improves patient functional status and QoL in the short term, 
with the added long-term benefits from supervised exercise would be superior to mono-
therapy with either one of the therapies11,12.
To investigate this, the Endovascular Revascularization And Supervised Exercise (ERASE) 
study was initiated to determine both effectiveness and cost-effectiveness of combining 
endovascular revascularization and supervised exercise versus the recommended care of 
supervised exercise only for intermittent claudication. Clinical results from the ERASE study 
showed that after 12 months follow-up the combination therapy resulted in significantly 
greater improvement in walking distance and health-related QoL scores compared to 
supervised exercise only13. To better inform policymakers on whether the added clinical 
benefits of the combination therapy are attained at reasonable costs, this article presents 
the results of a prospective preplanned cost-effectiveness analysis of the ERASE study 
from both the societal and healthcare perspective and taking a 12-month time horizon.
METHODS
Study Design and Patients
The study design and clinical outcomes of the ERASE study have been published 
previously13. In short, the ERASE study was a parallel-design randomized controlled trial 
(RCT) conducted in the Netherlands at 10 sites comparing a combination therapy of 
endovascular revascularization plus supervised exercise with standard care of supervised 
exercise only for intermittent claudication. All patients provided written informed consent 
and the institutional review board at each participating site approved the study protocol. 
Patients with stable intermittent claudication (≥3 months) referred to the outpatient 
clinic in the participating sites and having one or more vascular stenoses at the aortoiliac 
and/or femoropopliteal level were considered for inclusion. Patients with target lesions 
unsuitable for endovascular revascularization or patients with limited ambulation due to 
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a condition other than PAD not allowing them to walk on a treadmill were excluded. 
Eligible patients were randomized, in a 1:1 ratio, to either endovascular revascularization 
plus supervised exercise or supervised exercise alone using web-based randomization 
software based on the Pocock and Simon minimization method14.
Interventions
Details of the interventions have been described previously13. Briefly, supervised exercise 
was provided to the patients by trained physiotherapists in a network of physiotherapy 
clinics in the patients’ neighborhood. All physiotherapists were required to have completed 
a two-day course on supervised exercise for PAD certified by the Royal Dutch Society for 
Physical Therapy (KNGF) and follow the KNGF guidelines on treatment of intermittent 
claudication15. The recommended frequency of supervised exercise was two to three 
sessions per week of 30-45 minutes per session in the first three months, at least one 
session per week between three and six months and at least one session per four weeks 
up to 12 months follow-up. 
In the combination therapy group, endovascular revascularization was performed 
following current recommendations and in accordance with the normal practice of the 
participating site. For iliac and femoral revascularizations a stent was only used if the initial 
balloon angioplasty was not successful (selective stenting)16. In addition, within two to four 
weeks after the endovascular procedure patients were enrolled in the supervised exercise 
program.
Outcomes and Assessment
For this economic evaluation cumulative costs during the trial time horizon of 12 
months were collected from the societal and healthcare perspective for each patient. 
In addition, health-related QoL was assessed using the EuroQoL 5 dimensions (EQ-5D) 
from patient reported questionnaires, which were completed at baseline and at 1, 6 and 
12 months follow-up visits. The EQ-5D is a multi-attribute utility instrument that assesses 
5 dimensions of health-related QoL including mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Based on their scores for each dimension patients 
are classified into different health states17. To convert these health states to a utility score 
ranging from 0 (death) to 1 (perfect health), we used an established scoring algorithm 
based on preferences from a general Dutch population18. 
Costs
Information on the utilization of resources was generally obtained from patient reported 
cost-questionnaires completed at 1, 6 and 12 months assessments and resource utilization 
data collected for PAD-related interventions and in-hospital care during the 12-month 
follow-up. Valuation of resources used was based on prices obtained from billing and 
accounting data from two study hospitals and standard prices from the Dutch manual 
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for costing in economic evaluations19,20 where possible. All costs were recorded at patient 
level and converted to euros for 2012 using the general Dutch consumer price index21. All 
follow-up costs were limited to PAD procedures and related costs. Due to the one-year 
time horizon costs were not discounted.  
The per-patient costs related to PAD were estimated from both the societal and 
healthcare perspective using the Dutch manual for costing in economic evaluations19,20. 
In the societal perspective all changes in resource use (healthcare and non-healthcare) 
were taken into account, while in a healthcare perspective, only healthcare resources used 
were taken into account. Direct healthcare costs included costs of all diagnostic workup, 
contacts with physicians, primary and secondary interventions, supervised exercise 
sessions, personnel, materials, equipment and associated mean hospital admission. 
Indirect healthcare costs included costs of housing and hospital overhead. Direct non-
healthcare costs included patient travel costs, while indirect non-healthcare costs included 
costs resulting from loss of productivity from paid and unpaid work due to PAD.
Healthcare Costs
Diagnostic workup costs were calculated by multiplying the number of each non-invasive 
vascular imaging procedure (duplex ultrasound, CT angiography or MR angiography), 
ankle-brachial index measurements, treadmill exercise tests and laboratory blood tests 
for cardiovascular disease evaluation with the unit costs as derived from two study 
hospitals billing and accounting data. Costs for contacts with physicians included number 
of outpatient clinic visits and number of general physician contacts multiplied with 
a standard cost for each contact19,20. For intervention costs, including all primary and 
secondary endovascular or open surgical procedures, procedural costs were calculated 
by multiplying the units of resources used at the patient level (introducers, guidewires, 
catheters, angioplasty balloons, stents, medication, contrast material, vascular closure 
devices) by unit costs derived from two study hospitals’ billing and accounting data. For 
procedure personnel costs, the time each discipline spent performing the procedure 
was multiplied by the total compensation of that discipline based on standardized Dutch 
prices for contact with health care disciplines19,20. The cost for supervised exercise was 
calculated as the number of sessions times the costs per session. The costs per session 
were 28 euro based on physiotherapist billing data of 26 patients. The first supervised 
exercise session was counted as 1.45 times a normal session based on the same billing 
data which accounted for the extra time required to take the history and to explain the 
exercise program to the patient. The housing and overhead costs were estimated at 43% 
of direct assignable costs19,20.
Non-healthcare Costs 
Patient travel costs were calculated by multiplying a mean travel distance based on 
the average distance to a physiotherapy clinic, general practitioner or hospital in the 
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Netherlands with a fixed rate per kilometer19,20. Productivity costs were divided into costs 
resulting from loss of paid and non-paid work. Costs resulting from productivity loss of 
paid work were calculated by multiplying the number of days absenteeism from work 
due to PAD, as reported in the patient completed cost-questionnaire, with the sex- and 
age specific Dutch wage rate19,20. Finally, costs resulting from productivity loss of non-
paid work were calculated by multiplying the number of days normal activities were not 
performed due to PAD, as reported in the patient completed cost-questionnaire, with the 
wage of a professional housekeeper19,20,22.
Data Analysis
All analysis were conducted on an intention-to-treat-basis. Continuous variables 
are presented as means and standard deviations (SD) and categorical variables as 
proportions. Completeness of follow-up was computed as the ratio of the total observed 
person-time of follow-up to the maximum possible person-time of follow-up during 
the one year follow-up23. Missing cost-questionnaire data were imputed using multiple 
imputation based on information of all documented variables and the results from five 
imputed datasets were combined24.  The confidence intervals for the between-group 
differences for costs were estimated using bootstrap techniques given their skewed 
distribution. Between-group differences for the continuous outcome measures including 
the EQ-5D were analyzed using random-effects mixed models in order to account for 
the correlations in the repeated outcome measurement of each patient. We observed 
an unexpected statistically significant difference in the baseline EQ-5D between the two 
treatment groups. To adjust for this imbalance we incorporated the baseline EQ-5D as a 
covariate in the mixed model. 
The difference in quality-adjusted life-years (QALYs) between the two treatment 
groups for the in-trial period were obtained by calculating the difference in the area 
under the utility curve of each treatment group during the one year follow-up. The 
incremental cost-effectiveness ratios (ICERs) was calculated by dividing the difference in 
costs between the two treatment groups by the difference in QALYs, which represents 
the amount one would need to pay to gain one extra unit of effectiveness. To determine 
the associated uncertainty we used the net benefit approach25 and presented the results 
in cost-effectiveness planes and cost-effectiveness acceptability curves (CEACs) using 
bootstrap techniques26. 
Exploratory secondary subgroup analyses were performed in subgroups according 
to patient gender and age, patient employment status, level of disease, ankle-brachial 
index and maximum walking distance at entry. 
To account for multiple testing we used a stringent significance level of 0.01 (two-
sided) as statistically significant for all analysis. 
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RESULTS
Study Patients
In total 212 patients were included in the study, 106 were allocated to supervised exercise 
and 106 were allocated to the combination therapy of endovascular revascularization 
plus supervised exercise. The completeness of one-year follow-up was 96% (5211/5438 
persons-weeks) in the exercise group and 97% (5329/5518 persons-weeks) in the 
combination therapy group (Figure 1). In the exercise group 94 patients (89%) responded 
to the QoL and cost-questionnaire at 6 months and 92 patients (87%) at 12 months. 
Among those in the combination therapy group, 95 patients (90%) at 6 months and 95 
patients (90%) at 12 months responded. The two treatment groups were well matched 
for baseline characteristics except for the EQ-5D which was significantly higher in the 
combination therapy group (Table 1). The mean age was 65 years (SD 10) and 132 patients 
(62%) were male. The majority of patients (80%) had moderate to severe claudication 
(Fontaine IIb) with 112 patients (53%) having a predominant aortoiliac lesion and 100 
patients (47%) having a predominant femoropopliteal lesion (Table 1).
During the 12-month follow-up, patients in the supervised exercise group followed on 
average 43 exercise sessions of the recommended 46 to 59 sessions. In the combination 
therapy group, the endovascular revascularization procedure at baseline technically failed 
in 4 patients (4%), 3 of whom subsequently underwent open surgical revascularization, 
including endarterectomy (n=2) and bypass surgery (n=1), and one patient followed 
supervised exercise only. Among the 102 patients (96%) with a technically successful 
endovascular revascularization procedure at baseline the balloon angioplasty was 
followed by selective stent placement in 63 patients (62%). Patients in the combination 
therapy group followed on average 30 exercise sessions during the 12-month follow-up 
of the recommended 46 to 59 sessions.  
Resource Use and Costs 
A detailed overview of the relevant resources used and cost estimates for each treatment 
group is given in Table 2. The total mean cumulative healthcare and non-healthcare costs 
per patient during 12-month follow-up were €5988 following supervised exercise and 
€6149 following the combination therapy, resulting in a mean difference of €161 (99% CI 
-2286 ; 3106) in costs from the societal perspective in favor of supervised exercise only. 
The total mean cumulative healthcare costs per patient during 12 months were €3013 
following supervised exercise and €4475 following the combination therapy, resulting in 
a mean difference of €1462 (99% CI 388 ; 3862) from the healthcare perspective in favor 
of supervised exercise only (Table 2).
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Figure 1. Flow chart of the study patients
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Table 1. Baseline characteristics of the study population according to treatment group
Endovascular Revascularization 
plus Supervised Exercise
(n= 106)
 
Supervised Exercise
(n= 106)
Age (years) 64 (± 9) 66 (± 10)
Gender (male) 60 (57%) 72 (68%)
Smoker
Current
Former
65 (61%)
33 (31%)
55 (52%)
42 (40%)
Hyperlipidemiaa  47 (44%) 44 (42%)
BMI (kg/m2) 27.0 (± 4.1) 26.2 (± 4.4)
Hypertension 62 (58%) 66 (62%)
Diabetes 17 (16%) 27 (26%)
History of ischemic cardiac disease 35 (33%) 42 (40%)
History of cerebrovascular disease 11 (10%) 14 (13%)
Pulmonary disease 15 (14%) 17 (16%)
Renal insufficiency 7  (7%) 7 (7%)
Lower limb osteoarthritis 11 (10%) 12 (11%)
Dominant lesion
Aortoiliac
Femoropopliteal
58 (55%)
48 (45%)
54 (51%)
52 (49%)
Fontaine classification
IIa
IIb
18 (17%)
88 (83%)
24 (23%)
82 (77%)
Maximum Walking Distance (m) 264 (± 145) 285 (± 165)
Pain Free Walking Distance (m) 117 (± 83) 135 (± 88)
Ankle Brachial Indexb 
At rest 0.71 (± 0.18) 0.68 (± 0.16)
Post exercise 0.43 (± 0.21) 0.40 (± 0.24)
Quality of life
EuroQol-5Dc
Rating Scored 
SF-36 Physical Functioningd
SF-36 Role Physicald      
SF-36 Bodily PaindSF-36 General 
Healthd  
VascuQol e
0.76 (± 0.26)
67.9 (± 17.8)
51.4 (± 16.4)
59.2 (± 40.2)
52.7 (± 17.6)
59.3 (± 15.4)
4.48 (± 0.92)
0.68 (± 0.27)
64.9 (± 17.8)
52.7 (± 21.0)
53.4 (± 40.9)
53.1 (± 20.7)
53.9 (± 20.3)
4.51 (± 1.02)
Data are presented as means (± standard deviations) or number of patients (%) 
Abbreviations: BMI, body mass index; EuroQol-5D, the EuroQol five-dimension questionnaire score; SF-36, the 36-item short 
form health survey score; VascuQol, the vascular quality of life questionnaire score
a: Defined as total cholesterol level  ≥ 5.0 mmol/l
b: Minimum value of those for right and left legs
c: Expressed on a 0 (worst) to 1 (best) point scale
d: Expressed on a 0 (worst) to 100 (best) point scale
e: Expressed on a 1 (worst) to 7 (best) point scale
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Table 2. Total mean cumulative costs per patient during 12 months of follow-up after endovascular 
revascularization plus supervised exercise or supervised exercise only
Endovascular 
Revascular‐
ization plus 
Supervised 
Exercise
(n= 106)
Supervised 
Exercise 
(n=106)
Between‐Group
 Difference 
(99% CI)
Direct healthcare costs
Common study costs
Outpatient visits € 343 € 346
Walking test € 273 € 272
Blood test € 8 € 8
Imaging € 117 € 129
Total mean cumulative common costs € 741 € 756 € -15 (-50 ; 18)b
Primary intervention
Supervised exercise € 873 € 1.234
Endovascular procedure € 1.091 € 0
Hospital admission € 475 € 0
Total mean cumulative primary intervention costs € 2.440 € 1.234 € 1.205 (1050 ; 1375)b
Secondary interventions
Outpatient visitsa € 65 € 157
Imaging € 19 € 53
Endovascular procedures € 17 € 212
Surgical procedures € 242 € 167
Hospital admissions € 386 € 274
Total mean cumulative secondary  
intervention costs
€ 728 € 863 € -136 (-1066 ; 1915)b
Non‐direct healthcare costs
Housing/support/overhead costs € 567 € 159 € 408 (225 ; 630)b
Total mean cumulative healthcare costs € 4.475 € 3.013 € 1.462 (388 ; 3862)b
Non‐healthcare costs
Patient transportation costs € 168 € 227
Patient productivity losses paid work € 563 € 1.312
Patient productivity losses non-paid work € 942 € 1.435
Total mean cumulative non-healthcare costs € 1.67474 € 2.975 € -1.301 (-3117 ; 436)b
Total mean cumulative costs € 6.149 € 5.988 € 161 (-2286 ; 3106)b
Abbreviations: CI, confidence interval
a: Includes visits to general practitioner
b: Confidence intervals determined with the percentile bootstrap method
Quality‐Adjusted Life‐Years
During follow-up, EQ-5D improved significantly in both the supervised exercise and the 
combination therapy groups. Compared to supervised exercise the improvement was 
significantly greater in the combination therapy group at 1 month (mean difference 
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0.085; 99% CI 0.013 ; 0.158) but not at 6 (mean difference 0.038; 99% CI -0.034 ; 0.109) 
and 12 months (mean difference 0.012; 99% CI -0.060 ; 0.085). This was translated to a 
borderline non-significant cumulative mean difference of 0.042 QALYs (99% CI -0.009 ; 
0.118) between the groups accumulated during 12 months of follow-up in favor of the 
combination therapy group (Table 3).   
Incremental Cost-Effectiveness Ratios  
The estimated ICER for the combination therapy as compared with supervised exercise 
during 12-month follow-up from the societal perspective was €3833 (161/0.042) per QALY 
gained. The incremental cost-effectiveness plane using the bootstrapped replications for 
cost per QALY showed that the combination therapy had a probability of 0.56 to be 
more effective and cost more, of 0.01 to be less effective and cost less, of 0.42 to be 
more effective and cost less and of 0.01 to be less effective and cost more compared 
to supervised exercise only (Figure 2). Using a willingness-to-pay threshold of €80000/
QALY the probability of the combination therapy being the more cost-effective therapy 
from the societal perspective was 0.95 (Figure 3), which resulted in a higher net monetary 
benefit of € 3589 (99% CI -1544 ; 9931) per patient in favor of the combination therapy 
compared to supervised exercise only (Table 4).  
From the healthcare perspective the ICER for the combination therapy as compared 
with supervised exercise was €34810 (1462/0.042) per QALY gained. Using a willingness-
to-pay threshold of €80000/QALY the probability of the combination therapy being the 
more cost-effective therapy from the healthcare perspective was 0.87 (Figure 4 and 5), 
which resulted in a higher net monetary benefit of €2300 (99% CI -2754 ; 8471) per patient 
in favor of the combination therapy compared to supervised exercise only (Table 4).  
       
Table 3. Quality of life and accumulated QALY improvement per patient during 12 months of fol-
low-up after endovascular revascularization plus supervised exercise or supervised exercise only 
 Endovascular  
Revascularization plus 
Supervised Exercise
(n= 106)
Supervised 
Exercise 
(n=106)
Between‐Group
 Difference 
(99% CI)
EuroQol-5D 
Baseline 0.764 (0.698 ; 0.831) 0.684 (0.618 ; 0.751)
1 month +0.115 (0.064 ; 0.166) +0.030 (-0.022 ; 0.082) 0.085 (0.013 ; 0.158)
6 months +0.094 (0.044 ; 0.145) +0.057 (0.005 ; 0.108) 0.038 (-0.034 ; 0.109)
12 months +0.083 (0.032 ; 0.134) +0.071 (0.019 ; 0.123) 0.012 (-0.060 ; 0.085)
QALYs
Accumulated during  
12 months
0.093 (0.044 ; 0.141)a  0.051 (0.002 ; 0.101)a 0.042 (-0.009 ; 0.118)a
Abbreviations: CI, confidence interval; EuroQol-5D, the EuroQol five-dimension questionnaire score; QALYs, quality-adjust-
ed-life-years
a: Confidence intervals determined with the percentile bootstrap method
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Figure 2. Incremental cost-effectiveness plane of endovascular revascularization plus supervised 
exercise or supervised exercise only using 1000 samples in bootstrap analysis from the societal 
perspective.
Samples in the upper right quadrant indicate the combination therapy being more effective and 
more expensive; in the upper left quadrant the combination therapy being less effective and more 
expensive (dominated); in the lower right quadrant the combination therapy being more effective 
and cheaper (dominant); in the lower left quadrant the combination therapy being less effective 
and cheaper as compared to supervised exercise only.
Figure 3. Probability of endovascular revascularization plus supervised exercise being cost-ef-
fective compared to supervised exercise only in relation to willingness to pay per quality-adjust-
ed-life-year from the societal perspective.
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Figure 4. Incremental cost-effectiveness plane of endovascular revascularization plus supervised 
exercise versus supervised exercise only using 1000 samples in bootstrap analysis from the health-
care perspective.
Samples in the right quadrant indicate the combination therapy being more effective and more 
expensive; in the left quadrant the combination therapy being less effective and more expensive 
(dominated) as compared to supervised exercise only.
Figure 5. Probability of endovascular revascularization plus supervised exercise being cost-ef-
fective compared to supervised exercise only in relation to willingness to pay per quality-adjust-
ed-life-year from the healthcare perspective.
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Subgroup Analyses
In the subgroup analyses, the range of incremental costs (€-2619 to €2063) and incremental 
QALYs (-0.003 to 0.137) for combination therapy were relatively wide, resulting in a wide 
range of ICERs (Table 5). In patients with femoropopliteal disease supervised exercise 
only was both more effective and less costly.  In males the ICER for combination therapy 
was far above the willingness-to-pay threshold. Furthermore, in these two subgroups 
and in patients >65 years, the probability that combination therapy was cost-effective 
was less than 60%, suggesting that supervised exercise only may be preferrable in these 
subgroups. In all other subgroups analyses, combination therapy was either dominant 
or the ICERs remained below the willingness-to-pay threshold. The combination therapy 
seems to be the most cost-effective therapy in female patients, young patients (≤65 
years), employed patients, and patients with aortoiliac disease. 
DISCUSSION
In the ERASE study, we evaluated both effectiveness and cost-effectiveness of combining 
endovascular revascularization and supervised exercise compared to supervised exercise 
only in patients with intermittent claudication during 12-month follow-up. We have 
previously reported favorable clinical effects for the combination therapy with regard 
to improvement in walking distance and disease-specific QoL13. The utility outcomes 
presented in the current report point in the same direction as the clinical outcomes, with 
a small incremental QALY gain of 0.042 in favor of the combination therapy group over 
the 12-month time frame of the present study. Cost-effectiveness analysis demonstrated 
an estimated ICER of €3833 per QALY gained from the societal perspective and an ICER 
of €34810 per QALY gained from the healthcare perspective for the combination therapy 
compared to supervised exercise only. At a commonly used willingness-to-pay threshold 
in the Netherlands of €80000 per QALY27 the combination therapy had a probability of 
95% from the societal perspective and 87% from the healthcare perspective to be cost-
effective compared to supervised exercise only.
Table 4. Incremental cost-effectiveness ratio and probability of cost-effectiveness of endovascular 
revascularization plus supervised exercise or supervised exercise only after 12 months of follow-up .
Societal perspective
(99% CI)
Healthcare perspective
(99% CI)
Difference in cumulative total costs € 161 (-2286 ; 3106) a € 1.462 (388 ; 3862) a 
Difference in accumulated QALYs 0.042 (-0.009 ; 0.118) a 0.042 (-0.009 ; 0.118) a 
Incremental cost effectiveness ratio € 3.833 € 34.810 
Net monetary benefit 3.589 (-1544 ; 9931) a 2.300 (-2754 ; 8471) a 
Probability of cost effectiveness 0.95 0.87
Abbreviations: CI, confidence interval; QALYs, quality-adjusted-life-years
a: Confidence intervals determined with the percentile bootstrap method
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Although the ICER of the combination therapy was below the willingness-to-
pay threshold from both perspectives, the ICER per QALY gained was almost 10-fold 
higher when considered from the healthcare perspective as compared to the societal 
perspective. Healthcare costs were substantially higher following combination therapy 
compared to supervised exercise only, which was mainly driven by the higher procedural 
costs of endovascular revascularization at baseline. In contrast, the total cumulative costs 
of combination therapy from the societal perspective were only slightly higher than those 
of supervised exercise. This discrepancy in costs was mainly due to the higher productivity 
losses in the supervised exercise only group. Endovascular revascularization provides 
immediate relief of claudication symptoms and restoration of mobility, whereas patient 
mobility gradually increases over a period of months with a supervised exercise regimen. 
This probably explains why patients receiving the combination therapy resumed their 
work faster and returned to societal functioning earlier, which limited their productivity 
loss associated with claudication as compared to patients receiving supervised exercise 
only. In subgroup analysis this trend was even more pronounced with the combination 
therapy being more effective and costing less in the subgroup of younger (≤65 years) 
and employed patients. Thus, from a value based healthcare perspective, a combination 
therapy with endovascular revascularization followed by supervised exercise may be 
the preferred treatment strategy in the younger/employed subgroup of patients while 
a stepped care approach may be preferable in the elderly/unemployed patients, with 
endovascular revascularization provided only if supervised exercise fails.
A limited number of randomized studies assessed the cost-effectiveness of 
treatment strategies for intermittent claudication. Previous cost-effectiveness analysis 
have demonstrated that endovascular revascularization alone provides some benefit 
compared to supervised exercise but with ICERs above $100.000 per QALY gained, 
which is above the generally accepted willingness-to-pay threshold values28,29. The 
higher costs for the endovascular approach were not only due to the initial costs of the 
primary revascularization, but also due to the higher expenses of secondary (surgical) 
revascularizations during follow-up as compared to supervised exercise alone28.  Since 
supervised exercise after endovascular revascularization maintains clinical improvement 
and avoids the need for secondary revascularization in many patients13, this may translate 
into lower follow-up costs and consequently lower ICERs as compared to endovascular 
revascularization alone. In line with our results, a trial by Mazari et al. indeed showed that 
the combination therapy resulted in sustained clinical improvement without any of the 
patients requiring a secondary intervention after combination therapy which was cost-
effective as compared to endovascular revascularization alone30.  However, in this trial 
-which included only patients with femoropopliteal disease-, supervised exercise alone 
was still the most cost-effective first-line treatment from a healthcare perspective. The 
favorable cost-effectiveness of combination therapy in our current study as compared to 
supervised exercise only results from the greater cumulative QALY gain over 12 months, 
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0.04 in our study as compared to 0.02 in the aforementioned trial. Since both patients 
with aortoiliac disease and those with femoropopliteal disease were included in the ERASE 
trial, the better patency of aortoiliac endovascular revascularization31 may underlie the 
greater QALY gain in the combination group of the ERASE trial, which was confirmed 
by the subgroup analysis with greater improvement in QALY in patients with aortoiliac 
disease as compared to femoropopliteal disease. Furthermore the difference in QALY 
gain between the two trials might be explained by the difference in utility assessment. 
In the present study we used the EQ-5D questionnaire to assess utilities32, whereas the 
SF-6D utilities index, generated from the SF-36 generic QoL questionnaire, was used 
in the other trial. In addition to the effectiveness, it is difficult to compare the costs of 
various treatment strategies between studies as there are substantial differences in cost 
assessment between countries with their own finance and administration systems. For 
example, in the previous trial the National Health Service payment-by-results tariffs were 
used to calculate the costs of clinics and procedures, whereas in the ERASE study we 
used a more micro-costing approach for cost estimations by collecting data on units 
of resources utilized within each procedure as recommended by the U.S. Panel on Cost 
Effectiveness in Health and Medicine32. 
There are certain limitations to the ERASE study that deserve consideration. Inherent 
to the trial design, our results are only based on a subset of patients with intermittent 
claudication who were willing to participate in a RCT and met specific inclusion/exclusion 
criteria, which may not be representative for the overall population of patients with 
intermittent claudication. Furthermore, this cost-effectiveness analysis was performed 
from the Dutch healthcare system perspective with cost estimates being based on Dutch 
recommendations and thus our results may not be generalizable to other countries. Next, 
the study follow-up was limited to 12 months and given the observed decline in utility 
difference between the groups over time, the difference in QALY gain beyond 12 months 
remains uncertain and warrants further research. Finally, given the limited resources we 
could only evaluate a limited number of treatment strategies, yet treatment strategies 
including a stepped care approach with endovascular revascularization provided only if 
supervised exercise fails33 or new emerging structured home-based exercise programs 
with promising results34,35 are emerging and warrant further (cost-) effectiveness research. 
The cost-effectiveness of the various treatment options for patients with claudication most 
likely depends on patient and arterial lesion characteristics including age and comorbidity, 
level and extent of lower extremity arterial disease, and patency rates of the endovascular 
revascularization procedures. This was also seen in the subgroup analysis suggesting 
that supervised exercise alone instead of the combination therapy may be the preferable 
therapy in males, elderly and patients with femoropopliteal disease. Exercise rehabilitation 
should be provided to all patients with PAD for the benefits of increasing physical activity 
on reduction of cardiovascular and overall mortality36. Given the crucial role of health 
professionals in motivating behavior change, supervised exercise is an excellent way 
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to promote adoption of a healthy lifestyle in patients with PAD. Our data reaffirm the 
importance of access to and reimbursement of supervised exercise programs for all 
patients with claudication37. Further (cost-) effectiveness research is warranted to define 
which patient groups experience long-term benefit in terms of walking capacity by adding 
a revascularization procedure from a clinical as well as from a societal point of view. 
CONCLUSIONS
In conclusion, based on the results of the ERASE study, the combination of endovascular 
revascularization followed by supervised exercise is overall clinically and economically 
a more attractive approach than supervised exercise only in patients with intermittent 
claudication. Yet, the long-term benefits of both strategies remain to be defined and 
specific patient groups, such as males, elderly and patients with femoropopliteal disease 
might benefit more from a supervised exercise only strategy.
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Summary and general discussion
Part I Introduction 
Peripheral artery disease (PAD) which is caused by systemic atherosclerosis of the infrarenal 
aorta and the lower limb arteries is a major global burden with a prevalence of 200 million 
people worldwide and is increasing rapidly with the ageing world population. Intermittent 
claudication, i.e. exertional leg pain that resolves with rest, is the symptomatic form of 
PAD, affecting approximately 20-40 million people worldwide.1 Patients with claudication 
experience significantly limited walking ability and diminished ability to perform their 
daily activities leading to a sedentary lifestyle and impaired quality of life.2,3 Moreover, 
these patients face increased cardiovascular morbidity and mortality.4,5 In order to tackle 
these challenges, two policies need to be followed: improving limb symptoms and 
quality of life and reducing the risk for cardiovascular events. Modalities to improve limb 
symptoms are supervised exercise therapy or (endovascular) revascularization, either 
alone or in combination. The aim of this thesis was to determine the optimal treatment 
for improving walking ability and quality of life in patients with intermittent claudication. 
We first summarized the existing evidence regarding treatment options, then assessed 
the effectiveness of a novel treatment strategy compared to the standard care, and 
finally assessed the cost-effectiveness of this novel treatment strategy to better inform 
policymakers on implementation. 
Part II Systematic reviews
Supervised exercise therapy is being recommended as first-line treatment for intermittent 
claudication. However, uncertainty remains about the effect of supervised walking 
therapy and the different exercise components (e.g. treadmill use, intensity, duration and 
content). In chapter 2 we performed a meta-analysis and meta-regression to summarize 
the effectiveness of supervised walking therapy for intermittent claudication and identify 
the components of the walking program that provide maximal improvement in walking 
distances. Pooled data from 25 randomized controlled trials (RCT) with more than 1000 
patients showed an improvement in maximum walking distance of about 200 meters 
in patients who followed a supervised walking program as compared to those who did 
not. No specific component of the exercise program in isolation was responsible for the 
improvement in walking capacity.
Although supervised walking therapy is an effective first-line treatment for intermittent 
claudication, a substantial number of patients cannot train on a treadmill due to common 
comorbidities, such as pulmonary disease, heart failure, back pain, or osteoarthritis. For 
these patients, other modes of exercise therapy (e.g. cycling, upper-arm ergometer and 
strength training) might be a suitable alternative. In chapter 3 we performed a systematic 
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review and meta-analysis to compare alternative modes of supervised exercise with 
supervised walking therapy. Pooled results from five RCTs (135 patients) showed similar 
improvements in walking distance in patients who followed a supervised walking program 
and those who performed alternative modes of exercise.  
The benefit of supervised exercise in the management of intermittent claudication is 
well established and international guidelines recommend supervised exercise as first-line 
treatment for intermittent claudication. Supervised exercise requires patient motivation 
and time in order to be successful, while on the on the other hand endovascular 
revascularization offers instant symptom relief without patient compliance and is highly 
profitable for the physician. Endovascular revascularization provides an attractive alternative 
and the number of endovascular procedures for PAD has increased dramatically in the 
past 10 years. To assess the value of endovascular revascularization in the management 
of intermittent claudication, in  chapter 4 we performed a systematic review and meta-
analysis to summarize the comparative efficacy of endovascular revascularization versus 
conservative management.  Pooled results from three studies (125 patients) showed a 
moderate to large effect on improvement in walking distances in favor of revascularization 
as compared to a walking advice. Pooled data from five studies (345 patients) showed 
equal effectiveness for endovascular revascularization and supervised exercise therapy 
in terms of improving walking distances and quality of life. Finally, pooled data from five 
studies (618 patients) showed a moderate to large effect on improvement in walking 
distance and quality of life in patients receiving combination therapy (endovascular 
revascularization combined with supervised exercise or pharmacotherapy) as compared 
to conservative therapy (supervised exercise or pharmacotherapy) only.  
Part III Clinical effectiveness
Most of the clinical trials comparing endovascular revascularization with supervised 
exercise have limited their follow-up to one year, making long-term recommendations 
difficult. In chapter 5 we presented the 7-year results from a randomized controlled 
trial of supervised exercise versus endovascular revascularization. Patients in both groups 
showed comparable and sustained improvements in their walking distance and quality 
of life at long-term follow-up, which suggests that both therapies are also equivalent in 
the long term.
Supervised exercise programs are not widely available and not reimbursed in most 
countries. To overcome this issue of limited access, home-based exercise programs are 
being investigated. In chapter 6 we evaluated the effectiveness of a structured home-
based exercise program for patients with intermittent claudication and compared these 
results with those from a concurrent control group who received supervised exercise. At 
one year follow up the 142 patient receiving structured home-based exercise showed 
significant improvement in their walking distances and quality of life compared to their 
baseline values, yet patients in the control group receiving supervised exercise showed 
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significantly better results. In chapter 7 we presented results from the Endovascular 
Revascularization And Supervised Exercise (ERASE) trial, which compared the combination 
therapy of endovascular revascularization plus supervised exercise with supervised 
exercise only for claudication. In this multicenter study, 212 patients were randomized 
to the combination therapy or supervised exercise only. At one year follow up, patients 
receiving the combination therapy showed greater improvements in maximum and 
pain-free walking distances of 300 and 400 meters, respectively. Similarly, patients in the 
combination therapy group showed greater improvement in quality of life. A combination 
therapy of early endovascular revascularization followed by supervised exercise thus seems 
promising because it combines the immediate improvement in claudication symptoms 
after revascularization with the potentially long-term benefits of exercise therapy.  
Part IV Cost-effectiveness 
Data on long-term cost-effectiveness of supervised exercise versus endovascular 
revascularization for intermittent claudication is sparse. In chapter 8 we constructed 
a Markov model to assess the cost-effectiveness of supervised exercise versus 
endovascular revascularization from the healthcare perspective considering a 5-year time 
horizon. Supervised exercise was associated with significant cost-savings as compared 
to endovascular revascularization. Per quality adjusted life year (QALY) gained, an 
additional € 91.600 (incremental cost-effectiveness ratio) had to be paid for endovascular 
revascularization as compared to supervised exercise. Supervised exercise was determined 
as cost-effective primary treatment option for intermittent claudication as compared to 
endovascular revascularization. To address the question of whether the clinical benefit 
of the combination therapy (endovascular revascularization plus supervised exercise) 
as demonstrated in the ERASE trial was also cost-effective compared with supervised 
exercise only, we performed an extensive cost-effectiveness analysis in chapter 9. As 
compared with supervised exercise, the combination therapy cost an additional € 1.462 
from the healthcare perspective and an additional € 161 from the societal perspective over 
a time-frame of 1 year. The clinical benefit of combination therapy translated into an 0.042 
increase in accumulated QALYs during the study time horizon of 12 months. This resulted 
in an incremental cost-effectiveness ratio of € 34.810 / QALY gained from the healthcare 
perspective and € 3.833 / QALY gained from the societal perspective, which is well below 
the willingness-to-pay threshold of € 80.000. The probability of the combination therapy 
being cost-effective was 87% and 95% from the healthcare and societal perspective, 
respectively. Our data indicated that the combination therapy was less cost-effective in 
patients over 65 years of age, males and patients with femoropopliteal disease.
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RECOMMENDATIONS AND FUTURE PERSPECTIVES 
Cardiovascular risk management
In the management of PAD the main focus should be on prevention of future 
cardiovascular events, as at 5 years 15% to 20% of PAD patients will die, most of them 
due to a cardiovascular event, and another 20% of them will experience a nonfatal 
cardiovascular event.4,6 Despite strong recommendations in the excellent guidelines on 
cardiovascular risk management in patients with PAD7,8, these patients remain to be 
undertreated compared to patients with coronary heart disease.5 Studies assessing the 
efficacy of a guideline recommended risk reduction programs have shown improved 
limb outcomes, reduction of myocardial infarction and stroke, and improvement in 
overall survival in patients with PAD receiving guideline-based secondary prevention.9,10 
We should put our efforts into optimizing guideline adherence in routine clinical care. 
Current guidelines recommend that all patients with PAD should cease smoking, receive 
antiplatelet agents, high-density statin agents, angiotensin-converting enzyme inhibitors 
(ACEI) or angiotensin receptor blockers, blood pressure- and diabetic glycemic control if 
needed.7,8 The most important lifestyle intervention remains discontinuation of smoking 
in patients with PAD with regard to improved limb outcomes (prevention of progression 
to critical limb ischemia or amputation) and prevention of major cardiovascular events.9,11 
Thus all patients with PAD should be advised to quit smoking during each medical visit 
and assisted in developing a plan to cease smoking. New initiatives developing step-
wise standardized intervention methods to help the clinician addressing smoking 
cessation in PAD patients are being conducted and should be supported in future 
research projects.11 Antiplatelet therapy is the cornerstone of drug therapy in patients 
with PAD. Antiplatelet monotherapy with Aspirin or Clopidogrel is being recommended 
in all patients with PAD.7,8 Antiplatelet therapy with Aspirin alone is recommended in 
all patients with PAD based on results from a meta-analysis of 18 trials involving 5,269 
PAD patients which showed a statistically nonsignificant decrease in cardiovascular events 
and a statistically significant reduction in nonfatal strokes in patients receiving Aspirin.12 
In the subgroup of patients with symptomatic PAD in the CAPRIE (Clopidogrel versus 
Aspirin in Patients at Risk of Ischaemic Events) trial Clopidogrel monotherapy was shown 
to be more effective in reducing cardiovascular events as compared to monotherapy with 
Aspirin.13 And the recently published EUCLID (Examining Use of Ticagrelor in Peripheral 
Artery Disease) showed no superiority of monotherapy with Ticagrelor as compared 
to Clopidogrel in patients with symptomatic PAD.14 Based on this evidence Clopidogrel 
monotherapy is the preferred antiplatelet therapy to prevent cardiovascular events in 
patients with symptomatic PAD.  More uncertainty remains on the use of dual antiplatelet 
therapy (DAPT) with Aspirin and Clopidogrel versus monotherapy with either one 
of the medications. Although no conclusive evidence exists on the use of DAPT after 
endovascular or surgical revascularization most clinicians prescribe DAPT for usually 1 to 
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3 months post revascularization. The ongoing  Antiplatelet Strategy for Peripheral Arterial 
Interventions for Revascularization of Lower Extremities (ASPIRE-PAD) trial comparing at 
least one month of DAPT versus an additional 12 months of DAPT post endovascular 
revascularization will determine the optimal duration of DAPT use post revascularization. 
It should be noted that most of the recommendations on antiplatelet therapy in patients 
with PAD are based on trials in patients with clinical evidence of cardiovascular disease 
including subgroup of patients with PAD. This usually results in limited statistical power 
to show a significant effect of a certain antiplatelet regimen in the subgroup of patients 
with PAD. For this reason trials including exclusively patients with PAD are needed to 
determine the optimal antiplatelet regimen in these patients. Further elaboration on 
recommendations on cardiovascular risk factor management in patients with PAD are 
beyond the scope of this thesis. We focused on treatment options to improve walking 
distance and quality of life in PAD patients with intermittent claudication. 
Pharmacotherapy
Cilostazol is the single medication that is recommended for relief of claudication 
symptoms.8 However, its benefits in terms of improving walking distance are only modest, 
and its use is frequently discontinued due to side effects. Hence, there is great interest in 
the development of alternative pharmacological therapies. Since claudication symptoms 
are caused by ischemia of the leg muscles, interventions that promote angiogenesis are 
potential therapeutic candidates. Administration of colony-stimulating factors induces 
mobilization of endothelial progenitor cells from bone marrow and spleen, which may 
subsequently stimulate angiogenesis and improve endothelial cell function, thus improving 
blood flow. In spite of promising preliminary studies, however, the recently published 
PROPEL trial (Progenitor Cell Release Plus Exercise to Improve Functional Performance in 
PAD) did not support using granulocyte-macrophage colony-stimulating factor (GM-CSF) 
to treat walking impairment in patients with claudication.15 Repeated subcutaneous 
administration of GM-CSF did not significantly improve walking performance, either when 
used alone or when combined with supervised exercise. Thus, although cell-based and 
angiogenic therapies for improving claudication symptoms are theoretically promising, 
their value in clinical practice remains to be determined. Given the absence of an effective 
widely used medication for intermittent claudication more effort on the development of 
medical therapies for claudication symptoms is highly needed and should be one of the 
main focuses of PAD research. 
Exercise therapy
Supervised exercise
Exercise therapy is the cornerstone in the management of intermittent claudication and 
is being recommended by all guidelines as first-line treatment.7,8 Although the benefit of 
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supervised treadmill exercise is clear, a lot of uncertainty remains on the exact duration 
and content of the exercise program. In our review we showed the beneficial effects of 
supervised walking therapy yet none of the exercise components (e.g. intensity, duration 
or content) was independently associated with significant improvement in walking 
distances. This might have been caused by the limited number of studies in our meta-
regression analysis and the heterogeneity between the studies for the different exercise 
components, yet it is interesting that less intensive programs might be as beneficial 
as high-intensity training where patients are stimulated to walk to near-maximum 
claudication pain. The only RCT comparing supervised treadmill exercise programs of 
different duration concluded that the highest gain in walking distances is achieved within 
the first two months of exercise therapy16, suggesting that a relatively short-term exercise 
program may be preferred above extended programs with associated higher costs and 
patient burden. Future RCTs should focus on the comparative effectiveness of different 
types of supervised walking therapy programs.  
Home-based exercise
In spite of their reported efficacy, supervised exercise programs are underutilized due to 
limited access and reimbursement issues. Previous studies showed supervised exercise 
to be superior to a “go home and walk” advice.17 Recent evidence, however, supports 
structured home-based exercise regimens as valuable alternatives to supervised exercise 
programs.18 One trial comparing supervised exercise with structured home-based 
exercise in which patients were monitored by an activity monitor to record their walking 
performance and seen on a regular basis by a healthcare professional to motivate them 
to achieve their walking goals, showed the home-based program to be equally effective 
as the supervised exercise program.19 In the Group Oriented Arterial Leg Study (GOALS) 
showed that a home-based group-mediated cognitive behavioral walking intervention 
was superior to a health education control group to improve walking performance in 
patients with PAD.20 With the recent developments in implementation of electronic health 
portals, personal health records and monitoring options by eHealth technologies, the 
role of widely accessible home-based exercise programs will evolve and need further 
attention as it might overcome the barriers associated with supervised exercise programs. 
In addition to providing (remote) coaching by dedicated healthcare professionals, such 
home-based exercise programs should incorporate behavioural change interventions, 
including goal setting and self-monitoring. The clinical challenge is to effectuate home-
based exercise programs that maximize improvements in walking endurance and achieve 
a durable physically active lifestyle, while minimizing the use of healthcare resources. 
Endovascular revascularization
Endovascular revascularization continues to evolve as an attractive first-line treatment 
for intermittent claudication with the development of new devices and techniques. 
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Although supervised exercise is the recommended first-line treatment, endovascular 
revascularization has evolved as an attractive alternative due to high procedural success 
rates, insurance coverage, and immediate relief of ischemic symptoms. As a result, the 
number of endovascular procedures for claudication has increased dramatically over 
the past decade.21 Yet, it should be noted that endovascular procedures have limited 
durability with high rates of re-intervention and associated costs and complications in the 
long-term as compared to supervised exercise.22,23 In chapter 4 we showed from pooled 
data from RCTs comparing endovascular revascularization with supervised exercise that 
both therapies are equally effective in terms of improving walking distances and quality 
of life, even in the long-term. This underlines the need for a stepped-care approach, 
reserving revascularization for those patients who are unable to exercise or receive 
insufficient benefit from supervised exercise. 
All trials comparing supervised exercise and endovascular revascularization so far, 
only used conventional balloons or stents in the intervention arm, which are associated 
with high restenosis rates, particularly in the femoropopliteal arteries. Over the past few 
years, the domain of endovascular intervention has expanded with the introduction of new 
technologies, such as drug-coated balloons and drug-eluting stents. Recent trials show 
that these new technologies have better arterial patency, but are more expensive.24-27 To 
date, no comparisons have been made between the recommended supervised exercise-
first strategy and revascularization with drug-eluting balloons. In addition, most studies 
evaluating the effectiveness of endovascular revascularization techniques have focused 
on patency rates of the treated segments as the primary endpoint rather than clinically 
relevant endpoints, including improvements in walking capacity and quality of life. Future 
research should focus on the question whether revascularization with drug-coated 
balloons and stents confers any clinical benefits over supervised exercise in the course 
of time, i.e. are these invasive strategies really helpful or just expenditure of substantial 
health care resources?  
Combination therapy
Exercise therapy for PAD takes time, motivation, and compliance, whereas revascularization 
provides instantaneous symptom relief and requires little patient effort or intrinsic 
motivation. The two therapies also have different working mechanisms: exercise improves 
skeletal muscle mitochondrial metabolism, endothelial function and biomechanics of 
walking28, whereas revascularization increases blood flow to the affected muscles. We 
showed that the combination therapy of endovascular revascularization plus supervised 
exercise had superior clinical outcomes as compared to supervised exercise only at 12 
months of follow up. This approach combined the synergistic effects of these treatment 
modalities in the short term. However, during the 12-month follow up the results between 
the treatment modalities began to approximate each other while the majority of the 
patients in the supervised exercise group showed sustained improvement without the 
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need of a revascularization procedure during the follow up. This confirmation of the 
beneficial effects of both treatment modalities has important clinical implications and in 
clinical practice both treatment modalities with their pros and cons should be discussed 
with the patient. Further studies are needed to identify the best treatment strategy for 
specific subgroups of patients, based on their anatomical and clinical characteristics in 
order to realize a personalized treatment of intermittent claudication.
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Thesis conclusions
 – Supervised walking therapy is an effective first-line treatment to improve walking 
distance in patients with intermittent claudication.
 – The improvement in walking capacity seems unrelated to any particular component 
of a supervised walking program. 
 – Other modes of supervised exercise therapy, such as cycling or strength training 
are suitable alternatives to supervised walking therapy for patients who cannot 
train on a treadmill due to common comorbidities, such as pulmonary disease, 
heart failure, back pain, or osteoarthritis. 
 – Supervised exercise therapy and endovascular revascularization are equally 
effective to improve walking distance and quality of life in the short and long-term.
 – Compared to endovascular revascularization, supervised exercise therapy is more 
cost-effective as primary treatment for intermittent claudication considering a 
5-year time horizon.
 – A structured, unsupervised, home-based exercise program improves the walking 
distance and quality of life, though less so than a supervised exercise program. 
 – Combination therapy of endovascular revascularization plus supervised exercise 
offers greater improvements in walking distance and quality of life than supervised 
exercise monotherapy, at least in the short term. 
 – Combination therapy is also cost-effective in the short term as compared with 
supervised exercise monotherapy.
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Nederlandse samenvatting
Deel I Introductie
Perifeer arterieel vaatlijden (PAV) is een aandoening die veroorzaakt wordt door 
atherosclerose (slagaderverkalking) van de lichaamsslagader (aorta) en de beenslagaders. 
Het is een veel voorkomende aandoening: naar schatting lijden 200 miljoen mensen 
wereldwijd aan PAV en dit aantal neemt snel toe met de vergrijzing van de wereldbevolking. 
Ongeveer 20-40 miljoen mensen met PAV hebben last van claudicatio intermittens 
(etalagebenen), d.w.z. pijn in de benen bij inspanning die met stilstaan weer overgaat. 
Door deze klachten worden patiënten met claudicatio intermittens aanzienlijk beperkt in 
hun loopafstand, met als gevolg een verminderd vermogen om hun dagelijkse activiteiten 
uit te voeren, immobiliteit en een slechtere kwaliteit van leven. Bovendien hebben deze 
patiënten een sterk verhoogd risico op een hartinfarct of een beroerte en een verhoogde 
kans op voortijdig overlijden. 
Bij de behandeling van deze patiëntengroep moet dan ook een tweesporenbeleid 
worden gevolgd: het verbeteren van de claudicatio klachten en kwaliteit van leven 
enerzijds en het verminderen van het risico op hartinfarct, beroerte en overlijden 
anderzijds. Behandelingsmogelijkheden om claudicatio klachten te verbeteren zijn 
medicatie, (gesuperviseerde) looptherapie, herstel van de doorbloeding met behulp van 
een dotterbehandeling of (bypass)operatie, of een combinatie van deze behandelingen.
Het doel van dit proefschrift was om de optimale behandeling te bepalen voor het 
verbeteren van de loopafstand en de kwaliteit van leven bij patiënten met claudicatio 
intermittens. Om dit te bereiken hebben we eerst de wetenschappelijke literatuur van de 
bestaande gangbare behandelopties systematisch samengevat, vervolgens de effectiviteit 
van een nieuwe behandelstrategie vergeleken met de standaardzorg en uiteindelijk de 
kosteneffectiviteit van deze nieuwe behandelstrategie berekend om beleidsmakers beter 
te kunnen informeren over implementatie ervan in de dagelijkse praktijk.
Deel II Systematisch literatuuronderzoek
Gesuperviseerde looptherapie wordt aanbevolen als eerstelijnsbehandeling voor 
claudicatio intermittens. Er blijft echter onzekerheid bestaan over de effectiviteit van 
gesuperviseerde looptherapie in de praktijk en de effectieve componenten van het 
loopprogramma (bijvoorbeeld het gebruik van een loopband, intensiteit, duur of 
inhoud van het programma). In hoofdstuk 2 hebben we een meta-analyse uitgevoerd 
om de effectiviteit van gesuperviseerde looptherapie voor claudicatio intermittens 
samen te vatten en de componenten van het loopprogramma te identificeren die 
zorgen voor maximale verbetering in loopafstanden. Analyse van de resultaten van 25 
gerandomiseerde gecontroleerde studies (RCTs) met meer dan 1000 patiënten toonde 
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een verbetering van de maximale loopafstand van ongeveer 200 meter bij patiënten die 
een gesuperviseerd loopprogramma volgden in vergelijking met degenen die dat niet 
deden. Uit deze analyse bleek verder dat deze verbetering van de loopcapaciteit niet het 
gevolg was van een afzonderlijk onderdeel van het trainingsprogramma, maar eerder van 
het samenspel van alle componenten. 
Hoewel gesuperviseerde looptherapie dus een effectieve eerstelijnsbehandeling 
is voor claudicatio intermittens kan een aanzienlijke deel van de patiënten niet trainen 
op een loopband vanwege bijkomende aandoeningen, zoals een longziekte, hartfalen, 
rugpijn of artrose van de heupen of knieën. Voor deze patiëntengroep kan een andere 
vorm van oefentherapie (bijvoorbeeld fietsen, roeien of krachttraining) een geschikt 
alternatief bieden. In hoofdstuk 3 hebben we een systematisch literatuuronderzoek en 
meta-analyse uitgevoerd om alternatieve vormen van gesuperviseerde oefentherapie 
te vergelijken met de standaard behandeling van gesuperviseerde looptherapie. De 
verzamelde resultaten van vijf studies toonden vergelijkbare verbetering in loopafstanden 
bij patiënten die een alternatieve vorm van oefentherapie hadden gevolgd ten opzichte 
van patiënten die looptherapie hadden gevolgd.
Gezien deze gunstige effecten wordt gesuperviseerde looptherapie in de (inter)
nationale richtlijnen aanbevolen als behandeling van eerste voorkeur voor claudicatio 
intermittens. Echter, gesuperviseerde looptherapie kost tijd, motivatie en inspanning 
van de patiënt.  Daarentegen biedt endovasculaire revascularisatie (dotterbehandeling) 
snel en direct symptoomverlichting, zonder dat dit inspanning van de patiënt vereist. 
Endovasculaire  revascularisatie biedt om deze reden een aantrekkelijk alternatief als 
eerstelijnsbehandeling voor claudicatio intermittens en is het aantal endovasculaire 
procedures voor PAV in de afgelopen 10 jaar dan ook dramatisch toegenomen. 
Om de waarde van endovasculaire revascularisatie in de behandeling van claudicatio 
intermittens te evalueren hebben we in hoofdstuk 4 een systematisch literatuuronderzoek 
en meta-analyse uitgevoerd naar de effectiviteit van endovasculaire revascularisatie 
vergeleken met conservatieve, niet-invasieve, behandeling. Samengevoegde resultaten 
van drie onderzoeken toonden een matige tot grote verbetering in de loopafstand 
bij patiënten die een endovasculaire revascularisatie ondergingen ten opzichte van de 
patiënten die alleen een wandeladvies kregen. De resultaten van vijf studies tezamen 
lieten zien dat endovasculaire revascularisatie net zo effectief is als gesuperviseerde 
looptherapie, zowel ter verbetering van loopafstand als verbetering van kwaliteit van 
leven. Ten slotte bleek ook een combinatie van endovasculaire revascularisatie en 
gesuperviseerde looptherapie of medicatie tot een grotere toename in loopafstand en 
kwaliteit van leven te leiden dan alleen behandeling met gesuperviseerde looptherapie 
of medicatie.
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Deel III Klinische effectiviteit
De meeste klinische studies waarin endovasculaire revascularisatie wordt vergeleken 
met gesuperviseerde looptherapie voor claudicatio intermittens hebben een beperkte 
follow-up van maximaal 1 jaar waardoor aanbevelingen op de lange termijn niet mogelijk 
zijn. In hoofdstuk 5 onderzochten we de 7-jaars resultaten van een gerandomiseerde 
gecontroleerde studie onder patiënten met claudicatio intermittens die eerder waren 
behandeld met ofwel gesuperviseerde looptherapie ofwel endovasculaire revascularisatie. 
De verbeteringen in loopafstand en kwaliteit van leven 7 jaar na de behandeling waren 
vergelijkbaar in beide groepen. Dit suggereert dat beide therapieën ook op de lange 
termijn gelijkwaardig zijn ter behandeling van claudicatio intermittens.
Gesuperviseerde loopprogramma’s zijn niet overal beschikbaar en worden in de 
meeste landen niet vergoed door zorgverzekeraars. Om dit probleem van beperkte 
toegang te verhelpen wordt er onderzoek gedaan naar alternatieven, waaronder 
looptraining door de patiënt zelf thuis. In hoofdstuk 6 vergeleken we de effectiviteit 
van een gestructureerd looptherapieprogramma voor thuis met de resultaten van 
een controlegroep van patiënten met claudicatio intermittens die gesuperviseerde 
looptherapie hadden gevolgd in het ziekenhuis. De 142 patiënten die een thuisprogramma 
volgden, hadden na 1 jaar wel een verbetering van hun loopafstand en kwaliteit van leven, 
maar deze waren aanzienlijk minder dan de verbeteringen die hierin werden bereikt door 
patiënten die gesuperviseerde looptherapie ontvingen. 
In hoofdstuk 7 worden de resultaten beschreven van de Endovascular Revascu-
larization And Supervised Exercise (ERASE) studie waarin de combinatietherapie van 
endovasculaire revascularisatie plus gesuperviseerde looptherapie werd vergeleken 
met de standaardbehandeling van gesuperviseerde looptherapie alleen. In dit 
onderzoek dat in meerdere Nederlandse ziekenhuizen werd uitgevoerd, werden 212 
patiënten met claudicatio intermittens gerandomiseerd naar combinatietherapie of 
alleen gesuperviseerde looptherapie. Na één jaar follow-up toonden patiënten die 
de combinatietherapie ontvingen grotere verbetering in hun maximale- en pijnvrije 
loopafstand van respectievelijk 300 en 400 meter meer in vergelijking met patiënten die 
enkel gesuperviseerde looptherapie hadden ontvangen. Evenzo vertoonden patiënten in 
de combinatietherapie groep grotere verbetering in hun kwaliteit van leven in vergelijking 
met de patiënten uit controlegroep die enkel gesuperviseerde looptherapie hadden 
gevolgd. Een combinatietherapie van vroege endovasculaire revascularisatie gevolgd 
door gesuperviseerde looptherapie lijkt dus veelbelovend omdat het zeer waarschijnlijk 
de onmiddellijke verlichting van claudicatio symptomen na revascularisatie combineert 
met de potentiële lange termijn voordelen van gesuperviseerde looptherapie.
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Deel IV Kosteneffectiviteit
Gegevens over de kosteneffectiviteit op lange termijn van gesuperviseerde looptherapie 
ten opzichte van endovasculaire revascularisatie voor claudicatio intermittens zijn schaars. 
In hoofdstuk 8 construeerden we een Markov-model om de kosteneffectiviteit van 
gesuperviseerde looptherapie ten opzicht van endovasculaire revascularisatie te evalueren 
vanuit het gezondheidszorg perspectief over een tijdsbestek van 5 jaar. Gesuperviseerde 
looptherapie ging gepaard met aanzienlijke kostenbesparing in vergelijking met 
endovasculaire revascularisatie. Per gewonnen levensjaar, gecorrigeerd voor kwaliteit van 
leven, (QALY) bedroegen de extra kosten voor endovasculaire revascularisatie € 91.600 in 
vergelijking met gesuperviseerde looptherapie. Gesuperviseerde looptherapie werd dan 
ook geduid als de meest kosteneffectieve primaire behandelingsoptie voor claudicatio 
intermittens in vergelijking met endovasculaire revascularisatie. 
Om de vraag te beantwoorden of het klinisch voordeel van de combinatietherapie 
(endovasculaire revascularisatie plus gesuperviseerde looptherapie) zoals aangetoond 
in de ERASE-studie kosteneffectief zou zijn in vergelijking met alleen gesuperviseerde 
looptherapie hebben we een uitgebreide kosteneffectiviteitsanalyse uitgevoerd in 
hoofdstuk 9. Vergeleken met gesuperviseerde looptherapie kostte de combinatietherapie 
€ 1.462 extra per patiënt vanuit het gezondheidszorg perspectief en € 161 extra vanuit 
het maatschappelijk perspectief over een tijdsbestek van 1 jaar. Het klinisch voordeel van 
combinatietherapie leidde tot een toename van 0,042 gewonnen levensjaar, gecorrigeerd 
voor kwaliteit van leven, (QALY) tijdens de follow-up van 1 jaar. Omgerekend kostte het 
klinisch voordeel van de combinatietherapie €34.810 per QALY vanuit het gezondheidszorg 
perspectief en €3.833 per QALY vanuit het maatschappelijk perspectief wat ruim onder 
de betalingsdrempel van €80.000 per QALY ligt wat we als maatschappij accepteren. In 
87% van de gevallen berekend vanuit een  gezondheidszorg persepectief  en in 95% van 
de gevallen berekend vanuit een maatschappelijk perspectief was de combinatietherapie 
kosteneffectief  in vergelijking met gesuperviseerde looptherapie alleen. Verdere analyse 
van de gegevens toonde aan dat alleen gesuperviseerde looptherapie wel kosteneffectief 
is voor patiënten ouder dan 65 jaar, mannen en patiënten met een vernauwing of 
verstopping van de bovenbeens- of knieslagaders en dus voor deze patiënten een 
gesuperviseerde looptherapie mogelijk geadviseerd zou kunnen worden.
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de tegenvallers aan het begin een succes werd. Ik ben dan ook blij dat je eindelijk kan 
zeggen dat je af bent van het “JAMA drama” door de resultaten van de ERASE studie 
samen in de JAMA te publiceren. Ik ben je enorm dankbaar voor de manier waarop 
je mij hebt opgevangen in een moeilijke periode na het overlijden van mijn moeder 
en mij op het werk alle ondersteuning gaf. Ik baalde er natuulijk van dat je halverwege 
mijn promotietraject naar IGZ in Utrecht vertrok maar kon volledig je beweegredenen 
begrijpen en heb enorme waardering voor alles wat je hebt bereikt. 
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De leden van de beoordelingscommissie dank ik voor hun bereidheid om zitting te 
nemen in de boordelingscommissie van dit proefschrift.   
Prof. dr. J.A.W. Teijink, beste Joep, ik heb enorme waardering voor je inzet en passie voor 
het optimaliseren van de behandeling van patiënten met claudicatio intermittens. Met het 
opzetten van ClaudicatioNet is het aanbod aan kwalitatief hoogwaardige gesuperviseerde 
looptherapie een begrip geworden in Nederland waar de rest van de wereld van kan 
leren. Ik heb altijd met plezier met je van gedachten gewisseld over de diverse projecten 
in dit proefschrift en onze discussies waren enorm leerzaam voor mij.  
Prof. dr. G.P. Krestin, ik bewonder uw vermogen om uw werkzaamheden als hoofd van 
de bloeiende afdeling Radiologie & Nucleaire Geneeskunde binnen het Erasmus MC te 
combineren met uw talloze wetenschappelijke activiteiten wereldwijd, en toch nog altijd 
aandacht te hebben voor de promovendi binnen uw afdeling. 
Prof. dr. F. Zijlstra, ik ben vereerd dat u naast uw vele werkzaamheden als afdelingshoofd 
Cardiologie van het Erasmus MC de tijd heeft genomen om als vooraanstaande expert 
op het gebied van interventiecardiologie de inhoud van dit proefschrift kritisch te 
beoordelen.   
De leden van de grote commissie, prof. dr. J.A. Reekers, prof. dr. F.L. Moll, prof. dr. W.P.T.M. 
Mali, prof. dr. M.R.H.M. van Sambeek en dr. A. Moelker. Ik wil jullie van harte bedanken 
voor de bereidheid om zitting te nemen in de promotiecommissie.  
Mijn paranimfen en mijn maatjes, Roman Fakhry en Rahman Fakhry.
Roman, we hebben samen veel doorstaan wat onze band zo sterk heeft gemaakt. We 
weten precies zonder teveel woorden wat we aan elkaar hebben. Bovenal geniet ik elke 
keer weer van je onverwachts perfect getimede humor. Ik ben trots jou aan mijn zijde te 
hebben tijdens mijn verdediging van dit proefschrift. 
Rahman, ik geef toe dat jij de slimste in de familie zult worden. Ik blijf me elke keer weer 
verbazen over je geweldige rapportcijfers en je geweldige discipline. Met het succesvol 
afronden van je Junior Med School en straks op je 17de je eerste publicatie kan ik alleen 
maar trots op je zijn als oudere broer.  
Collega’s van de Clinical Epidemiology/ART groep.
Bob, Ik denk met heel veel plezier terug aan onze tijd samen op de 25ste waarbij we dagelijks 
meerdere malen bij de Espressobar te vinden waren en over van alles discussieerden 
behalve over onderzoek. We hebben veel gelachen maar bovenal veel van elkaar geleerd 
over onze kijk op de wereld om ons heen. Ik was jaloers op je vermogen dat je zo goed in 
staat was om zoveel dingen buiten de wetenschap te combineren met je werkzaamheden 
als PhD student. 
Bart, al snel konden we het goed met elkaar vinden en dat kwam denk ik vooral door 
onze gedeelde nuchtere kijk op de wereld en de wetenschap. Ik vind het geweldig hoe 
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jij jezelf binnen de wetenschappelijke wereld hebt ontwikkeld en in de V.S. je carrière 
als wetenschapper geweldig voort hebt gezet. Tessa Genders, Nathalie, Ineke, Marieke, 
Felisia, John, Rinske, Ewoud, Cecile, Reluca, Suman, Rachel, Marcus, Ruben, Loes, Minghui, 
Obaid en Tessa Kouwenhoven, dank voor alle goede gesprekken, gezelligheid en hulp 
om elkaar verder te brengen. Erica, jij bent de steun en toeverlaat van de groep, dank 
dat je altijd bereid bent geweest om mij bij alle administratieve zaken te helpen. Reinier, 
het was geweldig om je als Master student te mogen begeleiden. Je hebt enorm veel 
geholpen bij de kosteneffectiviteitspaper en ik was onder de indruk van je zelfstandigheid 
en  nauwkeurigheid.      
Hugo Fokkenrood, Gert-Jan Lauret, Marijn van den Houten, het was geweldig om met 
jullie groep vanuit Eindhoven onder leiding van prof. dr. J.A.W. Teijink samen te werken en 
onze krachten bij het onderzoek naar perifeer vaatlijden te bundelen. 
Prof. dr. D. Rizopoulos, beste Dimitris, bedankt dat je steeds de tijd nam om mijn statistische 
modellen samen te bekijken en mij op weg hielp om de modellen nog beter te maken. Je 
uitleg en hulp bij het optimaliseren van de modellen waren onmisbaar. 
Alle betrokkenen bij de ERASE trial, de vaatchirurgen, de interventieradiologen en de 
(research-) verpleegkundigen die geweldig hebben geholpen om de studie in elk centrum 
goed te laten verlopen en met toewijding eraan gewerkt hebben om genoeg patiënten in 
de studie te includeren, heel veel dank. Zonder jullie steun was dit proefschrift nooit tot 
stand gekomen. Sanne Klaphake, ik vind het geweldig hoe je aan de slag bent gegaan 
om vervolg te geven aan de ERASE trial door de lange-termijn gegevens te verzamelen. 
Ik kijk uit naar jouw promotie. 
Alle (oud-)collega’s, arts-assistenten en stafleden van de afdeling Thoraxchirurgie van het 
St. Antonius ziekenhuis, afdeling Chirurgie van het Erasmus MC en de afdeling Cardiologie 
van het LangeLand ziekenhuis en het HagaZiekenhuis, bedankt voor de leuke tijd, prettige 
samenwerking en de tijd die jullie mij boden om dit proefschrift af te ronden.   
De families Fakhry, Amery en Haidary en alle vrienden bedankt voor jullie ondersteuning, 
motivatie en bovenal grenzeloze liefde. Ondanks de gebrekkige contacten door alle 
drukte door de jaren heen zijn jullie mij altijd blijven steunen en geïnteresseerd geweest 
in mijn werk. Ik kan jullie daarvoor niet genoeg bedanken. 
Romina, mijn lieve zusje, ik ben er trots op hoe jij al je werkzaamheden en zorg voor 
iedereen goed weet te combineren met je studie. Ik kijk er naar uit om jou straks als 
apotheker te zien.  
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